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ABSTRACT
Granulomas are clusters of immune cells. These structures can be formed in reaction 
to infection and display signs of necrosis, such as in tuberculosis. Alternatively, in 
several immune disorders, such as sarcoidosis, Crohn’s disease and common variable 
immunodeficiency (CVID), non-caseating granulomas are formed without an obvious 
infectious trigger. Despite advances in our understanding of the human immune system, 
the pathogenesis underlying these non-caseating granulomas in chronic inflammatory 
diseases is still poorly understood. Here, we discuss the current knowledge about the 
immunopathogenesis of granulomas, and we discuss the different therapeutics.
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INTRODUCTION 
Inflammation is a physiological response of the body to invading pathogens. However, 
if the inflammatory state is not transient and persists chronically, this can result in 
irreversible tissue damage.1 Typical non-infectious causes of chronic inflammation are 
autoimmune diseases, which are characterized by T-cell and antibody responses to 
self-antigens. Disorders that are characterized by innate immune responses without 
obvious auto-antibodies are referred to as autoinflammatory diseases.2 In several 
autoinflammatory diseases, chronic inflammation can result in the formation of 
granulomas, which are clusters of immune cells in affected tissues. 
 The most common cause of all granuloma formation worldwide is tuberculosis.3 
The formation of granulomas in tuberculosis is thought to be a physiological reaction 
to prevent the systemic spread of the causative pathogen; the mycobacterium.4 This 
immune response typically results in a caseating granuloma with signs of necrosis.5 
Many other infectious agents can trigger granuloma formation (Table 1.), as well as 
foreign body material such as beryllium, and inherited defects in neutrophil function 
(chronic granulomatous disease; CGD).3,6-9 In chronic inflammatory diseases and 
primary immunodeficiencies with chronic inflammation, the granulomas have not 
been associated with specific external agents. With the exception of granulomatosis 
with polyangiitis (GPA), these granulomas are non-caseating and typically observed in 
patients with sarcoidosis,10 Crohn’s disease,11 and common variable immunodeficiency 
(CVID)12.
 In recent years, several new insights have been generated into granulomatous 
inflammation. These new insights might soon be translated to clinical care, as increasing 
numbers of therapeutic agents targeting various immune pathways are currently 
tested in clinical trials.13 Here, we review and discuss recent literature on granulomatous 
inflammation in sarcoidosis, Crohn’s disease and CVID, all chronic inflammatory 
disorders with similar types of granulomas without a known trigger. We will specifically 
address the immune components involved in granuloma formation and how these can 
be utilized as disease markers and targeted by new therapeutic approaches for chronic 
autoinflammatory diseases with granuloma formation. 
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TABLE 1. Overview of infectious and non-infectious diseases with granuloma formation.
Category Disease Type of granuloma Localization
Infectious
Bacterium tuberculosis caseating necrosis lung, extrapulmonary; 
disseminated
brucellosis necrotizing and fibrotic liver, spleen
bartonellosis necrotizing liver
actinomycosis non-caseating cervicofacial, abdominal, lung
Fungus histoplasmosis necrotizing lung
aspergillosis necrotizing lung
candidiasis necrotizing with abcesses skin
cryptococcal disease fibrotic with abcesses lung
Parasitic leishmaniasis necrotizing skin
dirofilariasis fibrotic and calcifying subcutaneous
schistomiasis non-caseating liver, intestines, bladder
Viral CMV unspecified spleen and liver
EBV unspecified skin
measles unspecified thyroid gland
Non-infectious with known cause
Primary 
Immunodeficiency
CGD non-caseating skin, intestines, liver
Malignancy lymphoma non-caseating lymphatic tissue
foreign body non-caseating tissue with contact to foreign 
body particle; skin, lung, 
intestines
Other berylliosis non-caseating lung
Non-infectious with unknown cause
Chronic inflammatory 
disease
GPA necrotizing lung, upper airways
sarcoidosis non-caseating lung, skin, eye, lymph node, 
liver, CNS, heart
Crohn’s disease non-caseating intestines, skin, liver, lymph 
node
Primary 
Immunodeficiency
CVID non-caseating lung, lymph node, liver, skin, 
spleen, intestines
 This Table is a non-exhaustive list of causes of granuloma formation. The affected organs are listed from the 
most commonly involved organ on the left to less common. The information is derived from references 3,6-9,14,15. 
Abbreviations: CGD, chronic granulomatous disease; CMV, cytomegalovirus; CNS, central nervous system; 
CVID, common variable immunodeficiency; EBV, Epstein-Barr virus; GPA, granulomatosis with polyangiitis.
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CHRONIC AUTOINFLAMMATORY DISEASES  
WITH GRANULOMA FORMATION
SARCOIDOSIS
Sarcoidosis is a multisystem granulomatous disease of unknown etiology. The hallmark 
of this disease is the presence of non-caseating granulomas affecting multiple organs. 
It is a rare disease with a worldwide prevalence ranging from 1 to 40 per 100,000 
and a peak incidence at 20-39 years of age.16 The clinical presentation of sarcoidosis 
is highly variable and dependent on the organs involved. Systemic complaints of 
fever, weight loss and fatigue are common. About 90% of patients have pulmonary 
granulomas with frequent involvement of other organs such as lymph nodes, skin, liver, 
eye, and heart.10 A rare manifestation of sarcoidosis is the involvement of the nervous 
system in about 5% of cases.17 Every aspect of the nervous system can be affected, 
however the central nervous system and the cranial nerves are most commonly 
affected.18,19Due to the high variability in clinical manifestations it can be challenging 
to diagnose sarcoidosis., especially in neurosarcoidosis, a rare and variable neurological 
manifestation. There is no definite test and diagnosis of sarcoidosis is based on three 
elements: 1) clinical and radiographic manifestations; 2) exclusion of diseases that may 
present similarly; 3) Identification of non-caseating granulomas by histological analysis 
of tissue.20 Chest X-ray and computed tomography (CT) are the most common used 
visualization techniques. Radiographic pulmonary manifestations can vary from bihilar 
lymphadenopathy, pulmonary infiltration or fibrosis.21 Nuclear techniques, such as the 
Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG PET), can also 
be used to evaluate extrapulmonary manifestations of sarcoidosis or to find a location 
for biopsy.22 Blood tests can provide supportive information for making the diagnosis 
through detection of high serum levels of angiotensin converting enzyme (ACE) or 
soluble interleukin 2 receptor (sIL-2R), which is a marker for increased activation of T 
cells.16,23 
 Fortunately, treatment is not necessary in over 50% of patients in whom the disease 
will resolve in three years without medication.10,16 Patients are only given medication 
when inflammation leads to organ damage. First-line therapy for sarcoidosis is 
based on corticosteroids such as prednisone. Second-line treatment comprises 
immunosuppressive medication such as methotrexate and azathioprine. For refractory 
cases, third line medication is available in the form of biologicals that block tumor 
necrosis factor (TNF)-α: infliximab or adalimumab.24 This approach is successful in about 
50% of treated patients in whom the granulomas resolve with no or little remaining 
organ damage. However, 20-25% of all diagnosed patients develop chronic disease 
with pulmonary fibrosis.16 Current therapies target inflammatory pathways and have 
little effect on fibrosis. This is a major limitation because fibrosis results in increased 
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morbidity and mortality and the need for lung transplantation.25 Patients with 
progressive neurological disease are often refractory to long term treatment with 
high dose corticosteroids and DMARD’s or experience serious side effects. Third line 
treatment with infliximab appears to be effective in the majority of patients leading to 
a partial or complete remission. However, the two largest cohort studies on this subject 
both show a relapse rate of 50-56% after discontinuation of this TNF-blocker.26,27 
 The lack of a cure for sarcoidosis underlines the need to find new, effective drugs.10,16 
CROHN’S DISEASE
Crohn’s disease is an inflammatory bowel disease (IBD).11 In recent years, the worldwide 
prevalence of Crohn’s disease has been reported to increase, with current estimates 
in Western countries of 25 to 318 per 100,000.28 Similar to sarcoidosis, Crohn’s disease 
typically affects young adults, but with a 10-fold higher prevalence. The chronic 
inflammation in the intestinal tract is thought to result from an interplay of the genetic 
background, environmental factors, intestinal microbiota and a dysregulated immune 
system.29 In Crohn’s disease, chronic inflammation can manifest throughout the 
gastrointestinal tract, mainly affecting the ileum and the colon resulting in abdominal 
pain and diarrhea with passage of mucus or blood.11 In addition, subsets of patients 
show inflammation of the skin, eyes or joints. Diagnosis of Crohn’s disease is based 
on clinical assessment and physical examination of the patient in conjunction with 
imaging and histopathology of inflamed tissues and with blood tests.11 Crohn’s disease 
has many overlapping features with ulcerative colitis (UC),30 the other major variant of 
IBD. In contrast to Crohn’s disease, inflammation in UC is restricted to the colon and does 
not result in granuloma formation. When IBD is suspected, a colonoscopy is performed 
during which biopsies are taken. The histological finding of a non-caseating granuloma 
is the most discriminating factor for Crohn’s disease.31 Supporting evidence from 
laboratory analyses include high CRP, low Hb and high fecal calprotectin.11 Furthermore, 
the majority of patients has detectable serum levels of anti-Saccharomyces cerevisiae 
antibodies (ASCA),32 or antibodies to the outer membrane porin C of E. coli (anti-
OmpC).33 Despite granulomas being a discriminating factor with UC, these structures 
are only identified in about 37% of patients with Crohn’s disease.30 The presence of 
granulomas is associated with higher rates for surgical bowel resection, indicating that 
these are an indicator for severe disease.30 Treatment of Crohn’s disease is similar to 
sarcoidosis and includes corticosteroids, immunosuppressive and biologicals. In spite 
of the introduction of infliximab, treatment outcomes remain suboptimal with disease 
control being achieved in only 60% of Crohn’s patients, 34 and intestinal complications 
and the requirement for surgery remain.11
13
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C VID WITH GR ANULOMATOUS COMPLIC ATIONS
CVID is a primary immunodeficiency (PID). It is a rare, heterogeneous disease with a 
prevalence of 2 to 4 per 100,000 and mean age of diagnosis between 30 and 40 years.36 
Patients suffer from recurrent sino-pulmonary infections and to a lesser extent from 
gastrointestinal infections. The hallmark of CVID is a B-cell defect leading to low or absent 
levels of immunoglobulins, and can be accompanied by abnormal T-cell responses 
and cytokine defects. Diagnosis of CVID is made when a patient has severely reduced 
levels of serum IgG with low IgM and/or IgA, and fulfills all of the following criteria: 1) 
onset after 2 years of age. 2) Poor or absent vaccination response. 3) Exclusion of other 
causes of hypogammaglobinemia.37 Despite these commonalities in immunological 
defects and recurrent infections, CVID represents a heterogeneous group of patients 
with ranging clinical features that include autoimmunity, granuloma formation and 
hematological malignancies. These non-infectious complications are associated with 
high morbidity and early mortality.38 Previously, only in 2-10% of patients a molecular 
cause of disease was identified in genes such as ICOS, CD19, CD81, TNFRSF13C (encodes 
BAFFR) and TNFRSF13B (encodes TACI).39-43 However, none of these correlated with the 
incidence of granulomatous complications in 8-22% of CVID patients.12 With the recent 
identification of autosomal dominant causes of complex antibody deficiencies and 
incomplete penetrance of some mutations (e.g. CTLA4, PIK3CD, PIK3R1 and NFKB1),44-47 it 
will become possible to relate granulomas to a genetic cause. 
 In CVID patients, granulomas most prevalently affect the lungs, followed by lymph 
nodes, liver, skin and spleen. The presence of granulomas can precede the diagnosis of 
CVID for years resulting in a potential misdiagnosis of sarcoidosis. However, sarcoidosis 
patients do not present with recurrent infections or low/absent immunoglobulins, 
because serum IgG levels are normal or even elevated in sarcoidosis.48 CVID patients 
can also present with abdominal complaints, such as chronic diarrhea, weight loss 
and histological evidence of intestinal inflammation, resulting in an overlap of clinical 
features with Crohn’s disease.49 CVID patients with granulomas are more frequently 
affected by other autoimmune manifestations and have a higher morbidity and 
mortality rate than non-granulomatous patients.12,50 The primary treatment of CVID is 
intravenous or subcutaneous immunoglobulin substitution, which is highly effective in 
reducing the infectious burden.51 However, this treatment does not ameliorate the non-
infectious complications. Conversely, granulomatous inflammation in CVID is treated 
with similar types of immune suppressive agents that are used for sarcoidosis and 
Crohn’s disease. The combination of immunodeficiency with inflammation highlights 
the complicated processes involved in CVID, because it appears contrasting to treat 
immunocompromised patients with immunosuppressive medication. 
 While granulomas are the hallmark of disease in sarcoidosis, these are only detected 
in subgroups of patients with Crohn’s disease and CVID. However, the exact incidence 
of granulomas in these disorders remains unclear and might be underestimated due 
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to sampling errors.30 Furthermore, granulomas in CVID are often poorly recognized 
by physicians or upon discovery the patient is misdiagnosed with sarcoidosis.12 As 
granulomatous complications are a predictor for poor disease outcome in CVID12,50 and 
a pathognomic feature in Crohn’s disease,52 detection of these inflammatory structures 
is important in diagnostic work-up. As the finding of a granuloma as a varied differential 
diagnosis demonstrated in Table 1, it is important to look for distinguishing features such 
as necrosis. Nevertheless, diagnosis of all these diseases is based on the combination of 
clinical characteristics, pathology reports and other diagnostic tests. 
KEY PLAYERS IN GRANULOMA PATHOGENESIS
ANTIGENIC TRIGGERS
Granulomas are thought to be formed following by a foreign trigger. Therefore, in 
diseases thus far characterized by non-infectious granulomatous inflammation, the 
search for a causative agent is still ongoing. In sarcoidosis there is a particular interest 
in finding the responsible trigger. An increased number of sarcoidosis cases was 
reported in rescuers after the terrorist attack on the World Trade Center in New York,53 
suggesting an external antigenic cause. Mycobacteria and Propionibacterium acnes are 
of specific interest, because DNA of these antigens was found in granuloma material 
from sarcoidosis patients with numbers ranging from 0-9 % for M. tuberculosis and 79-
100% for P. acnes.54 However, the causality of one single pathogen is debatable with 
such diverse pathogens being proposed.10 Antigenic agents have also been suggested 
to trigger granuloma formation in Crohn’s disease, mainly because of the associated 
defective bacterial clearance by autophagy. Polymorphisms in genes involved in 
autophagy have been reported,55 the mechanism by which cells degrade and recycle 
of cellular components. In Crohn’s disease this leads to the impaired capacity to handle 
pathogens by specialized intestinal epithelial cells, Paneth cells.56 Furthermore, the 
presence of ASCA and anti-OmpC antibodies are suggestive of fungal or bacterial triggers 
of granuloma formation.32,33 Finally, the high prevalence of M. avium in blood and tissue 
suggested that, similar to sarcoidosis, granulomas in Crohn’s disease were formed in 
response to mycobacteria.57,58 This theory is considered controversial, because M. avium 
is not typically pathogenic in humans and treatment of patients with anti-mycobacterial 
agents was proven ineffective.59 An antigenic driver for persistence of granulomas 
in CVID is unlikely, because these patients are regularly treated with antibiotic or 
antifungal drugs, and these do not effectively resolve this type of inflammation.12,60 Yet, 
a high prevalence of human herpesvirus type 8 (HHV8) is reported in granulomatous 
or lymphocytic interstitial lung disease (GLILD) patients (67%) as compared to the low 
prevalence of 4.8% in patients with CVID without GLILD. HHV8 infection might therefore 
15
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contribute to the poor prognosis of patients with granulomatous CVID.61
 In conclusion, there is no unambiguous evidence for specific causal factors that 
trigger non-infectious granulomatous inflammation. It is evident that the immune 
system drives tissue destructive inflammation, but it remains to be determined if certain 
infectious or non-infectious particles are prone to trigger formation or persistence of 
granulomas. 
MACROPHAGES
Macrophages are immune cells that are specialized in clearing of degraded extracellular 
substances through phagocytosis. These specialized immune cells are derived from 
circulating monocytes and are typically found in granulomas (Figure 2). Macrophages 
are thought to be one of the first cell types to migrate into affected tissue to clear debris 
and recruit other immune cells.62 An important cytokine produced by macrophages is 
TNF-α, which induces vasodilation and thereby facilitates the infiltration of monocytes 
and lymphocytes. Macrophages also release other pro-inflammatory cytokines 
such as IL-1, IL-6, IL-12 and IL-23. Together with TNF-α, these cytokines promote 
leukocyte infiltration and T-cell activation, while inhibiting regulatory T cells (Treg) 
and T-cell apoptosis.62 These activated macrophages are important in cell-mediated 
inflammation seen in granulomas, yet they also induce tissue damage. Polarization 
of macrophages mirrors the Th immune response status. Macrophages can acquire 
different functionalities in response to local triggers.63 One definition to describe the 
activated state of macrophages is the classical M1 and alternative M2 activation. M1 
macrophages are activated by Toll-like receptors and IFN-γ produced by Th1 cells.64,65 
M2 macrophages are activated through IL-4 and IL-13 and secrete extracellular 
matrix components promoting tissue remodeling.64,65 Inflamed tissue in patients with 
Crohn’s disease predominantly contain M1 macrophages,66 and these contribute to 
the intestinal inflammation by disrupting the epithelial barrier in Crohn’s disease.67 A 
similar M1 polarization was seen in alveolar macrophages of patients with sarcoidosis.68 
Interestingly, an M2 polarization has been reported in other interstitial lung diseases 
with fibrosis. This is in line with an M2 polarization in a Th2 environment that has been 
observed in neurosarcoidosis with myofibrisosis,69 and in fibrotic intestinal lesions of 
patients with Crohn’s disease.70 These studies suggest a M1 activation predominantly in 
the acute pro-inflammatory granulomatous inflammation with a possible shift towards 
M2 macrophages in fibrotic processes. 
 Stimulated macrophages can further mature into epithelioid cells that are elongated 
and resemble epithelial cells. Epithelioid cells appear to lose their phagocytic function 
and shift to more secretory capacities.71,72 However, to our knowledge, it remains unclear 
what soluble factors these epithelioid cells produce. Epithelioid cells can fuse together 
and create compact aggregations, which are called multinucleated giant cells.73 In 
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contrast to epithelioid cells, these multinucleated cells are capable of phagocytosis and 
cytokine secretion, esp. IL-1, TNF-α, and TGFβ.74 
 Our understanding of TNF-α and its role in granuloma integrity is mostly based on 
tuberculosis animal models.75,76 In the absence of TNF, primary granulomas can still be 
formed. However, granulomas appeared disorganized.75,76 Furthermore, a loss of TNF 
signaling disrupts already formed granulomas. This could in part be due to impaired 
lymphocyte recruitment and activation, in which TNF-α also plays a major role.75 
 Several abnormalities in monocyte and macrophage function have been reported 
in sarcoidosis, CVID and Crohn’s disease, and these might contribute to the chronic 
inflammation and granuloma formation. Specifically, monocytes in patients with 
sarcoidosis and Crohn’s disease have an increased ability to form multinucleated cells.77,78 
Furthermore, cultured alveolar macrophages of patients with sarcoidosis spontaneously 
produce more pro-inflammatory cytokines, including TNF-α, than controls,79 and these 
higher levels were associated with progressive disease.80 TNF-α production was also 
found to be increased in monocytes of patients with CVID.81 The TNF 488A allele leads to 
higher TNF production and is strongly positively associated with granulomatous CVID.82 
Furthermore, 82% of TNF 488A allele negative patients were IL-10 a-t-a allele positive, 
leading to lower IL-10 production resulting in a more pro-inflammatory TNF environment. 
Together, these two genetic variants seem to promote a cytokine shift contributing to 
an inflammatory environment leading to granulomatous complications.83 The intestinal 
microbiota can also affect the inflammatory environment. Intestinal macrophages 
of patients with Crohn’s disease produced more pro-inflammatory cytokines such as 
TNF-α after stimulation with commensal bacteria,84 whereas reduced levels of pro-
inflammatory cytokines were reported in response to E. coli.85-87 Furthermore, E. coli is 
able to survive and replicate in intestinal macrophages in patients with Crohn’s disease, 
is present in granulomas and can induce granuloma formation in vitro.88-90 Due to this 
apparent decreased macrophage function, it has been proposed that Crohn’s disease 
should also be considered a primary immunodeficiency.91,92 
T CELLS
The inflammatory mediators produced by macrophages in affected tissue trigger the 
recruitment of additional immune cells, especially CD4+ Helper T (Th) cells (Figures 
1 and 2). Th cells are important mediators of immune responses and are thought to 
organize the granulomatous structure together with the already present macrophages. 
Traditionally, helper T cells were divided in Th1 and Th2 subsets, and the Th cells in 
granulomatous tissue were assumed to be type 1 cells that produce IL-2 to induce T-cell 
proliferation and the accumulation of effector T cells. However, with the more recent 
detection of other subsets such as Th17 cells and Tregs, the concepts of Th mediated 
inflammation have changed.93 
17
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FIGURE 1. Non-caseating granulomas in Crohn’s disease and sarcoidosis. Haemotoxylin 
and eosin stainings reveal granulomatous structures in a lymph node biopsy of a patient with 
sarcoidosis (a) and a biopsy of the ileum of a patient with Crohn’s disease (b). Typically, CD4-
expressing Th cells are detected in an around the granulomas, whereas CD20-expressing B cells 
are found to accumulate around the granulomas.35
Naive Th cells have the ability to differentiate in a particular subset through a specific 
cytokine milieu. The major subsets are Th1, Th2, Th17 and regulatory T cells (Treg) 
that are defined by their cytokine profiles and distinct effector functions (Figure 3). 
Th1 cells develop in the presence of IFN-γ and IL-12 and protect against intracellular 
pathogens through the production of IFN-γ and the resulting macrophage 
activation.62,93 Upregulation of cytokines promoting Th1 differentiation have been 
reported in sarcoidosis: IL-2, IL-12, IL-15 and IL-18.94 Th cell involvement in sarcoidosis is 
underpinned by the typical CD4 T-cell lymphopenia in peripheral blood in combination 
with CD4 T-cell infiltrates at the site of inflammation, such as in bronchoalveolar lavage 
fluid (BALF).95,96 Despite these signs of local T-cell hyperactivity, the typical diminished 
cutaneous response to tuberculin is suggestive of T-cell anergy in non-granulomatous 
tissue.97 CD4 T-cell anergy in these patients is likely due to chronic stimulation and results 
from reduced availability of G proteins,98 and reduced NF-κB capacity of these cells.99 
 Patients with Crohn’s disease show overexpression of IL-12 in intestinal tissue 
leading to increased production of IFN-γ.100,101 Still, total blood CD4 T-cell numbers as 
normal, and even an expansion of CD4 memory T cells has been observed in patients 
with active Crohn’s disease.54 The hyperactive state of inflammation in Crohn’s disease 
is further illustrated by mucosal T-cell proliferation and expansion with resistance to 
apoptosis.102 Unlike sarcoidosis and Crohn’s disease, patients with granulomatous CVID 
have low levels of total T cells and naive CD4 T cells.82 This decrease could be related 
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to the immunodeficiency and result from increased T-cell turnover and apoptosis or 
decreased thymic output. It remains unclear whether this decrease also distinguishes 
granulomatous inflammation from Crohn’s disease and sarcoidosis or it is the result of 
migration of T cells from circulation to the affected tissue.
FIGURE 2. Model of the cellular organization of a non-caseating granuloma. Histology of 
granulomatous tissue (e.g. in Figure 1) display the presence of macrophages, epithelioid cells and 
multinucleated giant cells in the core of the granuloma. Th cells are localized in and around the 
granuloma. B cells are rarely seen in granulomatous structures, however they are numerously 
present around granulomas.35 
 In addition to Th1 responses, other Th subsets have been implicated in chronic 
inflammation. It is thought that the initial Th1 response during acute granulomatous 
inflammation shifts to a Th2 response in response when this becomes chronic. The 
production of Th2 cytokines can activate and stimulate fibroblasts and thereby 
contribute to fibrosis.25 
 More recently, Th17 have been shown to be disruptive in chronic inflammatory 
diseases.103 Th17 cells are generated in the presence of IL-6 and TGF-β, and in turn produce 
IL-17 and IL-22 that are major factors in responses against extracellular pathogens and 
fungi (Figure 3). IL-17 was proposed to be a key mediator of inflammation in rheumatoid 
arthritis (RA), yet anti-IL-17 therapy with secukinumab was not effective.104 Therefore, 
the exact role of Th17 cells in inflammatory disorders is not clear and information is 
mostly based on animal models. IL-17 overexpression leads to tissue damage in 
different organs such as lungs, intestines, joints and brain.105 Th17 cells have the ability 
to change to a Th1 phenotype enabling cells to produce both IFN-γ and IL-17 referred to 
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as Th1/Th17 cells.106 The plasticity of Th17 cells enables to further enhance infl ammation 
either directly through the co-production of IL-17 and IFN-γ, or through providing help 
in generation of new pathogenic Th1 cells.107 Moreover, Th17 cells in mouse models 
have recently been shown to adapt into a regulatory phenotype with a change in 
transcriptional profi le and regulatory capacities.108
FIGURE 3. Involvement of CD4+ Th-cell subsets in three chronic granulomatous infl ammatory 
diseases. (a) Model of Th cell maturation into Th1, Th2, Th17 and Treg subsets. Key cytokines 
are depicted. (b) Summary of observations on total CD4+ Th as well as Th1, Th2, Th17 and Treg 
subsets in tissue and blood of patients with sarcoidosis, Crohn’s disease and CVID.95,96,119,120,125-132
 In both sarcoidosis and Crohn’s disease IL-17 expression is increased in infl ammatory 
tissue, concomitant with an increase of Th17 cells in the peripheral blood.29,109 In contrast, 
CVID patients have low Th17 cell numbers in their peripheral blood, which is associated 
with higher numbers of CD21low B cells and lower numbers of memory B cells.110 The 
presence of an expanded CD21low B-cell population in CVID patients is associated with 
higher incidence of non-infectious complications.111 The concomitant decrease in Th17 
cells is suggestive of a combined defect in B- and T-cells in this subset of CVID patients. 
The nature of this defect remains to be determined and could be B- or T-cell intrinsic or 
arise from impaired regulation of Th maturation.110 
 Regulatory T cells (Tregs) are important to dampen immune responses and thereby 
maintain a physiological immune homeostasis and self-tolerance.112 Naive T cells can 
mature into Tregs through expression of the transcription factor Forkhead box p3 
(FoxP3) in the context of TGF-β, subsequently exerting immune regulatory functions 
through production of TGF-β and IL-10.93 Tregs became an intensively studied cell-
population after it was reported that CD4+CD25+ depletion in mice resulted in a variety 
of autoimmunity including gastrointestinal involvement.113 Furthermore, patients with 
immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), 
a genetic disorder caused by mutation in the FOXP3 gene, are aff ected by excessive 
gastrointestinal autoimmunity.114
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 In patients with sarcoidosis, higher frequencies of Tregs have been reported in both 
peripheral blood and BALF with accumulation of Tregs in the vicinity of granulomas.115 
These Tregs inhibited T-cell proliferation, yet several groups confirmed a decreased 
suppressor function on CD4+ cells.115-117 Moreover, Tregs from patients with active 
sarcoidosis were not able to suppress granuloma formation in an in vitro model, while 
Tregs cells from healthy controls were.118 However, it remains unclear whether Tregs were 
defective or were merely exhausted as a result of the continuous inflammation. Patients 
with active Crohn’s disease have decreased Treg numbers in blood, whereas these are 
increased in the intestinal mucosa.119,120 The anti-inflammatory function of Tregs is likely 
to be intact as they have preserved suppressor function,120 and are able to inhibit effector 
T-cell responses.119 However, it has been postulated that effector T cells in the lamina 
propria are unresponsive to the inhibiting effects of Tregs, implicating a contributing 
factor to the chronic inflammatory response.119 Treg function in CVID has been less well 
documented, yet decreased levels of Tregs in blood of CVID patients were specifically 
seen in patients with autoimmune complications.121 Importantly, Tregs require the 
inhibitory receptor cytotoxic T-lymphocyte-antigen 4 (CTLA-4) for suppressive function, 
and mutations in CTLA4 underlie an immunodeficiency in which Tregs have reduced 
suppressive function. These patients often present with granulomatous inflammation 
and intestinal inflammation with similarities to Crohn’s disease.47,122,123 As decreased 
CTLA-4 expression on Tregs has also been reported in patients with sarcoidosis, it is 
possible that defects in CTLA-4 and Treg function contribute to granuloma formation in 
autoinflammatory diseases.124 
B CELLS
The main focus in granulomatous inflammation has previously been directed to 
macrophage and T-cell dysfunction. However, in addition to macrophages and T cells, 
B-cell infiltrates are present in granulomatous tissue of patients with tuberculosis.133 
Furthermore, several studies showed that numerous B cells surround granulomas in 
affected tissues from patients with sarcoidosis as well as Crohn’s disease (Figure 1).35,134,135 
These B cells are likely to be essential for the development of granulomas as indicated 
by two findings: First, patients with CVID can develop granulomas, whereas patients 
with X-linked agammaglobulinemia (XLA) do not.136 CVID and XLA patients both have 
an antibody deficiency due to B-cell dysfunction, but mature B cells are completely 
absent in XLA.137 Second, in a mouse model of oil granulomas the absence of T cells did 
not affect the ability of granuloma formation, whereas granulomas were not formed in 
the absence of B cells.138 Traditionally, B cells are regarded the antibody producing cells 
of the immune system. While this is a major function of B cells, it has become clear that 
B-cell development is a complicated process with many B-cell subsets and functions 
involved. Other B-cell functions include the ability to act as antigen presenting cells, 
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co-stimulate T cells, have regulatory effects and produce cytokines that direct Th subset 
maturation.139 These insights, together with novel possibilities to target B cells with 
biologicals, provide a strong rationale to investigate the role of B cells in granulomatous 
inflammation. 
 Some recent insights have been generated into B-cell abnormalities in sarcoidosis 
and Crohn’s disease. Patients with sarcoidosis carry reduced numbers of IgM, IgG, and 
IgA memory B cells and plasma cells in blood with the exception of CD27-IgA+ memory 
B cells.35,140,141 Despite their reduced numbers, levels of somatic hypermutations in 
immunoglobulin (Ig) gene transcripts of these cells were increased, suggestive of 
chronic activation.35 This is potentially related to serum B-cell activating factor (BAFF), a 
critical factor for mature B-cell survival of which the levels are increased in sarcoidosis 
patients with active disease.140,141 Furthermore, levels of NF-κB transcription factors in B 
cells are reduced and potentially affect B-cell responses and proliferation.142 How these 
B-cell abnormalities affect the formation of persistence of granulomas still needs to be 
determined, yet combined these result do suggest a disturbed B-cell homeostasis.
 Similar to sarcoidosis, patients with Crohn’s disease also display reductions in blood 
IgM memory B-cell numbers.143 However, the B-cell compartment in Crohn’s disease 
has not been as extensively studied as in sarcoidosis and CVID. CVID is characterized 
by hypogammaglobinemia and all patients have reduced blood plasma cells, which in 
many patients is accompanied by memory B-cell defects.111 Furthermore, in subgroups 
of patients, expansions of transitional B cells, as well as CD21low B cells have been 
identified. Many of these abnormalities have formed the basis of flow cytometry-
based classifications.111 However, B-cell phenotypes do not seem to correlate well with 
severity of disease or non-infectious complications. Yet, granulomatous complications 
are found to be associated with lower numbers of Ig switched memory B cells.60,111 Still, 
it remains unclear if these reductions are related to the immunodeficiency or the result 
of migration towards the sites of granulomatous inflammation. Patients with mutations 
in ICOS and TACI gene can develop granulomatous complications and autoimmunity in 
general.144 These genes are involved in different pathways of B-cell survival and T cell-
dependent or -independent antibody responses. With the implementation of whole 
exome sequencing, the genetics of CVID unravels rapidly. Possibly, this will provide 
better insights into affected processes and will help to dissect the mechanisms that, 
when impaired, result in granuloma formation. 
 Although it remains unclear how B cells contribute to disease pathogenesis, the 
common signs of chronic activation of B cells in granulomatous autoinflammatory 
diseases is suggestive of their role in ongoing inflammation. The systemic B-cell 
abnormalities could provide good markers for disease and treatment monitoring. 
Moreover, disease-specific abnormalities could provide more insight into pathogenesis 
and starting points for novel therapeutic approaches.
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THERAPEUTIC IMPLICATIONS
REMISSION OR FIBROSIS?
In many patients granulomas persist and lead to organ damage due to fibrosis. Fibrosis 
is therefore a common problem in sarcoidosis and Crohn’s disease,16 145 The impact of 
granulomas on permanent organ damage in CVID patients is currently unknown due 
to the complications of recurrent respiratory infections that lead to bronchiectasis 
in 23% of patients.36 Despite fibrosis leading to increased morbidity and mortality,25 
to date, therapies targeting inflammatory pathways do not resolve or delay the 
process. Moreover, it is not yet possible to identify which patients will develop fibrotic 
complications.10 Therefore, exploring fibrotic pathways may lead to new and much 
needed therapies to prevent irreversible organ damage. 
MECHANISM OF CURRENT THER APIES
First and second line medication to treat patients with chronic inflammatory disease 
are corticosteroids and immunosuppressives such as methotrexate and azathioprine. 
Corticosteroids have anti-inflammatory properties though inhibition of leukocyte 
migration and pro-inflammatory cytokine production (esp. TNF-α and IFN-γ).146 
Methotrexate inhibits the purine metabolism and azathioprine purine synthesis, 
which both lead to decreased lymphocyte proliferation and cytokine release.147 While 
these therapies are administered to suppress pro-inflammatory cytokines through 
inhibiting T-cell responses, these immunosuppressive drugs also affect the B-cell 
compartment.148,149 
 With the introduction of biological therapies, a third line of treatment has become 
available, of which TNFα-blockers are most notable. The most widely used TNFα-blockers 
are antibodies against TNFα (infliximab and adalimumab), which have proven to be 
effective in Crohn’s disease and sarcoidosis (Figure 4).150,151 This treatment specifically 
disrupts the granuloma structure. As this can result in reactivation of latent tuberculosis, 
all patients need to be intensively screened for tuberculosis prior to treatment with 
TNFα-blockers.152 TNF-blockers infliximab and etanercept have proven to be beneficial 
in some patients with granulomatous CVID.60,153 Etanercept is a recombinant TNFα 
receptor fused to an Ig constant region and is often used to treat RA.154 Importantly, 
etanercept is not effective in sarcoidosis and Crohn’s disease, and can even lead to 
increased disease activity in these disorders.155,156 This might be related to its different 
biological properties as opposed to anti-TNF antibodies: 1) etanercept binds only to 
soluble trimeric and not monomeric soluble TNF-α; 2) Etanercept has low affinity to 
transmembrane TNF;157 3) Etanercept binds to both TNF-α and lymphotoxin alpha (LTα), 
a cytokine that is crucial for secondary lymphoid organ development, IgA regulation and 
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T-cell gut homing.158 These abilities could explain the reduced effectivity of etanercept 
in Crohn’s disease and sarcoidosis, as well as observed disease complications. Treatment 
with TNFα-blockers also affects the blood B-cell compartment in patients with Crohn’s 
disease and sarcoidosis.145,159 It remains to be determined if this is an indirect effect 
following modulation of inflammation or if this is through direct binding to TNFRII that 
is expressed on B cells. 
 Targeting of T cells in granulomatous diseases has yielded mixed results. A clinical 
trial for treatment of patients with Crohn’s disease with abatacept was ineffective.160 
Abatacept is a recombinant fusion protein of CTLA4 with an immunoglobulin. CTLA-4 
inhibits T-cell activation by binding to CD28 on T cells. Abatacept has shown beneficial 
effects in RA patients,161 and in animal models of intestinal inflammation. These results 
illustrate that, in spite of unravelling underlying immune mechanisms, translation into 
effective therapies for human autoinflammatory disease remains challenging.
 Targeting of Th17 responses have also been studied. However, blocking IL-17 with 
secukinumab was ineffective in patients with Crohn’s disease,162 whereas treatment with 
brodalumab an anti-IL-17 receptor monoclonal antibody, even resulted in exacerbation 
of Crohn’s disease.163
 Ustekinumab, a monoclonal antibody against both IL-12 and IL-23, resulted in 
a clinical response in patients with refractory Crohn’s disease164 and is currently 
implemented in patients who are resistant to TNFα-blockers.165 However, ustekinumab 
did not show therapeutic efficacy in sarcoidosis patients.166 
 Patients with Crohn’s disease do show a good response to treatment with 
vedolizumab, a humanized monoclonal antibody that binds to integrin α₄β₇.167 As α₄β₇ 
specifically mediates gut homing, it can selectively inhibit intestinal inflammation. 
Because granulomas in patients with sarcoidosis and CVID more frequently present in 
other tissues than the gut, vedolizumab is likely to have limited effects in these diseases. 
Targeting of B cells with rituximab has shown promising results in granulomatous 
CVID.60 Rituximab is a humanized anti-CD20 antibody that depletes all naive and 
memory B cells.168 The efficacy of rituximab in sarcoidosis is still unclear: several case 
reports show proven effectivity, however, one small prospective study with 10 patients 
only 5 of them showed a marginal (>5%) improvement of respiratory function.169 In 
contrast, a patient with Crohn’s disease displayed disease exacerbation following 
treatment with rituximab, implying a protective role for B cells in Crohn’s disease.170 
These different outcomes of rituximab treatment highlight the complexity of the 
underlying inflammatory processes. 
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AIMS AND OUTLINE OF THIS THESIS
Granulomatous inflammation consists of a complex interplay between macrophages, 
different types of T cells and B cells. Granulomas are the hallmark of sarcoidosis, but are 
also present in a subgroup of patients with Crohn’s disease. The immunopathophysiology 
of granulomatous inflammation is the backbone of this thesis. By unraveling the 
different components in tissue and blood we aim to eventually translate the bench 
into bedside to improve diagnostics, identify biomarkers for therapy and search for 
new therapeutic targets in these chronic inflammatory diseases. In Chapter 2 the 
hypothesis is that B cells are involved in (granulomatous) inflammation in Crohn’s 
disease. Therefore, we study whether B cells are, in accordance with sarcoid granulomas, 
present in the intestinal tissue of patients with Crohn’s disease, and if patients have 
systemic abnormalities in their blood B-cell compartment. In Chapter 3, the presence 
of B cells around granulomas is utilized to study if immunohistochemical stainings 
of biopsies for B cells can be used as a diagnostic tool to increase the sensitivity for 
detection of granulomas and improve differential diagnosis between ulcerative colitis 
and Crohn’s disease. Chapter 4  continues to dissect the role of B cells in sarcoidosis and 
its possible use as biomarkers for treatment outcome. Therefore, we analyzed the effect 
of successful infliximab therapy on blood B –and T-cell subsets, serum immune markers 
and infliximab trough levels in patients with sarcoidosis aiming to find biomarkers for 
successful outcome of therapy. In Chapter 5 we aim to elucidate the effect of infliximab 
on patients with neurosarcoidosis, a rare form of sarcoidosis which can be difficult to 
treat. As evidence in literature is limited to small case reports, we  describe a multicenter 
cohort study of patients with neurosarcoidosis treated with infliximab. Chapter 6  is 
the Discussion of this thesis and comprises the research results of these studies and 
compares results from both sarcoidosis and Crohn’s disease. Furthermore, it shows 
results from a small trial of patients with chronic sarcoidosis treated with sandostatin 
therapy. Eventually, future therapeutics will be discussed. 
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ABSTRACT
Background and aims
B-cell depletion can improve a variety of chronic inflammatory diseases, but does not 
appear beneficial for patients with Crohn’s disease. To elucidate the involvement of B 
cells in Crohn’s disease, we here performed an ‘in depth’ analysis of intestinal and blood 
B-cells in this chronic inflammatory disease.
Methods
Patients with Crohn’s disease were recruited to study B-cell infiltrates in intestinal 
biopsies (n=5), serum immunoglobulin levels and the phenotype and molecular 
characteristics of blood B-cell subsets (n=21). The effects of infliximab treatment were 
studied in 9 patients.
Results
Granulomatous tissue showed infiltrates of B lymphocytes rather than Ig-secreting 
plasma cells. Circulating transitional B cells and CD21low B cells were elevated. IgM 
memory B cells were reduced and natural effector cells showed decreased replication 
histories and somatic hypermutation (SHM) levels. In contrast, IgG and IgA memory B 
cells were normally present and their Ig gene transcripts carried increased SHM levels. 
The numbers of transitional and natural effector cells were normal in patients who 
responded clinically well to infliximab. 
Conclusions
B cells in patients with Crohn’s disease showed signs of chronic stimulation with 
localization to granulomatous tissue and increased molecular maturation of IgA and 
IgG. Therapy with TNFα-blockers restored the defect in IgM memory B-cell generation 
and normalized transitional B-cell levels, making these subsets candidate markers for 
treatment monitoring. Together, these results suggest a chronic, aberrant B-cell response 
in patients with Crohn’s disease, which could be targeted with new therapeutics that 
specifically regulate B-cell function. 
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ab therapy
INTRODUCTION
The human intestinal tract contains a complex interplay between commensal bacteria, 
food antigens and the host immune system to limit inflammation, while preventing 
the translocation of intestinal microbiota. This delicate balance is disrupted in Crohn’s 
disease, a chronic inflammatory disease characterized by transmural inflammation of the 
gastrointestinal tract (1). The pathogenesis of Crohn’s disease is of complex nature with 
genetic susceptibility and dysfunction of mucosal immunity that result in a disturbed 
intestinal balance (2). An abnormal Th1 response is induced by dendritic cells that 
present commensal bacteria (3), which leads to overproduction of pro-inflammatory 
cytokines, including interferon-γ (IFN-γ) and tumor necrosis factor-alpha (TNF-α). In 
combination with impaired regulatory T cell (Treg) function, this is thought to lead to 
persistent inflammation in Crohn’s disease (4). 
 In about one third of patients, histopathology of biopsy specimens show granulomas; 
a feature supporting the diagnosis Crohn’s disease (5, 6). As early as in the 1980s, a corona 
of B lymphocytes around the granuloma was described (7), which parallels granulomas 
in patients with sarcoidosis (8). Furthermore, similar to patients with sarcoidosis (8-10), 
patients with Crohn’s disease show signs of abnormal B-cell responses that include 
increased numbers of immunoglobulin (Ig)-secreting cells (11), and serum antibodies 
against Saccharomyces cerevisiae antibodies (ASCA) and neutrophils (ANCA) (12, 13). 
Being good antigen-presenters and cytokine producers, B cells can regulate T cell 
responses (14). Indeed, B-cells were found to affect regulatory T cell through production 
of IL-10 (15). However, it is not been clarified how B cells influence disease activity, 
because studies in murine models have reported ambiguous results, supporting either 
a suppressive or exacerbating role in gut inflammation (16-18). 
 In spite of a potential role of B cells in chronic inflammation, circulating naive B cells 
and class-switched memory B cells were found to be normally present in peripheral 
blood of patients with Crohn’s disease, whereas IgM memory B cell numbers were 
reduced (19). IgM memory cells consist of two types; IgM-only (CD27+IgM+IgD-) and 
natural effector B cells (CD27+IgM+IgD+). While all IgM-only memory B cells originate 
from germinal center responses, about one-third of natural effector cells in healthy 
controls are derived from T-cell independent responses in the marginal zone of the 
spleen (20-22).  
 These contrasting observations did not clarify the exact role of B-cell involvement 
in Crohn’s disease. Therefore, we here aimed to elucidate their contribution in Crohn’s 
disease through detailed molecular analysis and immunophenotyping in locally 
inflamed intestinal tissue and in peripheral blood. Moreover, to evaluate candidate 
B-cell markers for monitoring therapeutic efficacy, we studied, the B-cell compartment 
after anti-TNFα therapy in patients treated with infliximab.
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MATERIALS AND METHODS
PATIENTS
Clinical data and blood samples of 30 patients with Crohn’s disease and 28 healthy 
controls were collected after written informed consent was obtained (Table 1). In 
addition, surplus tissue materials from diagnostic colon biopsies of 5 patients were 
retrospectively analyzed. This study was performed according to the Declaration of 
Helsinki. This study was approved by the Medical Ethics Committees of Erasmus MC 
(ethics approval number MEC-2011-060) and Alfred Hospital (ethics approval number 
472/15) and patients were recruited from the Ikazia Hospital in Rotterdam (The 
Netherlands) and the Alfred Hospital in Melbourne (VIC, Australia).
IMMUNOHISTOCHEMISTRY OF GUT TISSUE BIOPSIES
Tissue slides were stained with hematoxylin and eosin. Immunohistochemistry was 
performed using monoclonal antibodies against CD4 (clone SP35), CD3 (2GV6), CD79a 
(SP18; all from Ventana, Tucson, AZ), CD8 (C8/144 B), CD20 (L26), IgG (rabbit polyclonal; 
all from Dako Cytomation, Glostrup, Denmark), IgA (rabbit polyclonal, Cell Marque, 
Rocklin, CA), CD138 (B-A38; IQ Products, Groningen, The Netherlands), and IgM (IgM88; 
Biogenex, Fremont, CA).
FLOWC YTOMETRY AND CELL SORTING  
OF BLOOD LYMPHOC YTES
Absolute counts of blood CD4 and CD8 T cells, CD16+/56+ natural killer cells, and CD19+ B 
cells were obtained with a diagnostic lyse-no-wash protocol. Eight-color flow cytometric 
analysis was performed as described previously to detect transitional, naive mature, six 
memory B cell subsets, plasmablasts and CD21lowCD38dim cells (Supplemental Figure 1) 
on a 3-laser FACS LSRII with standardized configuration according to Euroflow protocols 
(BD Biosciences, San Jose, CA) (23).  Detailed analysis of B cell subsets was performed 
with IgM-HorV450 (G20-127; BD), IgD-biotin (IA6-2), IgG-PE (G18-145), CD19-PE-Cy7 
(SJ25C1), CD19-PerCP-Cy5.5 (SJ25C1), CD21-PE-Cy7 (B-ly4), CD27-PerCP-Cy5.5 (L128), 
CD27-APC (L128), CD38-APC-H7 (HB7; all from BD Biosciences, San Jose, CA, USA) and 
IgA-FITC (IS11-8E10; Miltenyi-Biotec GmbH, Germany) (24). Biotinylated antibodies were 
visualized with streptavidin-Pac.Orange (Invitrogen).
 Naive mature and natural effector B cells were high-speed cell sorted to greater than 
95% purity on a FACSAria I (BD Biosciences), as described previously (25).
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QUANTIFIC ATION OF SERUM IMMUNOGLOBULIN LE VELS
Serum IgM, IgG, and IgA levels were measured with an immunoturbidimetric method 
(Hitachi Analyzer; Roche, Basel, Switzerland). IgG and IgA subclasses were determined 
using the immunonephelometric method (Sanquin, Amsterdam, The Netherlands).
MOLECUL AR ANALYSIS OF REPLIC ATION HISTORY AND 
IMMUNOGLOBULIN HEAVY CHAIN (IGH) TR ANSCRIPTS
IGHA and IGHG transcripts were amplified from PBMC cDNA of patients with Crohn’s 
disease (n=4) and healthy controls (n=4). IGHV3 and IGHV4 leader primers and consensus 
Cα or Cγ reverse primers were used (22). 
 DNA was isolated from sorted naive mature and natural effector B cells of patients 
with Crohn’s disease (n=4) to analyze the replication history with the kappa-deleting 
recombination excision circle assay as described previously (25). In addition, IGH 
gene rearrangements were amplified from DNA of sorted natural effector B cells. 
PCR products were cloned into the pGEM-T easy vector (Promega, Madison, WI) and 
prepared for sequencing on an ABIPRISM 3130XL (Applied Biosystems, Carlsbad, CA). 
Obtained sequences were analyzed with IMGT database (http://imgt.cines.fr), Joinsolver 
(https://joinsolver.niaid.nih.gov) and Bayesian estimation of Antigen-driven SELectIoN 
(BASELINe; http://selection.med.yale.edu/baseline/). IgA and IgG receptor subclasses 
were determined using the IGH reference sequence (NG_001019).
STATISTICS
Statistical analyses were performed using the Mann-Whitney test (SPSS version 18.0), 
χ2 test or Spearman correlation as indicated in Figure legends. A P-value <0.05 was 
considered statistically significant.
RESULTS
CLINIC AL AND BASIC IMMUNOLOGIC AL  
CHAR AC TERIZ ATION OF PATIENTS
In this study, 30 patients with biopsy-confirmed Crohn’s disease (11 males) were 
included with a mean age of 38.5 yr (range 22-62 yr; Table 1). Patients 1-21 had not 
received immunosuppressive drugs for at least three months prior to inclusion. Of these 
21 patients, 12 patients received 5-ASA medication, 9 were without any medication 
for Crohn’s disease and 11/21 patients had received systemic immunosuppressive 
medication in the past. All patients had clinically mild to moderate disease without a 
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need for systemic immune suppressive treatment at the time of study inclusion. Patients 
22-30 received infliximab treatment for >6 weeks at study inclusion and were clinically 
good responders. In 9/30 patients, granulomas were previously detected in ileal or 
colon biopsies and 16/30 patients had a history of surgical resection of the gut. The 
average duration of disease at study inclusion was 10.3 years (range 0-34 year). Mean 
values of B, T and NK cells, as well as mean serum IgM, IgG and IgA levels were within the 
normal range. The average IgA2 serum level of the patients was increased as compared 
to controls (0.7 g/L; range 0.1-2.4; normal range 0.1-0.6), with 9/23 patients having levels 
above the normal range.
B CELL LOC ALIZ ATION AROUND GR ANULOMAS 
All colon tissue biopsies showed inflammation compatible with Crohn’s disease. 
Haematoxylin and eosin-staining of the granulomas did not show any sign of necrosis. 
T cells were easily detectable with stainings for CD3, CD4 or CD8, and were located 
throughout the inflamed tissue, both inside and outside the granulomas (Figure 1). 
In agreement with previous observations (7), CD4+ T cells were more numerous than 
CD8+ T cells with a ratio of 4:1. CD20+ B cells were detectable in intestinal biopsies, 
but these were restricted to normal lymphoid follicles and were very sparse in the 
non-granulomatous inflamed tissue (Figure 1). However, directly surrounding the 
granulomas, B cells were numerous as visualized with CD20 or CD79a stainings (Figure 1). 
FIGURE 1. B-cells accumulate around granulomas in affected colon tissue in Crohn’s disease. 
A, Representative images of colon biopsies with granulomas and non-granulomatous tissue in two patients 
with Crohn’s disease. B, Magnifications of granulomatous tissue from panel A.
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Plasma cells are abundantly present in the human gut tissue of healthy individuals, with 
IgA as their major product (26, 27). Tissue sections from our patients with Crohn’s disease 
showed numerous CD138+ plasma cells, both in inflamed and in non-inflamed regions. 
These plasma cells were not specifically localized near granulomas, but were distributed 
over the gut tissue with the majority secreting IgA and smaller fractions IgG or IgM 
(Supplemental Figure 2). The specific localization of B cells surrounding granulomas 
indicates involvement of B cells in the immunopathogenesis of granulomatous 
inflammation in Crohn’s disease.
ABNORMALITIES IN BLOOD B CELL SUBSETS  
IN PATIENTS WITH CROHN’S DISEASE
To study whether local intestinal inflammation affected B cells systemically, we studied 
blood B-cell subsets in 21 patients with Crohn’s disease. Flowcytometric analysis 
revealed normal numbers of total CD19+ B-cells in patients (n=21) as compared with 
healthy controls (n=28). Further subsetting of these CD19+ B cells (Figure 2A) revealed 
significantly increased numbers of CD38highCD24high transitional B cells (P=0.009), while 
CD27-IgD+ naive mature B cells were normally present (Figure 2B). Within the antigen-
experienced B-cell compartment, IgM+  memory B cells were low with CD27+IgM+IgD+ 
natural effector B cells being significantly decreased (P<0.001), IgM-only B cells 
(CD27+IgM+IgD-) not-significantly decreased (P = 0.06). The numbers of class-switched
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FIGURE 2. Composition of the blood B-cell compartment in patients with Crohn’s disease. 
A. Schematic overview of peripheral B-cell subsets. B. Average numbers of blood B cell subsets of 21 patients 
affected with Crohn’s disease (black bars) and 28 healthy controls (light grey bars). C. Distribution of IgM, 
IgA and IgG within CD21low in patients and controls D. Total CD21low B cells in relation to disease duration. 
Statistical analyses were performed with the Mann-Whitney test or Spearman correlation; *, P<0.05; **, 
P<0.01.
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B cell subsets (CD27+IgG+, CD27-IgG+, CD27+IgA+ and CD27-IgA+) and plasma blasts were 
similar between patients and controls. Large fractions of the patients’ B cells showed 
low CD21 expression levels and these numbers were significantly higher than in healthy 
controls (P<0.0001). The increase was not related to disease duration (P=0.10; Figure 
2D), and a large fraction of these CD21low B cells were Ig class switched to IgA or IgG, 
suggestive of an origin from antigen-experienced B cells (Figure 2C). 
 To study whether the abnormalities in transitional, natural effector and CD21low B 
cells were associated with surgical treatment and current or past medication, additional 
analyses were performed following division of the total 21 patients into patients with 
(n=10) or without surgical resection (n=11), into patients currently treated with (n=12) 
or without 5-ASA medication (n=9) and patients with (n=11) and without (n=10) a 
history of systemic medication. All three analyses revealed similar patterns for the 
separate patient groups (Supplemental Figure 3), thereby excluding differential effects 
of these treatments on the blood B-cell compartment.
IMPAIRED GENER ATION OF NATUR AL EFFEC TOR B CELLS 
Our flowcytometric analysis showed decreased numbers of natural effector B cells 
in peripheral blood of patients with Crohn’s disease, line with previous findings (19). 
To study whether the decline was due to impaired generation of these cells, we 
analyzed the replication history and somatic hypermutation (SHM) levels in purified 
cells from four patients (Patient 15, 16, 18 and 19). Naive mature B cells of patients 
and controls showed a similar replication history of 1-2 cell divisions (25). However, 
the patients’ natural effector B cells showed a replication history of only 2 cell division 
versus 9 in controls (P=0.002; Figure 3A). These natural effector B cells carried diverse 
IGH gene rearrangements, with shorter IGH-CDR3 sizes than in naive B cells, which is 
a typical feature of antigen-experienced B cells (Figure 3D) (22). Still, the majority of 
rearrangements amplified from the patients carried unmutated IGHV genes (28 of 51 
unique rearranged IGHV). Moreover, the overall SHM levels were significantly lower 
than in controls (P<0.0001; Figure 3B), and hardly higher than in naive mature B cells. 
The few mutations in patients’ Ig genes were normally targeted (Supplemental Table 1). 
However, on top of their low numbers, the mutations in complementarity determining 
regions (CDR) were not selected for amino acid replacements as is typical seen in healthy 
controls (P<0.0001; Figure 3C). Thus, IgM+IgD+-expressing memory B cells in patients 
with Crohn’s disease are not only decreased in number, they also display a defects in 
replication history and SHM.
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FIGURE 3. Replication history and SHM levels in IGHV genes of natural effector B cells.
A. Replication history of naïve and natural effector B cells as assessed using the KREC assay (25).  B. IGHV 
mutation frequencies in rearranged IGH genes of natural effector B cells in patients and controls (total 
numbers of sequences indicated between brackets). Grey dots represent unique sequences; red lines 
represent median values. C. Selection for replacement mutation in IGHV-CDR (red line) and IGHV-FR regions 
(blue lines) as determined with the BASELINe program (28, 29). Solid lines represent patients; dashed lines 
represent healthy controls. Selection Strengths >0 indicate positive selection. D. IGH-CDR3 size distributions. 
All individual sizes are indicated as grey dots, red lines representing median values. The dashed line represents 
median values for centroblasts and centrocytes. Sorted cells were analyzed from patients 15, 16, 18 and 19. 
Controls were published previously (30, 31). Statistical analysis was performed with the Mann-Whitney test; *, 
P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.
INCREASED SHM LE VELS IN IG GENES  
OF SWITCHED MEMORY B CELLS
In contrast to IgM+ memory B cells, Ig class-switched memory B cells were normally present 
in blood of patients with Crohn’s disease (Figure 2) (19). Their IgA and IgG transcripts 
displayed a diverse usage of IGHV3 and IGHV4 subgroups with CDR3 size distributions 
similar to those of controls and typical for antigen-experienced B cells with a median of 
15 amino acids (Supplemental Figure 5). These transcripts showed high levels of SHM, 
which appeared to be normally targeted to the typical sequence motifs (Supplemental 
Table 1). In addition, nucleotide substitution spectra and transition/transversion ratios 
did not differ between patients and controls. To determine whether these transcripts 
showed signs of antigen selection, we analyzed selection for replacement mutations 
using the BASELINE program. Similar to healthy controls, sequences derived from 
patients with Crohn’s disease showed positive selection for replacement mutations in 
CDR and negative selection in framework regions (FR) (Supplemental Figure 5C). 
 To study whether the high SHM levels were the result of altered IgG and IgA subclass 
usage, we analyzed these in the rearranged transcripts (32, 33). Patients with Crohn’s 
disease showed increased IgA1 and IgG2 usage, to the expense of IgA2 and IgG3 (Figure 
4B). Still, these altered distributions did not underlie the difference in SHM levels. IgA1 
and IgA2, as well as IgG1 and IgG2 transcripts of the patients carried more SHM than 
those of controls (Figure 4C). More specifically, a substantial fraction of IgA2 transcripts 
from controls was hardly mutated, and this fraction was nearly absent in patients with 
Crohn’s disease. In conclusion, patients with Crohn’s disease show increased levels of 
SHM with otherwise normal targeting and selection for replacement mutations. This 
was independent of the concomitant reduction in IgA2 and IgG3 subclass usage.
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FIGURE 4. IgA and IgG subclass analysis. 
A. Schematic representation of the constant region of the human IGH locus. B. Distribution of IgA and IgG 
subclass use in switched transcripts of healthy controls and patients with Crohn’s disease. Total numbers of 
analyzed sequences are indicated in the middle of the plots. χ2 Test was performed to analyze differences 
in distributions. C. Combined IGHV mutation frequencies in IgA and IgG transcripts in patients and controls 
(total numbers of sequences indicated between brackets). Grey dots represent unique sequences; red lines 
represent median values. Statistical analysis was performed with the Mann-Whitney test; *, P<0.05; **, P<0.01; 
***, P<0.001. 
NORMALIZ ATION OF BLOOD B-CELL SUBSETS  
IN INFLIXIMAB-TREATED PATIENTS
Previous observations indicated normalization of spleen function and levels of 
circulating IgM+ memory B cells in Crohn’s disease patients following infliximab therapy 
(34).  To study whether successful treatment normalized the total peripheral B-cell 
compartment, we phenotyped blood B cells in 9 patients that were receiving infliximab 
(patients 21-30; Table 1). Infliximab was administered once every eight weeks for a long 
period of time (range 8 months-10 years), and all patients were in clinical response after 
treatment. In contrast to patients not receiving infliximab, transitional B cells and natural 
effector B cells were normalized to levels comparable with healthy controls (Figure 5A). 
However, IgM-only B cell numbers were still low, and CD21low B cells remained increased 
as compared to healthy controls. Within CD21low, the IgM, IgA and the IgG expressing 
subsets were higher in number than in healthy controls. Patients treated with infliximab 
showed a further increase in the IgA subset, with an accompanied (non-significant) 
decrease in IgM (Figure 5B). A substantial fraction of the CD21low subset expressed 
CD27, and CD27+ and CD27- was similar between controls and patients (Supplemental 
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Figure 4A). In absolute numbers, both fractions were elevated in patients. Thus, patients 
with Crohn’s disease show systemic abnormalities in their B cell compartments, which 
appear almost completely recovered by successful infliximab treatment.
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FIGURE 5. Effects of infliximab on blood B-cell and CD21low compartment. 
A. Blood B-cell compartments in patients under treatment with infliximab. B. Absolute total numbers of IgM, 
IgA and IgG with low CD21 expression in controls, patients and patients under treatment with infliximab.  Bars 
represent mean values ±SEM. Statistical analysis was performed with the Mann-Whitney test; *, P<0.05; **, 
P<0.01; ***, P<0.001. 
DISCUSSION
In this study, we demonstrate that patients with Crohn’s disease have an infiltration of 
B cells around granulomas and an altered B-cell compartment in the peripheral blood. 
While IgM memory B-cell formation was impaired, Ig class switched B cells showed 
molecular sings of chronic stimulation. Importantly, alterations in the peripheral B-cell 
compartment normalized after treating inflammation effectively with TNFα-blockers.
 Our findings of B cells surrounding granulomas in Crohn’s disease extend previous 
observations from the 1980s (7), and more recent ones from pediatric patients with 
Crohn’s disease with NOD2 gene mutations (35). These B cells appear to be lymphocytes 
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and not plasma cells and localize specifically around the granulomas. Still, the origin and 
types of B cell subsets remain unclear. Large amounts of B cells were also found to be 
present around the granulomas in sarcoidosis (8), and consequently researchers have 
evaluated treatment with anti-CD20 therapy (e.g. with rituximab) (36). It is possible that 
these B cells are crucial for the formation of granulomas. This is supported by studies in 
mouse models that were capable of granuloma formation in the absence of T cells, but 
not in the absence of B cells (37). Furthermore, granulomas are found in a large fraction 
of patients with antibody deficiencies in the presence of B cells (esp. Common Variable 
Immunodeficiency; CVID), while these have not been reported in patients with X-linked 
agammaglobulinemia, who lack circulating B cells due to a block in differentiation of 
precursor B cells (38). How these B cells would function in the formation of granulomas 
remains unclear. B-cell depletion therapy seems to induce and exacerbate colitis (39, 
40), while immunoglobulin substitution can induce rapid dampening of inflammation 
in patients with Crohn’s disease (41). Thus, it is well-possible that the local B cells have a 
regulatory function to control inflammation (42).
 Our patients showed alterations in blood B cell subsets in absence of systemic 
immunosuppressive therapy. One of these was a strong reduction in circulating IgM+ 
memory B cells, which was the result of impaired generation rather than increased loss, 
because the few remaining IgM memory ‘natural effector’ B cells showed severely reduced 
replication history, SHM levels and absence of selection for replacement mutations 
in CDR. The loss of IgM memory B cells was previously attributed to impaired spleen 
function (19). However, a large fraction of these ‘natural effector’ B cells is dependent on 
T-cell help and more likely originates from germinal center reactions (21, 22). Considering 
the strongly decreased natural effector B-cell numbers in our patients, it is therefore 
likely that in addition to IgM responses in the spleen, also germinal center responses 
are impaired in the generation of IgM+ memory B cells in patients with Crohn’s disease.
 In contrast to IgM+ memory, transitional and CD21low B-cell numbers were increased 
in our patients. Higher numbers of transitional cells were previously observed in 
patients with other chronic inflammatory diseases, including sarcoidosis and SLE (8, 
9, 43). This increase could reflect increased B-cell output from the bone marrow. Still, 
this did not result in higher numbers of circulating mature B cells and might be due to 
inability of these transitional B cells to further mature. CD21low B cells are peculiar cells 
that have been described to be functionally anergic with the downregulation of CD21 
suppressing their responsiveness and decreasing their survival (22, 44). The increase 
in transitional B cells could therefore be a compensation for the loss of mature B cells 
through downregulation of CD21. While CD21low B cells are scarce in healthy controls, 
their numbers are increased during infections, autoimmune diseases (22, 45, 46), CVID 
with autoimmunity and Down syndrome (44, 46-48). As these cells were not increased 
in patients with sarcoidosis (8), CD21low B cells could represent a marker of distinct 
pathophysiology between these two granulomatous inflammatory diseases. 
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 The numbers of natural effector B cells normalized under infliximab therapy, an 
observation that was made previously as well and was associated with restoration 
of spleen function (34).  More recently, Li and colleagues also confirmed these low 
numbers of pre-switched memory B cells in inflammatory bowel disease and its 
restoration with TNFα-blockers (49). Thus, infliximab therapy either directly or indirectly 
by dampening inflammation restores IgM memory in patients with Crohn’s disease. 
Whether natural effector B cells can predict successful therapeutic outcome would need 
to be investigated in future studies with longitudinal follow-up of patients. Treatment 
with 5-ASA did not show this effect on the B-cell compartment. This could be due to 
the difference in therapeutic mechanisms or the merely local application of 5-ASA 
medication in contrast to systemic effects of infliximab. Alternatively, infliximab can 
induce and maintain mucosal healing (50). Furthermore, the CD21low population was 
the aberrant B-cell subset in our patient group that did not normalize during treatment 
with infliximab, suggesting that the process to downregulate CD21 is either not affected 
by TNFα-blockers, or is maintained to dampen inflammation. 
 A large fraction of CD21low B cells was Ig class switched, suggesting their origin from 
memory B cells. Indeed, the increased SHM levels in IgA and IgG transcripts reflected 
abnormally high or strong activation of these class-switched memory cells. SHM levels 
are tightly regulated and even in individuals continuously exposed to parasites these 
are not increased (32, 33). Notably, IgA transcripts in patients with Crohn’s disease 
were highly mutated, and the frequencies of hypomutated transcripts were lower 
than in healthy controls. A substantial fraction of blood IgA+ memory B cells carries 
polyreactive immunoglobulins. These are typically highly mutated and bind strongly 
to mucosa-colonizing bacteria (51). Despite the high SHM levels, the Ig transcripts from 
patients with Crohn’s disease did not show signs of additional selection for replacement 
mutations in CDR regions. This is suggestive of a lack in additional affinity maturation, 
and the result of abnormal and chronic activation in patients with Crohn’s disease and 
in previously studied sarcoidosis patients (8). Despite the signs of chronic stimulation, 
total numbers of IgA and IgG memory B cells were not increased in blood of patients 
with Crohn’s disease. This is potentially due to their infiltration into tissue. Alternatively, 
these cells could be silenced by downregulating CD21 expression. This would make the 
cells more susceptible to cell death and would explain, at least in part, the expansion of 
the CD21low B cell population. 
 Our study demonstrates distinct B-cell maturation alterations in both local inflamed 
tissue and in peripheral blood of patients with Crohn’s disease. These effects were 
independent of 5-ASA treatment or past systemic therapy and surgical resections, 
and seemed homogeneous in our study population. Especially the Ig class-switched B 
cells show signs of chronic stimulation, while the generation of IgM memory B cells is 
impaired. Moreover, clinical improvement is heralded by normalization of the elevated 
circulating transitional and natural effector B cells in response to TNFα-blockers. Thus, 
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through dissection of the local and systemic B cell compartments, this study provides 
new insights into their role in chronic inflammation. Specifically, blood B-cell deviations 
could represent good markers to predict treatment success before or early after start of 
infliximab or other novel therapeutics in Crohn’s disease.
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SUPPLEMENTAL FIGURE 1. Flowcytometric gating strategy for the described B-cell subsets in 
a representative healthy control (A) and a patient with Crohn’s disease (B).  B cells were gated 
within CD19 gate with two naive subsets; transitional cells and naive mature cells, six memory 
cells, plasma cells and CD38dim C21low cells. Unswitched memory B cells were separated into natural 
effector (CD27+IgM+IgD+) and IgM-only cells (CD27+IgM+IgD-). IgA and IgG switched memory B 
cells were further separated into CD27- and CD27+ subsets.
SUPPLEMENTAL FIGURE 2. Immunohistological analysis of plasma cells in sections with (A) and 
without granulomas (B) in colon biopsies of two patients with Crohn’s disease. Both tissues show 
presence of CD138+ plasma cells, with the majority producing IgA, to a lesser extent IgG and low 
frequencies IgM. 
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SUPPLEMENTAL FIGURE 3. Blood B-cell compartments in (A) patients with a history of resection, 
(B) patients under treatment with 5-ASA medication, and (C) patients with a history of systemic 
immunosuppressive medication. Bars represent mean values ±SEM. No significant differences 
were found for any subset between Crohn’s patients with or with the indicated mode of treatment 
(Mann-Whitney U test).
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SUPPLEMENTAL FIGURE 4. CD21low population in controls, patients on infliximab and Crohn’s 
disease patients without systemic treatment. A, Relative distribution of CD27- and CD27+ cells 
within the CD21low compartment. B, Absolute cell counts of CD27- and CD27+ cells within CD21low 
compartment. Bars represent mean values ±SEM. 
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SUPPLEMENTAL FIGURE 5. Somatic hypermutation analysis of IgM, IgA and IgG B cells. Somatic 
hypermutation levels in IGHV genes of rearranged IgA (A) and IgG (B) transcripts of four patients 
with Crohn’s disease and four healthy controls. Grey dots represent unique sequences; red lines 
represent median values. C, Selection for replacement mutation in IGHV-CDR (red line) and IGHV-
FR regions (blue lines) as determined with the BASELINe program (28, 29). Solid lines represent 
patients; dashed lines represent healthy controls. Selection Strengths >0 indicate positive 
selection. D, IGH-CDR3 size distributions. All individual sizes are indicated as grey dots, red lines 
representing median values. The dashed line represents median values for centroblasts and 
centrocytes from controls (22).
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ABSTRACT
Background and aims
Histological identification of granulomas is a key finding in rendering a definitive 
diagnosis of Crohn’s disease. However, granulomas are only found in 9-29% of cases 
in H&E stained tissue. As a result, differential diagnosis between Crohn’s disease and 
ulcerative colitis often relies on a combination of clinical and histological features, 
which are suboptimal as illustrated by a change of diagnosis of up to 10% of patients 
during clinical follow-up.
Methods
Based on earlier reported observations that granulomas are surrounded by B cells, we 
retrospectively studied whether staining for B-cells could improve the detection of 
Crohn’s disease in patients with inflammatory bowel disease (IBD).
Results
CD20 stainings on 44 Crohn’s disease biopsies increased granuloma detection 1.8 fold 
from 20% to 36% of cases. Importantly, in 3/39 subtotal colectomy samples of IBD 
patients, CD20 staining retrospectively supported a diagnosis of Crohn’s disease instead 
of ulcerative colitis. Furthermore, dense B-cell infiltrates in biopsies of patients with 
Crohn’s disease were objective indicators for the presence of granulomas. 
Conclusions
CD20 staining improves sensitivity for detection of granulomas in Crohn’s disease can 
be straightforwardly implemented in the diagnostic work-up of IBD. Early and accurate 
differentiation of Crohn’s disease and ulcerative colitis can improve treatment outcomes, 
especially after surgery.
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INTRODUCTION
A correct diagnosis is still challenging in patients with inflammatory bowel disease (IBD). 
Eventually up to 9% of patients originally diagnosed with ulcerative colitis (UC) are later 
re-diagnosed as Crohn’s disease.1 Yet, it can be important to distinguish between UC 
and Crohn’s disease for optimal disease management and reliable research results.2,3 
Specifically, ileal-anal anastomosis is a widely accepted surgical procedure in patients 
with UC, while it is usually only recommended in a highly selected group of patients 
with Crohn’s disease, for example with isolated colitis without peri-anal disease, due 
to an increased risk of a number of complications including pouch failure.2,4 In spite 
of recent studies including genomic and serologic biomarkers, the diagnosis IBD is 
still made through combining clinical, endoscopic and histopathologic features. The 
presence of epithelioid granulomas in IBD is the single most defining histological 
finding to support the clinical diagnosis of Crohn’s disease.5,6 However, these collections 
of epithelioid macrophages are often small or undetectable in the tissue biopsies.7-9 
Granulomatous inflammation in both Crohn’s disease and sarcoidosis is associated with 
large B-cell infiltrates.10-12 As B-cells were usually not examined in non-granulomatous 
tissue,10 we hypothesized that staining of tissue biopsies with a B-cell marker (CD20) in 
addition to the standard hematoxylin and eosin (H&E) stain might improve detection of 
granulomas as compared to the routine pathology analysis using only H&E stain. In this 
study, we tested the value of additional CD20 staining through: 1) retrospective analysis 
of granuloma detection in biopsies of patients with a clinical diagnosis of Crohn’s 
disease; 2) retrospective analysis in IBD samples of subtotal colectomies. Furthermore, 
we tested whether the presence of more B cells were indicative of an increased rate of 
granuloma formation. 
METHODS
STUDY COHORTS
In this study, we performed retrospective analysis in two patient cohorts. The first 
consists of endoscopy biopsies from 50 randomly selected patients who were clinically 
diagnosed with Crohn’s disease from 2000 to 2005. Tissue blocks were retrieved from 
the pathology database containing diagnostic biopsies of colon or ileum obtained with 
colonoscopy. Inclusion criteria were: histologically proven Crohn’s disease, history of 
Crohn’s disease or a high index of suspicion for Crohn’s disease by the gastroenterologist 
when performing the endoscopy. Biopsies were excluded if there were only taken 
for colon cancer surveillance or if the tissue samples were from patients from other 
hospitals analyzed for a second opinion. 
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 The second cohort consists of all 47 patients who had undergone subtotal 
colectomies with an inflammatory character between 2000 and 2005. The same 
exclusion criteria were applied as for the biopsies above. 
 All tissue samples were obtained from the archives of the Department of Pathology 
of the Erasmus MC. Ethical approval was waived since in The Netherlands retrospective 
cross-sectional studies are not subject to consent. Still, this study was conducted in 
accordance with the Code of Conduct of the Federation of Dutch Medical Scientific 
Societies (FDMSS) for responsible use of human tissue in medical research.
HISTOLOGIC AL ANALYSIS
Tissue from the biopsies and resection specimens were fixed in 10% neutrally buffered 
formalin, processed and embedded in paraffin blocks according to standard pathology 
laboratory procedures. Slides of 2μm were cut from the paraffin blocks, mounted on 
glass slides and stained with H&E on the Symphony platform (Ventana, Tucson, USA). 
Immunohistochemistry was performed on 4 μm sections using the same monoclonal 
antibody against CD20 (L26, Dako Cytomation, Glostrup, Denmark) on the Benchmark 
Ultra platform (Ventana, Tucson, USA) that we had previously used to define the 
presence of B cells in biopsies of patients with Crohn’s disease, sarcoidosis and Behçet’s 
disease. 10,11,13
 To minimize selection and observer bias, all included biopsy samples were blinded 
to the researchers, making them unaware of the actual diagnosis of the resections 
and the initially reported presence of granulomas. All biopsies were independently 
scored for non-crypt-associated granulomas characteristic for Crohn’s disease by an 
experienced pathologist (KL) together with an investigator (WT). One slide per patient 
per staining was observed. A qualitative method of granuloma scoring was used. 
Biopsies were scored for either the presence or absence of granulomatous inflammation 
ranging from one small granuloma to many large granulomas. All crypt-associated 
granulomas were excluded because they are suggestive of ulcerative colitis. Observer 
bias was further reduced by randomly reevaluating the slides with the following 
sequential approach: 1) all H&E slides; 2) all CD20 slides; 3) linking results of H&E and 
CD20 and in case of a different outcome both were repeated together; 4) comparing 
the combined result of H&E with CD20 on the presence or absence of granulomas 
with the original H&E reports for statistical analysis. The presence of B cells was scored 
semi-quantitatively. The results were distributed over four groups: ‘CD20-’ (<10 B cells), 
‘CD20+’ (< 3 foci with <50 cells), ‘CD20++’ (>3 foci with >50 cells), CD20+++ (>5 foci 
with >100 cells).
 The resection samples were analyzed using a similar approach. As surgical resections 
have a large number of tissue sections, appropriate sections had to be selected first. All 
sections were screened using the original H&E slides, and the section containing the 
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densest lymphoid infiltrates was selected for analysis. Sections of the included samples 
were then cut, stained and analyzed as described above. Finally, the established 
diagnosis, the follow-up on surgical complications or whether the diagnosis changed 
in a later stage were retrieved from the medical record of the patients. There was no 
need to semi-quantitatively score B cells, as was performed in the biopsies, because all 
resection samples contained large B-cell infiltrates.
STATISTIC AL ANALYSIS
A sample size analysis was performed to test the hypothesis whether CD20 addition 
would lead to a higher prevalence of granulomas in biopsies of Crohn’s disease patients. 
Given the prevalence of granulomas in literature, sample size was calculated with 30% 
granuloma with standard H&E staining that would potentially increase to 60% with 
H&E and CD20 based on preliminary results of a small pilot study. With alpha 0.05, the 
sample size provided was 42 samples. Sensitivity and specificity were calculated by 
comparing the rate of granulomas found in the original histological report by H&E and 
with re-analysis with H&E to the rate found in our combined H&E with CD20 staining. 
In this calculation the reevaluation with the combination of H&E and CD20 staining 
was considered as golden standard. Differences in granuloma rates between H&E re-
analysis as compared to the combined CD20 and H&E analysis were evaluated using 
the χ2 test (GraphPad Prism version 7). The χ2 test was also applied to test differences 
in the degrees of B-cell densities (CD20-, CD20+, CD20++, CD20+++) between 
granuloma positive and negative biopsies. A P-value <0.05 was considered statistically 
significant.
RESULTS
CD20 STAINING INCREASES THE DETEC TION OF 
GR ANULOMAS IN CROHN’S DISEASE BIOPSIES
From the initially selected 50 biopsies, insufficient material was left for this study, 
resulting in inclusion of 44 biopsies. Of these 44 biopsies from patients with Crohn’s 
disease, 6 (14%) were documented to contain granulomas. H&E reanalysis alone also 
resulted in a higher number of cases with a certain presence of granulomas (9/44; 
20%). Two additional cases showed a potential presence of granulomas. Subsequently, 
independent analysis of these 44 biopsies with combined H&E and CD20 stained slides 
resulted in a significantly higher detection of granulomas than H&E alone: 16/44 (36%) 
biopsies (p=0.01; χ2 test). These concerned the same 9 as detected with H&E alone, and 
the additional 7 were later confirmed in the H&E staining by visual support of CD20 
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(Figure 1). Of the 6 granulomas reported in the original files, two could not be detected 
even with CD20 staining due to sampling error. When considering the combination of 
CD20 and H&E as the new golden standard, the original sensitivity and specificity for 
the original H&E staining were 25% (4/16) and 93% (26/28), respectively (Table 1) and 
for  the reanalyzed  H&E combined with CD20 staining was 56% (9/16) and 100% (28/28) 
respectively.
FIGURE 1. B cells visualize the presence of granulomas. (A) Representative images of biopsies 
from patients with Crohn’s disease. (B) Images of samples of subtotal colectomy in patients with 
IBD. 
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TABLE 1. Retrospective analysis of granulomas with combined H&E and CD20 stainings in 
biopsy and colectomy samples
Outcome H&E + CD20 analysis
Original H&E  Positive Negative Total
Biopsy (n=44)
positive 4 2 6 (14%)
negative 12 26 38
Total 16 (36%) 28 44
Outcome H&E + CD20 analysis
Re-analysis H&E Positive Negative Total
Biopsy (n=44)
positive 9 0 9 (20%)
negative 7 28 35
Total 16 (36%) 28 44
Colectomy (n=39)
positive 8 0 8 (21%)
negative 5 26 31
Total 13 (33%) 26 39
RETROSPEC TIVE IDENTIFIC ATION OF GR ANULOMAS  
IN COLEC TOMY TISSUE IN PATIENTS PRE VIOUSLY  
DIAGNOSED WITH ULCER ATIVE COLITIS
To further test the CD20 hypothesis we performed a similar analyses as above for 39 
samples of subtotal colectomies in IBD patients. The original pathology files reported 
17/39 (44%) specimens with a histopathological diagnosis of UC and 17 (44%) with 
Crohn’s disease, of which 8 (47%) contained granulomas. Four patients (10%) were 
classified as indeterminate colitis while one patient appeared to have an infectious 
cause. Reanalysis with H&E of Crohn’s disease resection samples confirmed the 
presence of granulomas in the 8 initially defined samples, without detection of these 
in additional cases. Combined H&E and CD20 analysis resulted in the detection of one 
additional granuloma-positive case in the Crohn’s disease group. Furthermore, the 
combined analysis revealed granulomas in 4 cases of the non-Crohn’s disease group, 
3 of which (18%) were originally diagnosed with UC. These 3 patients, in contrast to 
the other UC patients, experienced a complicated disease course after surgery, fitting 
better with Crohn’s disease than UC. One patient developed a peri-anal fistula two years 
after surgery and pouchitis six years after surgery. The second patient had a proctitis six 
months after surgery treated with a proctectomy and she developed a vaginal fistula 
with abdominal fluid pockets two years after surgery. The third patient had ileal pouch-
anal anastomosis reconstructive surgery with the development of pouchitis two years 
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after surgery with focal, patchy inflammation seen during histopathological testing. This 
patient developed sacroileitis years later with a good response to infliximab. In all three 
cases, treating clinicians favored the diagnosis Crohn’s disease years after surgery due 
to the course of disease. No granulomas were detected in the 4 indeterminate patients, 
while during follow up one patient was classified as UC, one as indeterminate colitis and 
two as Crohn’s disease.
DENSE B-CELL INFILTR ATES IN INTESTINAL BIOPSIES  
ARE INDIC ATIVE OF GR ANULOMA PRESENCE
To study whether the presence and densities of CD20+ B cells in histopathological 
slides of biopsies were indicative of the presence of granulomas, we semi-quantitatively 
scored the numbers of B cells and defined 4 groups: ‘CD20-’ (<10 B cells), ‘CD20+’ (< 
3 foci with <50 cells), ‘CD20++’ (>3 foci with >50 cells), CD20+++ (>5 foci with >100 
cells). In all 5 cases without B cells, no granulomas were detected. Granulomas were 
detected in 2/13 (15%) and 2/7 (29%) cases scored as CD20+ and CD20++ respectively. 
Finally, 12/16 (75%) cases in the CD20+++ group contained granulomas. Importantly, 
when split into groups based on presence of granulomas (Figure 2), it was found that in 
significantly more granuloma positive slides large B-cell infiltrates were found (p=0.01; 
χ2 test). 
28
CD20+
39%
CD20++
18%
CD20-
18%
CD20+++
25%
CD20+
12%
CD20++
13%
CD20-
0%
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16
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FIGURE 2. Relative densities of B cells in biopsy samples with and without granulomas. 
Biopsies were categorized based on B-cell densities (see main text). Statistical analysis was 
performed with χ2 test to analyze differences in distribution of samples over the 4 categories. 
Numbers of analyzed samples are depicted in centers of the pie charts.
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DISCUSSION
In this study, we demonstrate that the combination of H&E with CD20 staining increased 
the detection of granulomas in biopsies of patients with Crohn’s disease with 1.8 fold 
compared to the original approach with optimal H&E staining. These results suggest 
that additional CD20 staining may increase the sensitivity of IBD biopsies. 
 The reported granuloma rate reported in the original H&E of 14% is in the low-
normal range compared to literature, suggesting that our randomized samples are 
representative of biopsies from patients with Crohn’s disease.5,6,14-16 Reevaluation with 
H&E staining increases the yield with 1.5 fold. However, this reevaluation occurs in 
an optimal setting using two investigators and is therefore time-consuming and not 
representative of daily practice. Compared to the setting as representative for the daily 
practice, addition with CD20 staining increases the detection of granulomas 1.8 fold. 
In this study, only one slide per patient has been evaluated. The number of detected 
granulomas might be higher if more sections were scored, especially in the surgical 
resection specimens as is often done in clinical practice.
 The relative high prevalence of reported granulomas (47%) in the cohort of Crohn’s 
disease patients can be explained by the high availability of larger tissue specimens. 
Complete specimen analyses reduces sampling error and enables evaluation of 
transmural inflammation. This higher prevalence is often described in literature in 
surgical cohorts and another explanation of the higher granuloma prevalence is 
the reported association of more aggressive disease resulting in a need of surgery. 
15,17,18 Therefore, granulomas identified in surgical specimen can support a change of 
diagnosis in patients previously diagnosed with ulcerative colitis. In this study this was 
demonstrated as the combination of non-crypt-associated granulomas together with a 
complicated disease course with fistulas and pouchitis years after surgery retrospectively 
favored Crohn’s disease. An improved accuracy in the distinction between Crohn’s 
disease and ulcerative colitis could be important when new therapeutics targeting 
different yet specific inflammatory pathways will become available for patients with IBD. 
For example, Mongersen (an oligonucleotide targeting Smad7) is currently evaluated 
for patients with Crohn’s disease, whereas Janus kinase inhibitors are tested for UC.19 
CD20 staining can be easily implemented, because it is relatively inexpensive, 
pathologists are familiar with the staining as  it is standardly used in evaluation of 
hematological malignancies and the positive correlation between the number of 
B-cells and the probability to find additional granulomas, as demonstrated in this paper. 
In this report we have used CD20.20 However any readily available antibody used to 
demonstrate a B-cell phenotype may also be used.  Still, it will be important to have 
this new diagnostic approach externally validated, especially to ensure that it does not 
result in high false positivity and to research the additional benefit in clinical practice for 
diagnosing Crohn’s disease. 
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 In conclusion, this study shows that the addition of CD20 to routine H&E staining in 
biopsies of IBD patients increases sensitivity of granuloma detection. CD20 can easily 
be implemented in diagnostics, and contribute to a faster and more accurate diagnosis 
of Crohn’s disease. This will be of increasing importance in a time when new biologicals 
will become available for patients with either Crohn’s disease or ulcerative colitis. 
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ABSTRACT
Background and aims 
Infliximab is used as third-line treatment in sarcoidosis with mixed therapeutic efficacy. 
Therefore, it would be beneficial to establish markers that predict potential treatment 
success. Patients with sarcoidosis have reduced memory B cells and CD4 helper T-cell 
subsets compared to healthy controls. In this study, we evaluated cellular and serological 
immunological markers in sarcoidosis patients before and during infliximab therapy. 
Materials and Methods
The therapeutic response to infliximab was clinically evaluated in all 11 patients along 
with serum levels of sIL-2R, IgG, BAFF, and infliximab trough levels. Furthermore, 
extensive flowcytometric analysis of blood B and T-cell subsets was performed of all 11 
patients before and during infliximab therapy (2 and 6 weeks, 8 months). 
Results 
Nine (82%) patients showed an objective clinical response. sIL-2R levels rapidly declined 
after the first infliximab infusion, whereas serum IgG and BAFF levels did not alter. IgM+ 
memory B cell numbers increased in patients who clinically responded to infliximab 
therapy, as did the numbers of CD4, CD8 T cells, regulatory T cells, Th17 and Th17.1 T 
cells. Those who developed anti-drug antibodies (ADA), displayed lower levels of sIL-
2R and Tregs with higher IgM-only B cells at baseline than responders to infliximab. 
Most patient had infliximab levels within therapeutic range and at months these levels 
correlated significantly with sIL-2R levels. 
Conclusions
Our study confirms the potential of monitoring infliximab trough levels, sIL-2R and 
ADA as promising markers for therapeutic success in sarcoidosis patients. Moreover, 
infliximab therapy normalizes IgM+ memory B cells and Th subsets, demonstrating 
cellular immune effects and the potential for new laboratory markers of therapy success. 
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INTRODUCTION
Sarcoidosis is a chronic inflammatory disorder characterized by the presence of non-
necrotizing granulomas affecting various organs including lungs, eyes, skin and the 
central nervous system.(1) The etiology is still unknown and the clinical presentation 
is highly heterogeneous, which relates to the organs involved. Fortunately, over 50% of 
patients will have a spontaneous remission within 3 years. Therefore, only patients with 
organ threatening sarcoidosis are treated with medication.(1, 2)
 The pro-inflammatory cytokine tumor necrosis factor alpha (TNF-α) exerts a 
pivotal role in both granuloma formation and maintenance by promoting infiltration 
of macrophages and lymphocytes.(3) Accordingly, in animal models of tuberculosis, 
granulomas appear disorganized in absence of TNF-α, and established granulomas 
are disrupted upon blocking of TNF signaling.(4, 5) Cultured alveolar macrophages 
from patients with sarcoidosis spontaneously produce more TNF-α, and higher levels 
of TNF-α are associated with progressive disease.(6, 7) Subsequently, in addition to 
first and second line therapy with corticosteroids and disease modifying drugs, TNF-α 
blockers have emerged as an option for third line treatment in sarcoidosis.(1)
 Level 1 evidence for a beneficial effect of TNF-α blockers in sarcoidosis is restricted to 
one randomized controlled trial (RCT) with infliximab. It is thought that the selection of 
patients with stable, chronic disease including fibrosis has led to an unexpected modest 
response in FVC.(8) Therefore, concerns over its clinical significance in chronic pulmonary 
sarcoidosis have been raised. However, subsequent clinical trials and case series have 
shown significant beneficial effects in patients with extrapulmonary manifestations or 
in selected patients with severe and active disease.(9-12) Patients with severe or organ 
threatening disease are currently treated with infliximab after failing first and second 
line treatment. Especially patients with neuro, ocular, or cutaneous disease respond to 
infliximab in overall disease improvement ranging from 60% to 92%. (9-12) Furthermore, 
identification of potentially responding patients, timing of initiation and discontinuation 
of infliximab are challenging. In fact, most of our knowledge is derived from extensive 
experience with TNF-α blockers in Crohn’s disease and rheumatoid arthritis.(13, 14) In 
these diseases infliximab trough levels correlate well with therapeutic efficacy and are 
therefore monitored to adapt for dose and treatment intensifications.(15, 16) In general, 
a target range of infliximab trough levels between 3 and 10 µg/mL is aimed to optimize 
therapeutic efficacy, minimize adverse events and to reduce costs as ineffective and 
supra therapeutic dosage can be prevented. When infliximab levels measured are 
<1 µg/mL further testing for antidrug antibodies (ADA) is recommended as ADA can 
form immune complexes with infliximab leading to very low trough levels and therapy 
failure.(17) Several other immunological monitoring tools have been proposed in the 
past years in sarcoidosis. Currently, serum soluble (s)IL-2R level is mostly used in daily 
practice and regarded as most sensitive to monitor disease activity.(18, 19)  
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 Sarcoidosis patients typically display reduced CD4 T cell blood numbers due to 
accumulation of these cells in the affected organs.(20) Traditionally, sarcoidosis is 
regarded as a T-helper 1 (Th)1 driven disease, whereas more recently Th17.1 cells 
were identified as important cells contributing to the pro-inflammatory environment 
in sarcoidosis through production of IL-17 and IFN-γ.(21-23) Previously, we have 
demonstrated extensive B-cell infiltrates around granulomas, and reduced levels of 
blood IgM+ and Ig class switched memory B cells in patients with sarcoidosis.(24) 
 In this study, we aim to study if abnormalities in peripheral blood B-cell and T-cell 
subsets normalize in sarcoidosis patients during infliximab treatment and can be used 
in addition to sIL-2R as early markers for therapy success. 
  
MATERIALS AND METHODS
PATIENTS
Clinical data and blood samples were collected from 11 sarcoidosis patients who 
were scheduled to start with infliximab therapy based on clinical indications (Table 
1). The eleven patients were recruited from the Departments of Internal Medicine and 
Pulmonary Medicine of the Erasmus MC. Blood samples were collected before first 
infliximab infusion (week 0), at week 2 and 6 and around month 8 within hours before 
infliximab infusion. Infliximab treatment was started on a standard induction schedule 
at week 0, 2 and 6. After 6 weeks, patients received infliximab treatment every 6 to 8 
weeks depending on the individual needs. The therapeutic response of infliximab was 
monitored individually according to standard clinical care by the treating physician, 
and included blood tests, pulmonary function tests and imaging studies such as chest 
X-ray, CT-thorax and MRI of the brain. Participants were recruited after the clinical 
decision was made to start infliximab treatment, and clinical data and blood samples 
were collected after written informed consent was obtained. Inclusion in our study 
did not interfere with or alter decisions for treatment. In addition, blood samples from 
18 healthy controls, consisting of 10 males and 8 females with a mean age of 50 years 
(range, 31-70 years) were obtained once after informed written consent was given. This 
study was approved by the Medical Ethics Committee of Erasmus MC (ethics approval 
number MEC-2014-044) and in accordance with the Declaration of Helsinki.
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QUANTIFIC ATION OF IMMUNOLOGIC AL MARKERS
Blood was collected in heparin tubes for plasma preparation and whole blood analysis. 
Plasma was obtained from all blood samples to measure soluble protein levels. Plasma 
IgG was measured by an immunoturbidimetric method (Hitachi Analyzer; Roche, Basel, 
Switzerland). In addition, sIL-2R levels were measured with enzyme immunoassay 
according to the manufacturer standards (human sCD25/sIL-2R ELISA kit; Diaclone 
SAS). ELISAs were performed to quantify levels of B-cell activating factor (BAFF; R&D 
Systems), and trough levels of infliximab (Sanquin, Amsterdam, The Netherlands). 
Infliximab-specific IgG was measured by an antigen binding test (Sanquin, Amsterdam, 
The Netherlands).
FLOWC YTOMETRIC IMMUNOPHENOTYPING  
OF BLOOD B- AND T-LYMPHOC YTES
Flowcytometric analysis was performed within 24 hours after blood collection on whole 
blood. Absolute counts of blood lymphocytes, CD4+ and CD8+ T cells and CD19+ B cells 
were obtained with a diagnostic lyse-no-wash protocol. 10-Color flowcytometry was 
performed after red blood cell lysis to define B-cell subsets: transitional, naive mature, 
and six memory subsets, as described previously,(25) using monoclonal antibodies 
against CD27-BV421 (M-T271), CD21-BV711 (B-ly4), IgG-PE (G18-145), IgD-PE-CF594 
(IA6-2; all from BD), IgM-BV510 (MHM-88), CD38-BV605 (HIT2), CD275-APC (2D2; all from 
Biolegend), IgA-PE (IS11-8E10, Miltenyi-Biotec), CD19-PE-Cy7 (J3-119) and CD24-APC-
AF750 (ALB9; both Beckman Coulter). CD4 subsets were defined as follicular helper T(fh) 
cells, Tregs, Th1, Th2, Th17, Th17/IFNγ, using the following monoclonal antibodies; CD27-
BV21 (M-T271), CD4-BV510 (OKT4), CD45RA-BV605 (HI100), CD25-BV421 (BC96), CXCR3-
FITC (G025H7), CCR6/CD196-PerCP-Cy5.5 (G034E3), CCR4-PE-Cy7 (TG6/CCR4), CD127-
APC (A019D5), CD28-PerCP-Cy5.5 (CD28.2; all from Biolegend), CCR7/CD197-PE-CF594 
(150503), and CD8-APC-AF750 (SK1; all from BD), CD45RO-FITC (UCHL1; Exbio), CXCR5-
APC (51505; R&D systems).(26) All samples were acquired on a 4-laser LSRFortessa (BD 
Biosciences, San Jose, California, US) with standardized instrument settings.(27) 
MOLECULAR ANALYSIS OF IMMUNOGLOBULIN  
HEAVY CHAIN ( I G H )  GENE TR ANSCRIPTS
IGHA and IGHG transcripts were amplified from PBMC cDNA of patients 1, 2 and 3 
before infliximab treatment and around 8 months into treatment (n = 3). Data from 
healthy controls (n = 6) were obtained previously.(28) IGHV3 and IGHV4 leader primers 
and consensus Cα or Cγ reverse primers were used.(25) PCR products were cloned 
into the pGEM-T easy vector (Promega, Madison, WI) and prepared for sequencing 
on an ABIPRISM 3130XL (Applied Biosystems, Carlsbad, CA). Obtained sequences 
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were analyzed with IMGT database (http://www.imgt.org/IMGT_vquest/vquest) and 
Bayesian estimation of Antigen-driven SELectIoN (BASELINe; http://selection.med.yale.
edu/baseline/).(29, 30) IgA and IgG receptor subclasses were determined using the IGH 
reference sequence (NG_001019).
STATISTICS
To determine differences between healthy controls and baseline patient data, the non-
parametric Mann Whitney U test was used. To analyze pharmacodynamics from baseline 
until month 8, one way anova was used. When significant (p<0.05), this was specified 
by using a paired t-test between the various time points. As the aim was to identify 
lymphocytic markers in patients responding well to infliximab therapy, statistical 
analysis of T-and B-cell subsets was performed in patients with a consistent therapeutic 
response without formation of formation of anti-drug antibodies (ADA) during the 
eighth month study period. Spearman correlation test was used to confirm correlation 
between biomarkers and clinical data. Statistical analysis and Figures were prepared 
using GraphPad Prism Software. 
RESULTS
CLINIC AL CHAR AC TERIZ ATION OF PATIENTS
Eleven patients (10 female) with biopsy-proven sarcoidosis were included in this follow-
up study with a mean age of 48 years (range, 37-68 years). The majority of patients 
had multi-organ involvement demonstrated with PET-CT or somatostatin receptor 
scintigraphy positive disease (Table 1). All patients had a history of immunosuppressive 
treatments since all had serious and active disease. Four patients (1-4) had a more 
systemic, active disease including uveitis at the time of infliximab start, while patients 5-8 
had merely a pulmonary indication for infliximab therapy and patients 9-11 experienced 
severe neurological involvement. Most patients had concomitant use of corticosteroids, 
methotrexate or azathioprine which was tapered or stopped in some cases (Table 2). 
All patients started the induction schedule, receiving 300-500 mg (5mg/kg) infliximab 
at weeks 0, 2 and 6, and every subsequent 6 to 8 weeks as per decision of the treating 
medical specialist. Patients 1-8 were treated with Remicade, and patients 9-11 received 
the biosimilar Remsima, which has become the standard product in our center. 
 In 9/11 patients, a clinical response was objectified by ophthalmological examination, 
pulmonary function, Chest X-ray or MRI brain (Table 2 and Figure 1). Pulmonary function 
tests were consistently performed for patients 2, 5-8 prior to and during this study, and 
all five patients showed an improvement in forced vital capacity (FVC) with a mean or 
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12.4% (range 8-25%) of predicted FVC (Figure 1). Patient 4 initially showed improvement 
by chest CT, yet arthritis remained. This patient had a relapse associated with  formation 
of ADA against infl iximab after 16 months. Patient 6 initially showed a good response, 
yet she relapsed after 22 months with formation of ADA. Both patient 4 and 6 switched 
to adalimumab therapy because of failing on infl iximab, with stable outcome for patient 
4 and excellent response seen in patient 6. Patient 9 initially had a very good response 
with complete remission on brain MRI and remission of symptoms. However, the patient 
relapsed at the end of this study; the development of ADA occurred and increased 
presence of liver enzymes in serum (ASAT up to 133U/L; normal <31U/L, ALAT up to 
217U/L; normal <34U/L) necessitated cessation of infl iximab. Patient 11 did not show 
a therapeutic response, as evidenced by increased uptake of gadolinium on brain MRI. 
This patient developed ADA at month seven. Hence, infl iximab was discontinued, the 
patient was started on methylprednisolone together with adalimumab, and this patient 
was excluded from the study. 
 Infl iximab was generally well tolerated by the eleven patients in our study. Adverse 
events were restricted to pulmonary tract infections in patients 3, 4 and 7; and elevation 
of liver enzymes in patient 9, which normalized upon discontinuation of infl iximab.
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FIGURE 1. Clinical markers of follow-up of infl iximab treatment. (A). Pulmonary function 
tests with % of predicted FVC before and during treatment with infl iximab of fi ve patients. Each 
dot represents an FVC value. (B). Chest X-ray of patient 7 at baseline (left) and after 7 months 
of successful treatment showing improvement  with less prominent hilar lymph nodes and 
improved reticular opacities (right) (C). MRI Brain of patient 9 before therapy (left) and after 3 
months of successful treatment (right) showing complete remission of leptomeningeal uptake.
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DECLINE IN PL ASMA SIL-2R BUT NOT IGG AND BAFF  
LE VELS FOLLOWING INFLIXIMAB TREATMENT
To study immunological success of infliximab therapy, we measured sIL-2R plasma levels 
in all patients prior to and during therapy. Plasma sIL-2R levels, but not IgG and BAFF, 
declined during infliximab therapy, and were inversely correlated to serum infliximab 
trough levels (Figure 2). At baseline, all but two patients, patients 9 and 11 without 
long-term response with ADA (Figure 1A; triangles), had elevated sIL2-R levels above 
the upper limit of 2,500 pg/mL (range between 1,365 and 20,900 pg/mL, Figure 2A). 
Following the first infusion of infliximab, sIL-2R levels significantly decreased (p=0.002) 
at week two with a long-term effect up to 8 months (p=0.049). 
 Only patients 1 and 6 had an IgG at baseline that was above the normal range 
(Figure 2B). In the current study the levels of IgG appeared to be rather stable within 
patients during infliximab therapy. Similarly, only 6/11 patients had BAFF plasma levels 
above the upper limit of healthy controls (range healthy controls 728-1295 pg/mL), and 
these levels did not change significantly during therapy (Figure 2C), yet BAFF levels did 
correlate significantly at baseline with sIL-2R levels (Figure 2F; p=0.05).
 To study if the lack of response in clinical markers was related to suboptimal 
medication, infliximab trough levels were determined in all patients with the target. 
None of the 11 patients had infliximab levels above 10 µg/mL. At month 8, four patients 
had decreased infliximab trough levels (normal levels; 3-10 μg/ml). Despite this, only 
one patient (patient 9) also had ADA then. These were accompanied by infliximab levels 
in the undetectable range (0.06 μg/ml), whereas in the other three patients (1, 2 and 4) 
infliximab levels ranged from 1 to 2 μg/ml. Patients 1 and 2 displayed excellent long-term 
clinical responses without ADA formation, whereas patient 4 had a late relapse with ADA 
formation at 16 months, which is 8 months after the observation period of this study. 
 A significant inverse correlation was found at month 8 for infliximab trough levels 
and sIL-2R levels (Figure 2E; p=0.04). 
 
FIGURE 2. Immunological markers and infliximab trough levels during infliximab 
treatment. Plasma levels of (A) sIL-2R, (B) IgG, (C) BAFF, and (D) infliximab at baseline, and 
week 2, week 6 and month 8 following start of infliximab treatment. Each dot represents 
a single measurement with lines connecting measurements of the same patient. Triangles 
represent data of the two patients who eventually developed ADA during this study, patient 
9 and 11. The dashed line in panel A represents the upper limit of the normal range of sIL-2R 
(2500 pg/mL; upper limit of normal with the used test in our center). The upper and lower 
limits of the normal range of serum IgG are shown in panel B (7 and 16 g/l, resp), and well 
as the recommended target range of infliximab levels (between 3 and 10 µg/mL) in panel 
D.(17) The Mann-Whitney U test was used to statistically analyze differences between healthy 
controls and patients at baseline, whereas a paired T-test was used to examine therapy effects 
in patients; *, P<0.05; **, P<0.01. E. Regression analysis of infliximab trough levels and sIL-
2R levels at month 8 using Spearman’s rank correlation coefficient. F. Regression analysis of 
serum BAFF levels and sIL-2R levels at baseline using Spearman’s rank correlation coefficient.
→
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TREG, TH17 AND TH17/IFN-Γ CELL NUMBERS INCREASE 
IN PATIENTS RESPONDING TO INFLIXIMAB THER APY
Patients with a therapeutic response throughout the eight months of study showed low 
blood CD4 T cells prior to treatment. CD8 T cells were also low, therefore CD4/CD8 T cell 
ratio was normal. Absolute numbers of Tfh cells prior to start of infl iximab treatment 
were lower than in controls (p=0.02), and these remained low during therapy. Kinetics 
of Treg cell numbers were similar between patients and controls, with a parallel increase 
at week two (Figure 3B, p=0.04) followed by a decline as week 6 and month 8. 
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FIGURE 3. T-cell response before and during infl iximab therapy in responders to infl iximab. 
A. Gating strategy of T-cell subsets including CD4, CD8, CD4/CD8 and absolute counts of CD4, 
CD8 and CD4/CD8 of healthy controls (ctrl) at baseline (W0) and after 2, 6 weeks (W2, W6) and 
8 months (M8) of responders to infl iximab therapy (patients 1-8, 10).B. Gating of Tfh, Treg, Th1, 
Th2, Th17 and Th17.1 T cells. C. Absolute cell counts of T-cell subsets of healthy controls (ctrl) and 
patients at baseline (W0) and after 2, 6 weeks (W2, W6) and 8 months (M8) Statistical analysis 
performed with Mann Whitney U test between controls and baseline patients. Statistical analysis 
during therapy was performed with a paired analysis with Wilcoxon signed rank test; *, P<0.05; **, 
P<0.01; ***, P<0.001.
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 Our cohort did not show diff erences in Th1 or Th2 cells, whereas both Th17 and 
Th17.1 (IL-7/IFNγ double producers) cell numbers in patients before therapy were 
signifi cantly lower than in controls (Figure 3B; p=0.002 and p=0.0004, respectively). 
In addition, these cell numbers changed during therapy: Th17 cells showed a rapid 
increase at week 2, lasting for 8 months, whereas Th17.1 cell numbers increased at 8 
months.
 R APID NORMALIZ ATION OF BLOOD IGM MEMORY 
B CELLS IN PATIENTS RESPONDING TO INFLIXIMAB
As previous studies have demonstrated signifi cant diff erences in blood memory B cells 
in patients with sarcoidosis as compared to healthy controls,(19, 24, 31) we here studied 
how these changes were aff ected by successful treatment with infl iximab. The group of 
nine remaining patients with a therapeutic response to infl iximab had reduced absolute 
numbers of all six types of memory B cells prior to the start of treatment (Figure 4). 
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FIGURE 4. B-cell memory before and during therapy in infl iximab responders. A. Gating 
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CD27+IgG+. (B). Absolute cell counts of B-cell subsets of healthy controls (ctrl) and patients at 
baseline (W0) and after 2, 6 weeks (W2, W6) and 8 months (M8) of responders to infl iximab therapy 
(patients 1-8, 10). Statistical analysis performed with Mann Whitney U test between controls and 
baseline patients. Statistical analysis during therapy was performed with a paired analysis with 
Wilcoxon signed rank test; *, P<0.05; **, P<0.01; ***, P<0.001.
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The numbers of both IgM-expressing memory B cell subsets, (CD27+IgM+IgD+ natural 
effector and CD27+IgM+IgD- IgM-only) memory B cells rapidly increased with a significant 
rise in week 2 (p=0.004 and p=0.04), that lasted up to month 8 (both p=0.04). For the 
four Ig class switched memory B-cell subsets (CD27-IgA+, CD27+IgA+, CD27-IgG+ and 
CD27+IgG+), no significant change in numbers was detected during treatment. Thus, 
within the memory-B-cell compartment, specifically the IgM-expressing cells were 
affected by infliximab therapy. 
          
LOWER LE VELS AT BASELINE OF SIL-2R AND  
TREG CELLS, AND HIGHER IGM-ONLY B CELLS  
IN NON-RESPONDERS TO INFLIXIMAB
In the studied period, 2 patients (9 and 11) developed ADA which correlated with 
clinical response. Those patients were considered non-responders. The most significant 
related response parameters identified were Tfh, Treg, Th17, Th17.1 and IgM memory B 
cells. The values of those parameters between responders were compared with those 
of non-responders and with healthy controls and correlated for response (Figure 5A, 
B). As this group is small, no statistical analysis was performed. Yet, at baseline non-
responders showed lower numbers of Tregs and Tfh with higher number of IgM-only B 
cells in respect to responding patients. When sIL-2R was related to Tregs and IgM-only B 
cells at baseline; both non responders (in red) showed the lowest sIL-2R levels and Treg 
numbers while IgM cells were higher (Figure 5C; p=0.004 and p=0.06, respectively). 
NO EFFEC T OF INFLIXIMAB THER APY ON INCREASED 
SOMATIC HYPERMUTATIONS IN IGA AND IGG TR ANSCRIPTS
We previously reported that B cells of patients with sarcoidosis carried increased levels 
of somatic hypermutations (SHM) in the variable regions of IgA and IgG genes.(24) 
To study if these levels persist during successful treatment with infliximab, we here 
analyzed Ig transcripts of three patients before and after ~8 months of treatment with 
infliximab (Supplemental Figure 1A/C). Similar to the previously reported patients who 
were not receiving anti-inflammatory medication, our patients carried increased levels 
of SHM in their IgA transcripts (Figure 6C, p=0.0005) at the start of the study period. This 
increase remained after 8 months of treatment with infliximab (Figure 6C). A slight, but 
not significant, increase was seen for SHM levels IgG transcripts of the patients as well 
(p=0.12). The increase in SHM levels did not result in enhanced selection for replacement 
mutations in the complement determining region, i.e. the antigen-binding domains 
(Supplemental Figure 1B,D). 
 IgG subclass usage changes with age towards increased IgG2 and IgG4 subclasses, 
and the latter were found to be used more frequently in patients than in controls.(24, 
28, 30) In our patients, the combined use of IgG2 and IgG4 before therapy (35%) was 
88 Chapter 4
significantly lower than after infliximab treatment (43%; p=0.01). However, for both time 
points, these were not higher than in controls (47%; Figure 6B). Within IgA, the relative 
usage of IgA2 in our patients prior to infliximab treatment was similar to controls, but 
was significantly reduced after 8 months of therapy (Figure 6B, p=0.02).
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FIGURE 6. Molecular analysis of B cell maturation. A. Schematic representation of the constant 
region of the IGH locus. B.  Distribution of IgA and IgG subclass usage in switched transcripts 
of six healthy controls and three patients with sarcoidosis before and during infliximab therapy 
(patients 1, 2 and 3). Total numbers of analyzed sequences are indicated in the middle of the 
plots. χ2 Test was performed to analyze differences in distributions. C. SHM levels in IGHV genes of 
rearranged IgA and IgG transcripts of healthy controls and patients before and during infliximab 
therapy at month eight. Grey dots represent unique sequences; red lines represent median values 
(total numbers of sequences indicated between brackets). Statistical analysis was performed with 
the Mann-Whitney U test; *, P<0.05; **, P<0.01; ***, P<0.001.
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DISCUSSION
Among patients with active sarcoidosis treated with infliximab, infliximab trough levels 
can be used as therapeutic biomarkers in addition to sIL-2R. sIL-2R levels combined with 
ADA formation, infliximab trough levels and B- and T-cell kinetics indicate therapeutic 
success.
TREATMENT OPTIMIZ ATION – TROUGH LE VELS AND ADA
The therapeutic response in this selective patient cohort consisting of patients with 
active and severe disease corresponds with that observed in similar a prospective 
open label studies.(10) Furthermore, most of our patients (7 out of 11) also had 
extrapulmonary disease, a clinical situation correlated with responses to infliximab.(9-
12) Therefore, our cohort would have the potential of more gain in overall clinical scores 
due to more active inflammation and more extrapulmonary disease prior to treatment. 
 As sarcoidosis is a rare disease, little has been standardized for infliximab treatment 
and monitoring.(17) The only two studies examining infliximab trough levels in 
sarcoidosis have reported a mean of 7.5μg/ml and 18μg/ml between 24 and 26 
weeks of infliximab treatment, respectively.(8, 10) In our study, 6 patients had trough 
levels within the recommended range for other diseases (3-10 μg/ml) 8 months after 
initiation of  therapy. However, levels below 3 μg/ml have not led to therapy failure 
in two patients on infliximab combined with disease modifying antirheumatic drugs 
(DMARDs; methotrexate or azathioprine). DMARDs have been shown to prevent ADA 
formation and loss of response to infliximab in other immune mediated diseases.(32) 
Interestingly, disease relapse in the two patients in our cohort seemed related to DMARD 
discontinuation. The 7 patients with a long-lasting therapeutic response all continued 
their DMARDs, suggesting that co-medication favors a lasting beneficial therapeutic 
response as is also described in Crohn’s disease.(32) The optimization of infliximab 
therapy through a tailor-made approach measuring ADA and trough levels and using 
co-medication can enhance the chances of therapeutic response and might therefore 
be cost-reductive and reduce toxicity as unnecessary high dosage are prevented.(33, 
34) 
SEROLOGIC AL AND CELLUL AR MARKERS
Our experiences with sIL-2R as biomarker for therapy monitoring were consistent with 
those reported earlier.(18, 19) In the presented study, significant decline in sIL-2R levels 
occurred directly after the first infusion of infliximab. In contrast to sIL2-R, BAFF levels 
were not significantly elevated as earlier reported in patients with active sarcoidosis.(19, 
35) Furthermore, BAFF levels did not change during infliximab therapy either. However, 
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6/11of our patients had high BAFF levels that were correlated to sIL-2R levels at baseline. 
IgM memory B-cells, including both the CD27+IgM+IgD+ and CD27+IgM+IgD- subsets, 
increased over time during therapy in patients responding to infliximab. Interestingly, 
similar results in the pre-switched memory B-cell compartment were found in studies 
involving rheumatoid arthritis and spondyloarthritis patients upon treatment with 
TNF-α blockers.(36, 37) Salinas et al. proposed that TNF-α blockers might influence 
germinal center reactions leading to decreased isotype switching in spondyloarthritis 
patients.(37) In this cohort less sequences containing SHM after therapy with infliximab 
were found.(37) In contrast to this, the presented data in sarcoidosis patients showed 
stable elevated levels of SHM before and during therapy. The observations of decreased 
baseline Tfh cells unresponsive to infliximab therapy might indicate that infliximab does 
not affect germinal center function in sarcoidosis since Tfh cells interact with B cells 
at these locations.(38) Another potential explanation might be that these memory B 
cells might accumulate in inflamed sarcoid tissue as has been observed in rheumatoid 
synovial tissue and therefore are undetectable in peripheral blood.(36) Hypothetically, 
redistribution from the inflamed tissue to the peripheral blood could also attribute to 
the increase seen after ignition of TNFα-blockers. Earlier, our group proposed that CD27-
IgA+ cells could be a biomarker for successful infliximab therapy.(24) Actually, in the 
current study patients already showed low numbers of this cell type at baseline, making 
it likely that this decrease is more of a general medication effect, rather than a specific 
infliximab effect. 
 Increased Tregs in peripheral blood and accumulation in the vicinity of granulomas 
occur in untreated patients with active sarcoidosis and decrease after effective therapy.
(39) Our results in treated patients did not show a difference in absolute Tregs numbers 
in comparison to controls, however a rapid yet non-lasting increase in Tregs was seen 
at week 2 after the first infliximab infusion. Another study analyzing the effect of 
infliximab on Tregs after 14 and 26 weeks, reported also increased percentages of Tregs 
in sarcoidosis, but with normal absolute numbers without change during therapy.(40) 
No disturbances were seen in Th1 and Th2 cell numbers, wheras both Th17 and Th17.1 cell 
numbers were decreased at baseline and increased during therapy. Broos et al. reported 
decreased frequencies of Th17.1 cells in peripheral blood while these were increased in 
BAL fluid.(22) The role and function of Th17.1 cells seems to be rather complex, yet our 
results support the notion that Th17.1 cells more prominently contribute to the pro-
inflammatory environment in sarcoidosis than Th1 cells, especially via secretion of IFNγ. 
Furthermore, increased percentages of Th17.1 cells in BAL fluid in sarcoidosis patients 
was correlated to developing chronic disease.(41) Our increase of Th17.1 cells during 
successful infliximab therapy is perhaps a general effect of improvement of disease by 
clearance of granulomas. 
 The two patients with a failed response had formation of ADA. Interestingly, these 
were the only two patients without an elevated baseline sIL-2R plasma level (< 2500 
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pg/ml), despite having serious and active neurosarcoidosis. Furthermore, compared to 
infliximab responders, these two patients had lower levels of Tregs at baseline while their 
IgM-only B cells were within the range of healthy controls. Additionally, the absolute 
number of Treg and IgM-only B cells were related to sIL-2R baseline levels. Although 
the group of non-responders is very limited and might be sub-group dependent, our 
results carefully indicate patients responding well to infliximab have elevated levels of 
sIL-2R combined with Treg numbers more in line with healthy controls while their IgM 
memory B cells are substantially reduced. 
 This study has several strengths, including the thorough immune analysis and 
individual follow-up both on the short- and long-term. However, the size of our cohort 
is limited. Yet, especially in this limited group with active and severe disease after failing 
immunosuppressive medication, the value of infliximab in sarcoidosis is emphasized 
with most of our patients showing excellent clinical improvement. It would have been 
valuable if statistical analysis could have been performed with larger subgroups of 
responders/non-responders. With only 2 patients failing infliximab during this study, 
statistical analysis was not possible. Furthermore, our group was a varied group of 
indication for therapy intensification including extra pulmonary involvement. This 
diversity in disease manifestation is common in daily clinical practice and our results 
still showed clear patterns irrespective of different disease entities. 
 In conclusion, infliximab can be a very effective agent in serious and active 
sarcoidosis. Monitoring the therapeutic effectivity of infliximab combined by sIL-2R, 
B-and T-cells subsets, ADA and infliximab through levels shows to be promising. Patients 
responding well to infliximab in general may be characterized by elevated levels of sIL-
2R together with Tregs more in line with healthy controls and substantially decreased 
IgM-only B cells before start of therapy. These findings may implicate that therapeutic 
monitoring with these biological and pharmacological parameters in patients with 
active sarcoidosis requiring infliximab could contribute to optimizing infliximab 
treatment in these patients.
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ABSTRACT
Introduction 
Neurosarcoidosis is a manifestation of sarcoidosis with inflammatory involvement of 
the nervous system. Infliximab is a tumor necrosis factor-alpha (TNF) blocker and used 
as a third line treatment for sarcoidosis. 
Methods 
In a retrospective study in two tertiary referral centres in the Netherlands, data were 
collected data on clinical characteristics and outcome of patients with biopsy proven 
neurosarcoidosis who were treated with infliximab. 
Results 
A total of 28 patients were identified with a mean age at baseline of 42 of whom 16 
(57%) were male. The clinical presentation of severe neurosarcoidosis at the start of 
infliximab treatment was consistent with cerebral parenchyma localization  (16/28 
patients, 59%), pituitary gland/hypothalamic sarcoidosis  (15/28, 54%), peripheral 
nerves involvement (12/28, 43%) and chronic meningitis (11/28, 41%). Infliximab 
treatment led to complete remission in 6 patients (21%), improvement in 14 (50%), stable 
disease in 7 (25%) and deterioration in 1 (4%). At the end of follow-up with a median 
of 32 months, 5 patients (18%) had died. Successful tapering or discontinuation of 
corticosteroids was achieved in 19 of 28 patients (68%). In patients of whom the dosage 
of infliximab was decreased or discontinued, a relapse occurred in 5 of 19 patients (26%). 
Complications of infliximab were reported in 10 of 28 patients (36%) and consisted of 
infections in 8 (29%) and elevated liver tests and an allergic reaction both in 1 (4%). 
Conclusion
Infliximab is an effective and relatively safe third line treatment option in neurosarcoidosis 
and leads to remission or improvement in the majority of patients. However, relapses 
may occur in patients in whom infliximab was either tapered or discontinued. 
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INTRODUCTION
Sarcoidosis is a multisystem disorder and is characterized by the presence of granulomas 
that can affect every organ system.1 The prevalence of sarcoidosis is estimated to 
be between 5-50 per 100.000 of the population with the highest prevalence in 
Northern Europe.1 Approximately 5% of sarcoidosis patients have neurosarcoidosis 
in which granulomas involve the nervous system. 2 Neurosarcoidosis is a severe form 
of sarcoidosis in which one-third of patients either remain stable, deteriorate or die 
despite immunosuppressive treatment.2 No clinical trials have been performed in 
neurosarcoidosis patients and treatment choices are mainly based on evidence from 
non-neurological sarcoidosis.
 In patients with neurosarcoidosis refractory to first or second-line treatment with 
infliximab, a tumor necrosis factor alpha (TNF) blocker has emerged as a treatment 
option in the past years.3 TNF-α is a pivotal pro-inflammatory cytokine produced 
by macrophages and activated T-cells and plays a central role in the formation and 
maintenance of granulomas.4 Corticosteroids lead to decreased TNF-α excretion 
by alveolar macrophages which may indicate a therapeutic effect in patients with 
pulmonary sarcoidosis.5, 6 This rationale led to two randomized controlled clinical trials 
evaluating the efficacy of infliximab in chronic pulmonary sarcoidosis.7, 8 These trials 
showed mixed results, with a statistically significant improvement of the predicted forced 
vital capacity at 24 weeks after initiation in one study, albeit small with 2.5%.7  However, 
chronic steroid-responsive sarcoidosis patients with nervous system involvement 
may profit from infliximab treatment.9 Moreover, a beneficial effect has consequently 
been described in several case reports and two retrospective cohort studies.3, 10, 11  To 
substantiate this potential beneficial effect of TNF-blockers we analyzed the use of 
infliximab in biopsy proven neurosarcoidosis patients and evaluate the treatment 
response and safety in a large multicenter tertiary center cohort. 
METHODS
A retrospective study was performed with inclusion of all patients with biopsy proven 
sarcoidosis and neurological involvement who were treated with infliximab before the 
1st of June 2017 at the Academic Medical Center (AMC) in Amsterdam and the Erasmus 
Medical Center (EMC) in Rotterdam, two tertiary referral centers for (neuro)sarcoidosis in 
the Netherlands. Ethical approval is not required in the Netherlands for a retrospective 
study with anonymized patient data such as our study. Patients were identified by their 
treating physician and data was collected in a database. The diagnosis of neurosarcoidosis 
was based on the Zajicek criteria, later modified by Tavee.12, 13 In this study we included 
only cases with biopsy proven neurosarcoidosis. A positive histology for sarcoidosis was 
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defined as the presence of histological features consistent with sarcoidosis defined as 
non-caseating granulomas with epithelioid cells and macrophages.6
 For all patients, a case record form was created containing baseline characteristics, 
disease course and immune modulating medication used at baseline, clinical 
characteristics and results of ancillary investigations at baseline, infliximab treatment 
and treatment response, disease course and clinical outcome up to the last time of follow-
up and adverse events. Baseline was defined as the initiation of infliximab treatment. 
All patients were treated with a dosage of 5mg/kg. In the EMC patients were treated 
at week 0, 2, 6 during the induction phase, followed by an infusion once every 4 to 8 
weeks based on the clinical features and seriousness by their treating physician. In the 
AMC patients did not undergo an induction phase and immediately received infusions 
once every 4 to 8 weeks based on the clinical features and seriousness. All patients were 
initially treated with Remicade® and were switched in 2016 to the biosimilar Remsima®. 
All infections, infusion reactions and laboratory abnormalities that occurred during 
the use of infliximab were reported. The response rate to treatment in each case was 
scored as “improvement on therapy”, “stable disease” (e.g., unchanged compared to 
clinical situation prior to treatment), “deterioration” and “spontaneous improvement” 
(e.g., improvement in patients not treated for neurosarcoidosis or improvement after 
ceasing treatment in patients). Clinical outcome was graded into functional disability 
at the last recorded presentation in in- or outpatient setting. The functional disability 
in each case was scored, using the Modified Rankin Scale (mRS), as “asymptomatic”, 
“complaints without functional disability”, “complaints with minor functional disability” 
(e.g. neurological deficits mildly interfering in everyday life, such as inability to cycle 
due to motor dysfunction), “complaints with moderate-to-severe functional disability” 
(e.g. neurological deficits interfering everyday life, resulting in failure to return to job or 
school, requirement of special equipment such as crutches or a wheelchair, or assistance 
with everyday activities) and death.
 Statistical analysis was performed to compare differences between groups using the 
Fisher’s exact test for dichotomous variables and binary logistic regression for ordinal 
and continuous variables. A p-value <0.05 was considered significant.
RESULTS
CLINIC AL CHAR AC TERISTICS
A total of 28 patients were included, 11 in the AMC and 17 in the EMC. Baseline 
characteristics, clinical manifestations and ancillary investigations at the start of infliximab 
are described in table 1 and were similar in both centers. The median time of follow-up was 
32 months (IQR 17-54). The included patients had a mean age at baseline of 42 (SD 10.3) 
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and 16 (57%) were male. Of these patients 16 (57%) were Caucasian, 6 (21%) of African 
descent and 6 (21%) had other ethnic backgrounds. Neurological involvement at the 
start of infliximab consisted of parenchymal involvement in 16 patients (59%), pituitary/
hypothalamic involvement in 15 (54%), peripheral nerve involvement in 12 (43%), chronic 
meningitis in 11 (41%), cranial nerve palsy in 7 (25%), hydrocephalus in 6 (22%), spinal 
cord involvement in 5 (18%) and muscle involvement in 1 patient (4%). The majority 
of patients had systemic involvement including lymph node (27%), intrapulmonary 
(27%) and ophthalmologic (22%) involvement. According to the Zajicek criteria 2 
patients were diagnosed with definite and 26 patients with probable neurosarcoidosis. 
TABLE 1. Baseline characteristics and disease course at baseline
Characteristic n/N (%) Characteristic n/N (%)
Age at baseline (SD), years 42 (10.3) Ancillary investigations
Male sex 16 (57) Serum ACE elevated 0/12 (0)
Ethnicity Serum sIL2r elevated 4/6 (67)
 Caucasian 16 (57) Serum CRP elevated 7/21 (33)
 African descent 6 (21) Serum ESR elevated 8/19 (42)
 Othera 6 (21) CSF leukocytes elevated 6/6 (100)
Neurological involvement CSF protein elevated 6/6 (100)
Parenchymal 16/27 (59) Chest CT suggestive 3/4 (75)
Neuro-endocrine 15/27 (56) 18F-FDG PET-CT suggestive 1/6 (16)
Peripheral nerve 12/27 (44) MRI brain suggestive 21/22 (95)
Chronic aseptic meningitis 11/27 (41) MRI spinal cord suggestive 2/7 (29)
Cranial nerve palsy 7/27 (26) Immunosuppressant use at baseline
Hydrocephalus 6/27 (22) Corticosteroids 11/28 (39)
Spinal cord 5/27 (19) Corticosteroids + methotrexate 6/28 (21)
Muscle 1/27 (4)  Corticosteroids + azathioprine 4/28 (14)
Systemic involvemente Methotrexate 2/28 (7)
Lymph node 18/25 (72) Corticosteroids + hydrochloroquine 1/28 (4)
Lungs 7/26 (27) Corticosteroids + MMF 2/28 (7)
Eye 6/27 (22) None 3/28 (11)
ENT 3/28 (11) Total immunosuppressant use before IFX
Skin 2/27 (7) Corticosteroids 28/28 (100)
Joints 1/28 (4) Methotrexate 14/28 (50)
Zajicek criteria Azathioprine 13/28 (46)
 Definite neurosarcoidosis 2/28 (7) Mycophenolate Mofetil 5/28 (18)
Probable neurosarcoidosis 26/28 (93) Cyclophosphamide 2/28 (7)
Hydroxychloroquine 1/28 (4)
Cyclosporine 1/28 (4)
a Other ethnicities: 2 (7%) North African 2 (7%) Hindustan, 1 (4%) Asian and 1 (4%) Hispanic
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Treatment used at the start of infliximab consisted of corticosteroids in 11 patients (39%), 
prednisolone and methotrexate in 6 (21%), prednisolone and azathioprine in 4 (14%), 
methotrexate and prednisone with mycophenolate mofetil in 2 (7%) and prednisone with 
hydrochloroquine in 1 patient (4%). Three patients were not receiving immunosuppressive 
medication at the start of infliximab, but had received this previously. Before the start of 
infliximab, all patients had been treated with corticosteroids, 14 (50%) with methotrexate, 
13 (46%) with azathioprine and 5 (18%) with mycophenolate mofetil, 2 (7%) with 
cyclophosphamide and 1 (4%) with hydroxychloroquine or cyclosporine. Overall, 24 
of 28 patients (86%) had been treated with second line treatment previously (table 2).
TABLE 2. Treatment and outcome
Characteristic n/N (%) Characteristic n/N (%)
Duration of infliximab treatment in months 26 (18) 1st or 2nd line treatment change
Total number of infliximab infusions XX (8-30) Taper of 1st line treatment 6/28 (21)
Infliximab dosage Stop of 1st line treatment 13/28 (46)
    5mg/kg 1x/4 weeks 5/28 (18) Stop of 2nd line treatment 4/28 (14)
    5mg/kg 1x/6 weeks 12/28 (43) Auto-antibodies 1/5 (20)
    5mg/kg 1x/8 weeks 11/28 (39) IFX dosage decrease or stop 19/28 (68)
Reason to start with infliximab Good treatment response 8/28 (29)
Relapse when tapering 1st line,  
despite 2nd line
16/28 (57) Insufficient treatment response 2/28 (7)
Serious side effects 1st or 2nd line  
treatment
8/28 (29) Major side effects 3/28 (11)
Chronic progression despite 1st or 2nd  
line
3/28 (11)
Stable symptoms, no disease 
activity
4/28 (14)
Relapse after tapering 1st line 1/28 (4) Other 2/28 (7)
Treatment response No change/stop IFX 9/28 (32)
Remission 6/28 (21) Result of change/stop IFX
Improvement 14/28 (50) None 11/19 (58)
Stable disease 7/28 (25) Relapse 5/19 (26)
Deterioration 1/28 (4) Unknown 3/19 (16)
Change of sIL2r Complications of IFX treatment 10/28 (36)
Improved to normal levels 9/14 (64) Infections 8/28 (29)
Remained elevated 2/14 (14) Elevated liver tests 1/28 (4)
Remained stable 2/14 (14) Allergic reaction 1/28 (4)
Deteriorated to abnormal 1/14 (7) Modified ranking score
Change of neurological imaging No disability 7/28 (25)
Improvement 15/21 (71) Low disability 9/28 (32)
Stable 4/21 (19) Moderate disability 6/28 (21)
Other abnormalities 2/21 (10) Severe disability 1/28 (4)
Death 5/28 (18)
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sPt. 1 - before infliximab sPt. 1 - after infliximab sPt. 2 - before infliximab sPt. 2 - after infliximab
FIGURE 1. Results of MRI brain before and after start of infliximab Contrast enhanced MRI 
T1 sequence before and during infliximab of two patients of the AMC cohort (patient 10 and 11). 
Both patients had a complete clinical and radiological response to infliximab.
THER APEUTIC OUTCOME
The starting dose of infliximab was 5 milligrams per kilogram in all patients and was 
given once every 4 weeks in 5 patients (18%), once every 6 weeks in 12 patients (43%) 
and once every 8 weeks in 11 patients (39%). The median total number of infusions was 
17 (interquartile range [IQR] 8 – 39) and infliximab treatment had a median duration 
of 23 months (IQR 12 – 38). The most frequent reason to start infliximab was a relapse 
when tapering corticosteroids despite second line treatment in 16 of 28 patients 
(57%). Other reasons were serious side effects of first and/or second line treatment in 
8 (29%), chronic progression despite first and/or second line treatment in 3 patients 
(11%) and a relapse after tapering corticosteroids in 1 patient (4%). The treatment 
response consisted of remission in 6 patients (21%), improvement in 14 patients (50%), 
stable disease in 7 patients (25%) and death in 1 patient (4%). Treatment responses 
were similar in both centers. The sIL-2R values returned to normal levels in 9 (64%) and 
improved in 2 of 14 patients (14%). Neurological MRI was repeated in 21 patients at 
follow-up and radiological abnormalities attributed to neurosarcoidosis decreased in 
15 (71%), remained stable in 4 patients (19%) and deteriorated in one patient (7%). 
Additionally, one patient developed hydrocephalus. A favorable treatment response 
was not dependent of ethnicity (p=0.85), age at the start of infliximab (p=0.13) and time 
between diagnosis neurosarcoidosis and the start of infliximab (p=0.08) in a logistic 
regression analysis. Furthermore, a favorable treatment response was not significantly 
associated with the use of second line therapy in combination with infliximab (13/15 
[87%] versus 7/13 [54%], p=0.10). A favorable treatment response was seen more 
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frequently in men compared to women (14/16 [88%] versus (6/12 [50%], p=0.044). First 
line therapy was tapered in 6 of 28 patients (21%) and stopped in 13 patients (46%), 
without signs of disease reoccurrence. Second line treatment was stopped in 4 (14%) 
and did not change in 9 of 28 patients (32%). The infliximab dosage was decreased in 
4 of 27 patients (15%) during follow up and was stopped in 15 of 27 patients (56%). 
Before infliximab After infliximab
 
FIGURE 2. Systemic imaging before and after start of infliximab 18F-FDG PET/CT imaging of 
patient 2 of the AMC cohort, before and after the start of infliximab showing a decreased uptake 
of hilar FDG avidity and decrease in lymphadenopathy.
This was done due to a good treatment response without signs of disease activity in 
8 patients (29%), stable disease without signs of disease activity in 4 patients (14%), 
major side effects in 3 patients (11%) and insufficient treatment response in 2 patients 
(7%). In patients of whom the dosage was decreased or the infliximab was discontinued, 
a relapse was reported in 5 of 19 patients (26%), which was not associated with the 
length of infliximab use before discontinuation. Infliximab was restarted or dosage 
was increased in all these patients leading to a favorable treatment in four patients 
and stable disease in 1 patient. Of the remaining 9 patients in whom infliximab was 
continued a relapse occurred in 1 of 9 patients (11%), which was attributed to the 
stop of methotrexate because of liver toxicity. Auto-antibodies against infliximab were 
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tested in 5 patients who experienced a relapse and was positive in three patients. These 
patients were switched to adalimumab, which led to improvement in two patients and 
stable disease in one patient. At the last time of follow up, 7 of 28 patients (25%) had no 
disability, 9 (32%) had low disability, 6 (21%) had moderate disability, 1 patient (4%) had 
severe disability and 5 (18%) died. Of the patients who died, cause of death was sepsis in 
two patients and brain stem hemorrhage, malignancy and an unknown cause of death 
in one patient. Of these patients, only the two patients with infectious complications 
used infliximab at the time of death and both were on concomitant corticosteroid 
therapy. Complications attributed to infliximab treatment occurred in 10 of 28 patients 
(36%) and consisted of infections in 8 patients (29%), elevated liver tests and an allergic 
reaction both in 1 patient (4%). Infections consisted of pneumonia in 4 patients, urinary 
tract infection in combination with pneumonia in 1 patient and urinary tract infection 
in 1 patient, all necessitating hospital admission. Three out of 6 patients with infections 
also used corticosteroids and 2 already suffered from these infections before the start of 
infliximab. Three patients with infections eventually died during follow-up. In 3 of the 15 
patients (20%) in whom infliximab was stopped this was due to side effects, consisting 
of elevated liver tests, recurrent infections or an allergic reaction.
DISCUSSION
In this multicenter retrospective cohort study, we report a favorable long-term outcome 
and safety of neurosarcoidosis patients treated with infliximab. To date, the evidence for 
the use of infliximab in neurosarcoidosis consists of case reports and two retrospective 
multicenter cohort studies describing 18 and 66 patients with probable or definite 
neurosarcoidosis.10, 11 Both papers described treatment responses with improvement 
or remission in 89% and 77% of patients respectively, which is comparable to those 
described in the present study.10, 11 Naam et al. described an inversed correlation between 
the duration of neurosarcoidosis and a favorable treatment response. This finding 
could not be reproduced in this cohort, however given the severity of the neurologic 
manifestation it seems reasonable to start infliximab when first line treatment fails and 
a quick treatment response is required or when second line treatment fails. 
 In our cohort starting infliximab was followed by tapering of concomitant first line 
treatment in 67% of patients and eventually complete discontinuation of corticosteroids 
in 46% of patients. This is in line with another study describing discontinuation of steroids 
after the start of infliximab in 40% of the patients and maintenance of prednisone on 
5 milligrams per day or less in 27% of the patients.11 This suggests that infliximab has 
prednisone sparing effects, which is in accordance to trials performed in patients with 
refractory or severe Crohn’s disease in which infliximab is found to increase the steroid 
free interval.14 Furthermore, this is important given the side effects associated with 
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long-term corticosteroids use.15
 Currently, no international guidelines exist on how to proceed after a favorable 
treatment response following infliximab treatment. In patients in whom infliximab 
treatment was stopped or dosage was decreased, one-fourth had a relapse of disease 
activity. This is a lower relapse rate then described previously in 56% of the patients.11 
Observational studies describing the use of infliximab in patients with a clinical 
remission of Crohn’s disease, found relapse rates of between 40 and 50% of patients 
after infliximab cessation.16 These data stresses the importance of monitoring disease 
activity after infliximab cessation, although it remains unknown if there are predictors 
for relapse in neurosarcoidosis. In case of a relapse, dosage can be increased and/or 
intervals between infusions can be shortened quickly. In our cohort, when patients 
were reintroduced to infliximab, they were likely to again show a good treatment 
response, similar as seen in inflammatory bowel disease.17 Also, it is essential to assess 
auto-antibody formation and infliximab trough levels when a patient shows signs of a 
relapse.18, 19 Concomitant methotrexate is advised as this has been shown to be efficient 
in reducing immunogenicity.20 Furthermore, combination therapy with another steroid-
sparing agent may be associated with a favorable treatment response to infliximab.11
 An important side effect of infliximab is the occurrence of infections in 29% of 
the patients, which is a well-known complication. Importantly, 2 patients died of 
sepsis when using infliximab during follow-up, however it is not known whether it is 
only the effect of infliximab or merely the concomitant use of corticosteroids in these 
patients. The infection rate is in accordance to other studies describing infliximab use 
in neurosarcoidosis varying between 10 and 39%, however in these studies none of the 
patients died due to infectious complications.10, 11 In a phase 2 randomized controlled 
trial assessing the efficacy of infliximab in non-neurological sarcoidosis, authors 
described infections in 54 of 91 patients (59%) of which 11 were defined as serious.7 
In a larger randomized controlled trial performed in patients with moderate to severe 
Crohn disease, infections were reported in 44% of patients treated with infliximab of 
which 10% were defined as serious.14 The risk of infectious complications is considered 
to be higher when patients are treated in combination with corticosteroids or other 
immunosuppressive drugs.21, 22 This data suggest that tapering corticosteroids remains 
essential when signs of disease activity have diminished. Sequentially, infliximab 
infusions can be delayed and stopped. One study found that most opportunistic 
infections occur in the first year of treatment, stressing the importance of preventing 
screening of opportunistic infections before the start of infliximab, most importantly 
tuberculosis as is routinely performed.21
 In our cohort both hospitals treated patients with the biosimilar Remsima from 
2016 onwards for both new and patients already receiving infliximab. To date, there 
is limited evidence on the use of biosimilars in sarcoidosis. An expert opinion paper 
advised that patients who were not treated before with infliximab may safely start with 
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a biosimilar, however the authours advised to avoid switching patients to biosimilars 
when already using infliximab.23 Furthermore, in a small retrospective cohort study 
biosimilar Inflectra showed comparable efficacy and safety compared to Remicade in 
patients with refractory sarcoidosis.24 Although our cohort is small, our study does not 
provide evidence for the advice not to switch patients already using infliximab, as was 
to be expected from large studies in other immune mediated diseases.25, 26 
 Our study has several limitations. Firstly, both the retrospective and multicenter 
approach of our study resulted in heterogeneous assessment of disease activity, 
treatment strategies and outcome, as well as missing data in some patients. Furthermore, 
treatment strategies differed between the two centers. In the EMC an induction phase 
used when they started patients on infliximab, while the AMC initiates treatment once 
every 4 to 8 weeks without an initial induction phase. Despite these differences, baseline 
characteristics and treatment response did not differ between the two centers. However, 
sIL-2R measurements were only performed in the EMC cohort. These limitations are 
inherent to the study design and to overcome the problem of missing data we gave 
an overall of n of N (%) in presenting our results. In addition, a majority of patients 
were treated with first – and/or second line therapy possibly contributing to treatment 
responses and the occurrence of side effects. Lastly, we included only patients treated in 
our tertiary referral centers, introducing a selection bias. We feel that neurosarcoidosis 
patients treated with infliximab must be treated at specialized centers, which is the 
norm in the Netherlands.
 In conclusion, these results provide additional evidence for the use of infliximab in 
neurosarcoidosis as our results suggest that it is effective and can prevent long term use 
of high dose corticosteroids reducing long-term side effects. Physicians should be aware 
of possible side effects as seen in 36% of patients in our cohort, with a risk of serious 
infectious complications. In addition to the high response rate to infliximab, this study 
provides further evidence that infliximab is relatively safe to use in neurosarcoidosis. 
Most importantly, it remains essential to perform prospective cohort studies and 
randomized controlled trials in neurosarcoidosis patients. These should shed light 
over when to start with infliximab, whether mono- or combination therapy is preferred 
and when to decrease and/or stop infliximab dosage during follow-up. Given the high 
relapse rate after discontinuation of infliximab, possible predictors of relapses are 
warranted.  
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The research described in this thesis focuses on granulomatous auto-inflammation. 
Granulomas are inflammatory structures with a complex interplay between 
macrophages, T cells and B cells. Typically, granulomas are formed in response to 
infections. For example, in patients with tuberculosis, the most prevalent infection 
worldwide, pulmonary granulomas are presumed an effective immunological response 
by encapsulating the tubercle bacillus. However, certain chronic immune-mediated 
non-infectious diseases are also characterized by granulomatous inflammation. 
The most well-known example is sarcoidosis, for which granuloma formation is the 
hallmark of disease. In other disorders, including Crohn’s disease and common variable 
immunodeficiency (CVID), granulomas are present in substantial subsets of patients. In 
contrast to infectious causes, in which granulomas show signs of necrosis, granulomas in 
sarcoidosis and Crohn’s disease do not usually have necrotic characteristics. Granuloma 
formation and maintenance in general, highly depends on the production of tumor 
necrosis factor alpha (TNF-α), explaining the effectivity of TNF-blocking therapy in both 
sarcoidosis and Crohn’s disease. Infliximab is the most commonly used TNF-blocker 
in both diseases. We have aimed to study as described in this thesis, the immune 
compartment in granulomatous inflammatory diseases, with a focus on B cells in tissue 
and blood in order to improve diagnostics and identifying disease targets and markers 
for therapy.
 Analysis of intestinal tissue in patients with Crohn’s disease demonstrated numerous 
B cells around granulomas (Chapter 2). These patients had increased transitional B cells 
and anergic CD21low B cells in the peripheral blood. Furthermore, patients had fewer 
IgM memory B-cells and increased levels of somatic hypermutation (SHM) in IgA and 
IgG transcripts.  In Chapter 3, we correlated the amount of B cells in the intestinal tissue 
with the presence of granulomas in Crohn’s disease. With the addition of B-cell staining 
to the conventional hematoxylin and eosin (H&E) staining, the detection of granulomas 
was enhanced. Improved granuloma prevalence results in a better distinction between 
Crohn’s disease and ulcerative colitis, another type of inflammatory bowel disease (IBD) 
with overlapping clinical features. 
 The observations in Chapter 2 and 3 on the relevance of B cells in Crohn’s disease add 
to the B-cell aberrations that are seen in sarcoidosis. Whether these observations were 
clinically relevant was described in Chapter 4. B- and T-cells analysis before and during 
infliximab therapy demonstrated a rapid response in increase of numbers of IgM memory 
B cells, Tregs and Th17 T cells in patients who respond well to infliximab. Patients who 
developed anti-drug antibodies (ADA) during this study had normal levels of sIL-2r with 
lower levels of Tregs and higher levels of IgM memory B cells compared to responding 
patients at baseline. These observations indicate that sIL-2R, Tregs and IgM memory B 
cells may represent early markers for therapeutic success. More in depth B-cell analysis 
demonstrated increased levels of SHM in rearranged Ig transcripts persisted during 
therapy, indicating persistent chronic activation in this compartment. Remarkably, a 
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majority of the treated patients described in this chapter had an excellent response to 
infliximab. They represent sarcoidosis patients with a variety of organ involvement. The 
role of infliximab in neurosarcoidosis, an uncommon but often severe progressive type 
of sarcoidosis, was unclear with limited evidence from small number of case reports. In 
Chapter 5, results were presented from a multicenter retrospective cohort study of the 
effects of infliximab in neurosarcoidosis. Most of the patients showed a good response 
to infliximab with either improvement or remission of disease, however, there was a 
high chance of relapse after discontinuation. For the majority of patients who relapsed 
after discontinuation, a clinical response was present upon reintroduction of infliximab.
IMMUNOPATHOGENESIS
GR ANULOMATOUS AUTO-INFL AMMATION
In Chapters 2 and 3, we demonstrated abundant B cells surrounding granulomas in 
Crohn’s disease. Several studies have made similar observations in the past.(1) However, 
this was not actively pursued and both sarcoidosis and Crohn’s disease were typically 
considered to be Th1 driven diseases. In more recent years, scientific opinion appears to 
be expanding for example, different types of T-cell subsets have been identified, and have 
been shown to be involved in these chronic immune-mediated diseases, such as Tregs 
and Th17 cells. Additionally, more research has been performed on the involvement of B 
cells.(2-5) The latter has become of interest as other immune-mediated diseases, such as 
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and granulomatosis with 
polyangiitis, display B-cell involvement. B-cell depletion in these disorders, for example 
with rituximab, generally results in clinical improvement. 
 In Chapters 2 and 3 of this thesis we have described that on top of CD4+ T cells 
scattered in and around granulomas; a vast amount of B cells was seen around 
granulomas (Figure 1). B cells are typically known for their capacity to differentiate 
into plasma cells that produce antibodies. B cells also exhibit important other 
roles in the immune system, including antigen presentation, cytokine production, 
promoting a more Th1 or Th2 environment and B-T cell co-stimulation.(6) In Chapter 
2 we showed that to a lesser extent, CD138 positive plasma cells were also present 
around granulomatous tissue, perhaps contributing to antibody production around 
granulomas. The question, therefore, is raised as to whether B cells contribute to a 
pro- or anti-inflammatory environment in granulomatous inflammation. B cells are also 
present around tuberculosis granulomas and in infected tissue.(7) It is hypothesized 
that further systemic damage is reduced by isolating the microbe within a granuloma.
(7) However, in the case of chronic inflammatory diseases where no antigen can be 
truly identified, a microbiotic containment seems less relevant. Colitis murine models 
115
6
G
eneral discussion
underline the importance of B cells as these cells can suppress colitis resembling Crohn’s 
disease by regulating T cells through IL-10 production,(8, 9) while in another model B 
cells prohibit regulatory T cells from suppressing T-cell function.(10) Costimulatory 
pathways including ICOS, CD40 and CD80 are involved in these murine models.(9-11) 
These data cannot be translated directly to human disease, yet it implies that the many B 
cells surrounding granulomas are not mere bystanders and may, therefore, have a more 
active role in this inflammatory state. This may be enhanced by the proximity to T cells, 
enabling B and T cells to interact.  The exact role of B cells in granulomatous inflammation 
needs to be further studied, particularly due to the increased availability of treatments 
targeting B cells or B-T cell co-stimulatory pathways for immune-mediated diseases. 
FIGURE 1. Model of the cellular organization of a non-caseating granuloma. Histology of 
granulomatous tissue (e.g. in Figure 1) displays the presence of macrophages, epithelioid cells 
and multinucleated giant cells in the core of the granuloma. Th cells are localized in and around 
the granuloma. B cells are rarely seen in granulomatous structures, however they are numerously 
present around granulomas.(3)
SYSTEMIC B-CELL ABNORMALITIES IN  
CROHN’S DISEASE AND SARCOIDOSIS
In Chapter 2, the peripheral blood compartment was extensively studied in patients 
with Crohn’s diseases. This resulted in the identification of elevated levels of transitional 
and anergic CD21low B cells, while both IgM+IgD-CD27+ ‘IgM only’ and IgM+IgD+CD27+ 
‘natural effector’ cells were decreased with normal absolute numbers of class-switched 
memory cells. The observed decrease in IgM memory B cells in Crohn’s disease was in 
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line with previous studies, as was the increase in these cell numbers during infliximab 
therapy. (2, 12, 13) In addition to this, we showed that natural effector B cells in Crohn’s 
disease might not be produced normally. Not only were IgM B-cell numbers decreased, 
but they also carried reduced SHM levels and their replication history was reduced 
and more in the range of naive B cells. In addition to decreased switched memory B 
cells, IgM memory B cells were also decreased in sarcoidosis, (3, 4, 14) and showed 
an increase in numbers during successful treatment with infliximab (Chapter 4). 
Interestingly, this finding extends to other immune-mediated diseases such as RA, SLE 
and spondyloarthritis.(15-17) In RA, natural effector B cells accumulate in the inflamed 
synovium of patients and traffic to the peripheral blood upon treatment with TNF-
blockers.(15) As decreased IgM memory B cells are such a common finding throughout 
many immune-mediated diseases, it would be an interesting future research topic. 
For example, synovial inflamed tissue in RA, intestinal biopsies from colonoscopies in 
patients with Crohn’s disease or skin biopsies of patients with skin sarcoidosis together 
with blood withdrawal from the same patient at the same time would represent the 
local and systemic inflammatory response. Through flowcytometric analysis, different 
lymphocytic subsets could be quantified and IgM memory B cells could be sorted for 
further analysis. IgM memory B cells in Crohn’s disease showed less replications and 
SHM, but this has not been tested in any of the other diseases, let alone in IgM memory 
cells derived from inflamed tissue sites. One group explains the decrease in IgM memory 
B cells in Crohn’s disease with decreased splenic function.(2) However, this seems less 
likely as another study showed low prevalence of hyposplenism in patients with Crohn’s 
disease and the increased risk of infections with patients with Crohn’s disease is mostly 
attributed to the use of immunosuppressive medications and not the disease itself since 
hyposplenism of decreased splenic function is seldomly described.(18, 19) Furthermore, 
only a subset of IgM memory B cells are derived from T-cell independent reactions and 
an estimated 67% is derived from germinal center reactions.(20, 21) Ideally, functional 
assays would be performed with the purified IgM-memory cells as, in general, function 
of these cells is still poorly understood. In healthy controls, IgM-memory B cells have 
higher expression of IFN-γ which can lead to an induction of class-switching to IgG2 
and have the potential to re-enter germinal center reactions.(22) In both sarcoidosis 
and Crohn’s disease we observed higher SHM levels and more IgG2 subclass usage, 
indicative of repetitive germinal center responses (Chapter 2 and 4). Perhaps these 
repetitive germinal center responses, with ongoing Ig class switching, could partly 
explain the lower level of IgM memory cells in peripheral blood.  Future research on 
IgM memory cells in inflammatory disease, and specifically addressing their functional 
capacities, would be of significant interest as it could be translated to the function of 
IgM memory in healthy individuals and other immune-mediated diseases. 
 One noted difference in B-cell subsets between sarcoidosis and Crohn’s disease is 
the distribution of CD38dim CD21low B cells: these were increased in patients with Crohn’s 
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whereas these numbers were normal in patients with sarcoidosis. These CD21low B 
cells are an intriguing subset of cells because of the minimal occurrence in healthy 
controls. In contrast, increased levels were seen in patients with CVID, infections and 
autoimmunity.(20, 23-26) In general, these cells are functionally anergic and yet there 
is little understanding of the exact role of the function of CD21low B cells. Interestingly, 
it was the only aberrant subset of B cells in our patients with Crohn’s disease that 
did not normalize during treatment with infliximab suggesting that downregulation 
of CD21 is not affected by TNF-blockers. Furthermore, patients were treated with 
infliximab for a significant time (8 months to 10 years) and all had excellent therapeutic 
responses suggesting the expansion of CD21low B cells is not related to a long-term 
therapeutic response. Further analysis of this subset would be of interest, particularly 
to study whether these cells show signs of normal apoptosis and exhaustion or have 
autoreactive B-cell receptors as these characteristics are described in other diseases.
(24, 27, 28)
transitional naive
mature
CD27+IgM+
CD27-IgG+
extrafollicular
CD27+IgG+
CD27-IgA+
CD27+IgA+
natural effector
naive B cells memory B cells plasma cellsCD21low B cells
germinal center
SHM
SHM
N
N
N
N
N
FIGURE 2. Characteristics of the peripheral B-cell compartment in Crohn’s disease and 
sarcoidosis. Patients with Crohn’s disease have elevated levels of transitional and CD21low B 
cells while normal in sarcoidosis. The IgM memory compartment is decreased in both diseases 
and in addition natural effector B cells were found to have decreased proliferation and SHM in 
Crohn’s disease. Switched memory B cells on the other side, had normal values in Crohn’s disease, 
yet were decreased in sarcoidosis. Interestingly, both diseases showed elevated levels of SHM in 
IgA en IgG transcripts. Red arrows represent results from Crohn’s disease (Chapter 2); blue from 
sarcoidosis patients, derived from Kamphuis et al.(3)  N; normal.
DIAGNOSTICS AND BIOMARKERS
The two most important types of IBD are Crohn’s disease and ulcerative colitis, which 
differ in clinical symptoms, colonoscopy findings and histological features. However, 
due to the large overlap in symptoms and colonoscopy and histological findings there 
is currently no gold standard in how to diagnose and differentiate IBD. Diagnosis 
is considered a joint approach between clinical symptoms and features seen with 
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endoscopy and histology(29), however, this approach results in a change of diagnosis 
in up to 15% of patients during the course of disease and similar rates of patients being 
unclassified.(29)   
 The most discriminating histological feature is the presence of epithelioid 
granulomas.(30, 31) However, granulomas are only identified in 9-29% of biopsies of 
patients with Crohn’s disease.(32-34) This is likely due to the fact that not all patients 
have granulomas, and due to sampling errors as the percentage of granulomas is higher 
in surgical resection samples of patients. However, granulomas in Crohn’s disease can 
be very small (microgranulomas) and are therefore difficult to detect. We identified 
the presence of many B cells, specifically around granulomatous tissue in patients with 
Crohn’s disease, while B cells were not present in non-granulomatous inflammatory 
tissue of patients with Crohn’s disease (chapter 2). We hypothesized that by focussing 
on B cells in inflamed tissue of IBD patients, it might be possible to increase the yield of 
granulomas and thereby identify true Crohn’s disease patients. Indeed in Chapter 3, we 
demonstrated that dense B-cell infiltrates were indicative of granuloma formation. In this 
retrospective study, the addition of CD20 staining also resulted in a higher prevalence of 
granulomas. Therefore, CD20 staining could be a logical addition to the currently used 
H&E staining in order to optimize the diagnostic process of IBD. This is of clinical relevance 
as disease management is increasingly based on disease specific regimens. For example, 
methotrexate is only used to treat Crohn’s disease, while ileal-pouch-anal anastomosis 
surgery is preferred in patients with ulcerative colitis, or in a highly selected group of 
patients with Crohn’s disease.(29, 35) Moreover, recent studies with vedolizumab, a 
biological inhibiting the adhesion of lymphocytes to the endothelial cells in the intestinal 
tract, showed that this compound was more effective in ulcerative colitis than in Crohn’s 
disease. This indicates that both entities differ not only in immunopathogenesis, but 
also in therapeutic approach. Those findings strengthen the value for optimal clinical 
differentiation for example by adding a simple CD20 staining in the histological samples.
(36, 37) The increasing availability of new biologicals will prompt, even more so, the 
need for a correct diagnosis in IBD patients in order to direct disease-specific targeted 
therapy (precision medicine). The results of our retrospective study are merely a first 
step into optimizing diagnostics with CD20 staining. A prospective trial with a larger 
cohort of newly-diagnosed IBD patients would be necessary to identify whether adding 
to the diagnostic process for IBD would positively impact daily practice. In Chapter 3, we 
were only able to analyze one biopsy site and one slide per patient. Hence, there was a 
substantial risk of sampling error, and the rate of granuloma detection would most likely 
be further increased by analysis of slides from multiple biopsy locations. CD20 is a pan 
B-cell marker which is used on a routine basis as a diagnostic tool for haematological 
malignancies.(38) This staining is relatively straight-forward and inexpensive, and can 
be implemented easily into the clinical work-up. It would be interesting to combine this 
method with analyzing anti-Saccharomyces cerevisiae antibodies, which are present 
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in the majority of patients with Crohn’s disease, but not in ulcerative colitis, and could 
support differential diagnosis between the two disease entities.(39) Potentially, the 
described combined approach will lead to a decrease of misdiagnosis in IBD patients 
of 9%.(40) More refined diagnostics will become of greater importance as many new 
disease specific drugs and targeted therapies are currently being trialled or are expected 
on the market in the immediate future.(41)
TREATMENT MONITORING
With the increasing variations and opportunities for disease-specific targeted biological 
therapies, it has become increasingly important to appropriately select patients who 
are likely to benefit from a targeted therapy. While several agents can be efficacious 
in patients, there are still subgroups of patients with refractory disease.(42, 43) For 
example, only 60% of patients with Crohn’s disease achieve disease control within 26 
weeks.(44) Starting a patient on ineffective therapy can be expensive and will delay the 
start of a potentially effective treatment with the additional risk of disease exacerbation 
and subsequent morbidity. Therapeutic drug monitoring for infliximab has been 
extensively studied in both Crohn’s disease and RA.(45, 46) Serum infliximab trough 
levels have become a standard monitoring tool, because low drug levels are indicative 
of the formation of antibodies against infliximab, ADA that can hamper therapy success.
(47) In contrast to RA and Crohn’s disease, both optimal trough levels of infliximab and 
the formation frequency of ADAs in patients with sarcoidosis had not been thoroughly 
examined. Chapter 4 described a mean serum infliximab trough level of 4.6 μg/mL with 
4 out of 10 patients in this study with a level below the 3 μg/mL threshold. However, only 
one these patients relapsed at that time-point with nearly undetectable infliximab levels 
together with ADA, whereas the other three patients had infliximab levels between 2 
and 3 μg/mL without formation of ADA. Furthermore, 2 out these 3 patients showed a 
long-term response (several years) to infliximab. Infliximab trough levels below 3 μg/mL 
in patients with a successful long-term therapeutic response raise the question whether 
the optimal infliximab levels might be disease-specific and therefore may be different 
in patients with sarcoidosis, or whether serum trough levels do not necessarily reflect 
tissue levels. Infliximab tissue levels have not been well studied in general, yet patients 
with Crohn’s disease only have higher tissue levels of inflamed and non-inflamed 
tissue when serum trough levels were also higher which is associated with long-term 
response.(48) So far, in two studies with sarcoidosis patients, mean trough infliximab 
levels ranged between 7.5 and 18 μg/mL.(43, 49) Furthermore, optimizing therapy can 
be cost-reductive in these rather costly biological therapies and therefore this should be 
further studied in sarcoidosis, especially in relation to ADA, optimal serum trough levels 
and tissue levels. 
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 Currently, serum sIL-2R levels are most widely used as a biomarker in sarcoidosis as 
these seem to reflect disease activity better than angiotensin converting enzyme (ACE) 
levels.(50, 51) The relevance of sIL-2R as a biomarker is further stressed in Chapter 4, in 
which we show that 9 out of 11 patients had elevated levels before the start of infliximab 
treatment with a subsequent decrease following a good response to infliximab. 
Interestingly, the 2 patients who initially presented with sIL-2R levels within the normal 
range did not have a good therapeutic response with detectable ADA within 8 months of 
treatment. These observations suggest that patients with active disease, here reflected 
by higher sIL-2R levels, most likely benefit most from infliximab. To our knowledge, 
only one small study (n=11 patients) specifically analyzed sIL-2R in neurosarcoidosis, 
and concluded it to be a valuable marker of disease for such patients.(52) The results 
in Chapter 5 confirm sIL-2R as a useful biomarker in neurosarcoidosis with the majority 
of patients (9/14; 64%) showing normalization of levels during infliximab treatment. 
Therefore, it can be recommended for sIL-2R to be routinely measured in patients with 
both neurosarcoidosis and sarcoidosis. 
 Another biomarker that has been suggested to monitor therapeutic efficacy in 
sarcoidosis is B-cell activating factor (BAFF). Serum BAFF levels are elevated in patients 
with chronic active sarcoidosis.(14, 53) However, these results were not confirmed by 
the follow-up study with infliximab in this thesis (Chapter 4). The serum BAFF levels did 
not differ significantly between the control and patient groups. While there were some 
patients with very high levels, the BAFF levels in many patients were within the range 
of controls. In addition, no change was seen during infliximab therapy, indicating that 
BAFF is less suitable as a biomarker or monitoring tool in sarcoidosis. 
 Other suggested biomarkers include sCD163.(54) Indeed, in preliminary analysis 
patients with active sarcoidosis had significantly higher levels of soluble (sCD163) than 
healthy controls (Figure 3, unpublished data). These levels were decreased in week 6 
of infliximab therapy. However, despite the significant difference between groups, 
there was a large overlap in levels from patients and controls. sCD163 levels at baseline 
correlated significantly with sIL-2R at baseline (p=0.04), and this correlation nearly 
reached significance at month 8 (p=0.07). CD163 expression in sarcoidosis biopsies was 
significantly increased compared to tuberculosis samples, suggesting a polarization 
of macrophages to the M2 phenotype which is generally associated with chronicity 
towards a fibrotic state in other studies.(55) In accordance to this data, sCD163 was also 
found to be elevated in the serum of sarcoidosis patients with active disease, suggesting 
this assay could be used as a biomarker.(54, 55) However, the overlap in levels between 
controls and patients in our study indicate that the sole use of sCD163 as a biomarker 
will not suffice and a combination with other markers might be needed to increase 
sensitivity.
 In this thesis, we demonstrated differences in specific lymphocyte subsets between 
patients with active sarcoidosis and controls (Chapter 4). Since these subsets can be 
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readily detected by flowcytometry, such measurements could be incorporated in daily 
practice to monitor disease activity and therapeutic efficacy. Numbers of IgM memory 
B cells, Tregs and Th17 cells are candidate tools. To date, lymphocyte subset analysis is 
rarely used in other immune-mediated diseases as reproducibility appears to hamper 
accurate results for example, due to differences in patient groups or differences in 
sample processing procedures.(56) For now, the results presented in this thesis identify 
key areas in the inflammatory processes ongoing in immune-mediated diseases. In the 
near future, when distinct patterns are identified in larger cohorts, the potential use of 
subsets in a more standardized and applicable manner could be more easily applied to 
routine clinical practice. 
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FIGURE 3. Scatter-dot plot of plasma sCD163 levels during infliximab treatment in patients 
with sarcoidosis and correlation with sIL-2R at baseline (B) and month 8 (C) of therapy. 
Statistical analysis includes paired Mann-Whitney test (A) and Spearman correlation analyzations 
(B and C); patients and controls are from Chapter 4.
*, P<0.05; **, P<0.01. 
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THER APY
In this thesis we showed clinical efficacy of infliximab in pulmonary and extra-pulmonary 
sarcoidosis (Chapter 4) and neurosarcoidosis (Chapter 5). The initial randomized 
controlled trial (RCT) from Baughman et al. in pulmonary sarcoidosis only identified a 
minor effect of mean increase in FVC of 2.5%.(43) However, subsequent studies identified 
more positive outcomes with an overall disease improvement ranging from 60-92%. 
(49, 57-59) Our own experiences in extra-pulmonary sarcoidosis have prompted the use 
of infliximab in patients with sarcoidosis in daily practise as a third line therapy, and 
as induction therapy in some instances such as neuro-sarcoidosis or vision-threatening 
sarcoid-induced uveitis. The positive effects described in Chapter 4 and 5 might be 
explained by including patients with active and serious sarcoidosis reflected by the 
high levels of sIL-2R and/or positive nuclear scans. Furthermore, such patients with 
active and organ-threatening disease have high levels of TNF-α and represent a cohort 
that has been associated to benefit most from TNF-blocking therapy in other studies 
with sarcoidosis patients.(49, 60) The data presented in this thesis emphasizes the need 
for follow-up studies with designs that better reflect daily clinical practice. The data 
of patients with neurosarcoidosis studied in Chapter 5 also illustrates that, in spite of 
overall high response rates with improvement or remission of disease, patients often 
show a relapse of disease after discontinuation of therapy. In line with data from Crohn’s 
disease, patients who were reintroduced to infliximab often remain responsive. This data 
indicate that infliximab can be safely discontinued when a long and stable period of 
remission is achieved.(61) The exact duration of that response needs to be determined.
 Recently, biosimilars of infliximab have become available.(62) Since 2016, our center 
(and many others) treat all patients with a biosimilar (Remsima). Patients enrolled in 
the studies presented in Chapter 4 and 5, were started on therapy in 2016 or 2017, and 
were therefore treated with Remsima. Large studies in RA and Crohn’s disease have 
shown that efficacy was similar to the original Remicade, while being cost-reductive.
(63, 64) Recently, the safety and effectivity of biosimilars has also been demonstrated 
for sarcoidosis.(65) In addition to the clinical effectivity of infliximab biosimilars, the 
immunogenicity of biosimilar Remsima was similar to that of the original Remicade, 
as reflected by the infliximab trough levels and ADA assays in Chapter 4. The ability to 
prescribe biosimilars and therefore reducing the overall costs of health care, is of particular 
interests in patients with sarcoidosis as it is a rare disease with off-label restrictions. 
OC TREOTIDE (SANDOSTATIN ©) THER APY  
IN PATIENTS WITH CHRONIC SARCOIDOSIS
Many patients with chronic sarcoidosis face side effects of treatment and refractory 
disease. Therefore, there is still a need for new therapeutic options, and the search 
for novel treatment strategies is warranted. A better understanding of the immune-
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pathophysiology and cellular and molecular characteristics of specific diseases could 
help to identify targets for new therapeutic agents.
 Octreotide is one of these drug candidates. Treatment with this somatostatin 
(SS) analogue has demonstrated significant therapeutic effects in patients with in 
cystoid macula edema, neuro-endocrine tumors (NET) and various other diseases.(66) 
Octreotide is thought to exerts its therapeutic effect in NET by binding to somatostatin 
receptors sst2 and sst5 in SS-positive lesions. As a result, the hormone secretion from 
the tumor is inhibited resulting in apoptosis and cell cycle arrest.(67) Sst2 is widely 
expressed by monocytes and macrophages in steady state as well as by monocytes, 
macrophages and epithelioid cells in granulomatous tissue, e.g. in sarcoidosis.(68, 69) 
Somatostatin receptor scintigraphy (SRS) is a valuable tool in diagnosis of sarcoidosis 
through detection of sst2 positive lesions with imaging.(70, 71) Therefore, it can be 
hypothesized that by inhibiting sst2 with octreotide the activity of sst2 positive sarcoid 
lesions can be influenced similarly to those of NET. Indeed, two sarcoidosis patients 
have been treated with octreotide.(69) One patient with pulmonary and mediastinal 
involvement did not show a clinical response, while the other patient with refractory 
skin and lymph node sarcoidosis showed a decrease in SRS uptake and remission of 
skin lesions and lymph node size.(69) Both patients had biopsies positive for sst2 and 
positive SRS, yet only one patient showed a clinical response to octreotide.
 We therefore performed a preliminary analysis of the clinical effects of Sandostatin, 
a long-acting octreotide preparation, in two SRS positive chronic sarcoidosis patients in 
a prospective Phase II study (MEC-2014-099, NTR4655). Included patients had biopsy-
proven, SRS positive chronic sarcoidosis for >3 years with indication for therapy with 
involvement of skin, joint, lymph node and/or lung (diffusion capacity between 60-75%) 
(Table 1). The primary endpoint of this study was change in uptake per organ measured 
with the four point scale as previous described.(71) The secondary endpoint included 
blood tests, RAND-36 score and pulmonary function test. Due to the limited number 
of enrolled patients in this study, we have also reported the results of our two therapy-
refractory patients treated with octreotide outside this trial.
 Uptake on SRS did not change during treatment (Table 1). In addition, no substantial 
or durable improvement was seen in secondary endpoints including pulmonary function 
and sIL-2R. Furthermore, clinical evaluation did not show a decrease in disease activity. 
In this respect our patients still showed symptoms in spite of Sandostatin; patient 1 had 
evident arthritis, patient 2 experienced general systemic complaints, while patient 3 
had a uveitis flare and patient’s 4 kidney function continued to decrease. 
 The adverse events caused by Sandostatin are well known due to its extensive use in 
other diseases. Most common side effects of Sandostatin are gastrointestinal complaints; 
nausea and diarrhea, these side-effects usually show spontaneous resolution.(66) All 
patients reported mild gastrointestinal complaints as described in literature. Patient 1 
developed a significant increase in liver enzymes of more than 3 times the normal values. 
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Sandostatin was discontinued whereupon the enzymes quickly decreased to a stable 
level as they had been prior to the study and the patient chose to discontinue with 
the study. Additionally, gallstones can be formed and have been reported in 20-30% of 
patients, although in most cases these are asymptomatic and therefore do not lead to 
any significant events.(66) Patient 2 developed symptomatic gallstones after 11 months 
leading to a cholecystectomy. Patient 3 had significant weight loss during treatment 
necessitating stop of treatment. Patient 4 discontinued sandostatin after 5 months 
due to lack of effectivity.  In conclusion, we did not observe a response on SRS or other 
any clinical parameter. Adversely, our patients did experience gastrointestinal adverse 
events including one serious adverse event; cholelithiasis leading to cholecystectomy.
 Unfortunately, the negative results from the Sandostatin trial in sarcoidosis, are 
not the only failed study in sarcoidosis. For example, studies with etanercept and 
golimumab, other TNF-blockers and ustekinumab, anti p40 targeting the IL12/IL23 
pathway reported negative results.(72, 73) All these studies included patients with 
chronic, stable disease with a stable dose of corticosteroids, which may contribute to 
the minimal benefits reported. The infliximab RCT in a similar cohort of sarcoidosis 
patients also demonstrated, at best, a very modest result, raising doubts over the clinical 
significance.(43) However, these discreet results have not prevented others from using 
infliximab and it is now widely accepted as a clinical therapeutic agent for many patients 
with sarcoidosis.(43, 57) The results suggest a differential response to infliximab with 
patients with less active disease and pre-existent fibrosis. Infliximab is not registered 
for the use of sarcoidosis and is used off-label, resulting in challenges and restrictions in 
prescribing this costly agent. Interestingly, the results coming from the use of infliximab 
in daily practice in patients with active and severe sarcoidosis are better than the RCT, 
as shown in Chapter 4 and 5. Therefore, it is necessary to organize well-structured trials 
to determine if patients with biopsy proven and active sarcoidosis can truly benefit from 
new treatment strategies. 
POTENTIAL FUTURE TARGETS FOR TREATMENT  
OF GR ANULOMATOUS DISEASES
New therapies are in high demand for refractory patients with chronic inflammatory 
disorders. As new therapeutic targets become evident and new biologicals may become 
available, even for patients with granulomatous disorders, there are several therapeutic 
candidates involving the B- and/or T cells (Figure 4). 
 IL-21 is a cytokine produced by Th cells and stimulates B and T cells through the 
IL-21 receptor. Increased levels of IL-21 were seen in inflamed tissue of Crohn’s disease 
patients with infliximab inducing a downregulation of IL-21.(74) IL-21 is also implicated 
in the immunopathogenesis of RA and therefore treatment with a new monoclonal 
antibody binding to IL-21, NNC0114-0005, is currently being tested in a clinical trial.
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(75) When safety and efficacy is proven in RA, this treatment could be translated into 
other inflammatory disorders such as Crohn’s disease. However, caution should be 
taken because genetic defects in IL-21 were recently reported to cause a severe CVID-
like disorder,(76) and early onset IBD.(77) 
 Interestingly, T-cell function might be improved through targeting of the inhibitory 
receptor programmed death-1 (PD-1).(78) In patients with sarcoidosis, PDL-1 expression 
is increased on T cells in granulomatous tissue, and numbers of PD1-expressing Th cells 
in blood are increased.(79) As a downregulation of PD-1 on CD4 cells was seen in patients 
with spontaneous clinical resolution, blocking the PD-1/PD-1L pathway could be a 
therapeutic target.(79) A variety of malignancies also show upregulation of the PD-1/
PD-1L pathway and currently several antibodies against PD-1, such as pembrolizumab 
and nivolumab, are being tested in treatment of solid and haematological malignancies.
(80) Still, a cautious approach is warranted as sarcoidosis-induced disease has also been 
reported with the use of pembrolizumab in a patient with sarcoma.(81) This case could 
be explained by the enhanced CD4 T-cell proliferation that was reported when PD-1 was 
blocked, which could lead to a Th1 pro-inflammatory response that is also observed in 
sarcoidosis. 
 Inducible T-cell COStimulator (ICOS) and ICOSL are important factors in adaptive 
immunity through B-T cell interaction and genetic defects in ICOS have been reported to 
result in adult onset CVID.(82) Moreover, ICOSL gene polymorphisms are associated with 
Crohn’s disease,(83) and increased ICOS expression was reported on Tregs in patients 
with sarcoidosis.(84) A monoclonal antibody targeting ICOSL, AMG-557, has been 
developed and is currently undergoing the first trial in SLE. While treatment targeting 
the ICOS/ICOSL pathway is still under development, it is a potential target of interest for 
granulomatous inflammatory diseases, because ICOS/ICOSL might be involved in the 
immunopathophysiology of both sarcoidosis and Crohn’s disease. Moreover, targeting 
this co-stimulatory pathway affects both T- and B-cell activation without their cellular 
depletion.(85)
 Finally, promising therapeutics offering alternative approaches to target B cells 
in addition to CD20 blocking agents are in development. Currently, belimumab, a 
monoclonal antibody targeting BAFF has been implemented in the treatment of SLE. 
BAFF is a cytokine produced mainly by macrophages, and it is essential for mature 
B-cell survival.(86) Autoreactive B cells are especially dependent on high BAFF levels.
(87) Patients with active sarcoidosis, Crohn’s disease and CVID can display increased 
BAFF levels.(14, 53, 88, 89) Furthermore, BAFF promotes a Th17 response and produces 
TNF-α, both of which are involved in these diseases. Belimumab may, therefore, be an 
interesting candidate as not only pathogenic B cells are targeted, but also the complex 
interplay between T cells and pro-inflammatory cytokines is covered.(86, 90, 91)
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FIGURE 4. Novel therapeutics that are currently used or in trial for treatment of 
granulomatous autoinfl ammatory diseases that target B- and/or T cells. Indicated are 
monoclonal antibodies that specifi cally target T cells (ustekinumab), or B cells (rituximab and 
belimumab). Anti-TNFα (infl iximab, adalimumab) and anti-IL-21 monoclonal antibodies block 
cytokines that aff ect both B and T cells. Finally, AMG-557 targets ICOSL and aff ects the B-T cell 
interaction: BCR, B-cell receptor; mAb, monoclonal antibody; MHCII, major histocompatibility 
complex class 2; TcR, T-cell receptor.
CONCLUDING REMARKS
Granulomatous infl ammation seen in sarcoidosis and Crohn’s disease is a complex 
interplay between mature macrophages, Th cells and B cells. In this thesis we demonstrate, 
with in depth B-cell analyses, that B-cells are indeed involved in the infl ammatory 
process of granuloma formation. The most important fi ndings that B-cells are involved 
in granuloma formation/homeostasis in this thesis are: 1) the B-cell compartment in 
patients with Crohn’s disease shows dysregulation particularly in the IgM-memory 
compartment with decreased IgM memory cells accompanied by decreased number of 
SHM and fewer cell divisions. 2) B cells are numerously present around granulomas in 
Crohn’s disease. 3) numbers of IgM memory B cells correlate with a therapeutic response 
to infl iximab in patients with sarcoidosis and Crohn’s disease. These fi ndings implicate 
that B cells are not only vastly present in granulomatous infl ammation, they have an 
active role in this process, possibly through B-T cell interaction. Our understanding 
of the immune system is improving, which has led to the development of targeted, 
molecular designed agents (biologicals) of which the TNF-α blockers are the most 
studied and successful examples. In this thesis, we describe the results of infl iximab 
beyond the environment of a randomized controlled trial, in patients with diff erent 
types of sarcoidosis including pulmonary sarcoidosis and neurosarcoidosis. These 
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observations demonstrated better therapeutic responses than initially described in the 
randomized controlled trial. Therefore, infliximab seems to be an effective therapeutic 
agent in, yet to be determined, subgroups of patients with sarcoidosis. Such subgroups 
might include patients with active, extra pulmonary but also pulmonary sarcoidosis 
(Chapter 4 of this thesis) and neurosarcoidosis (Chapter 5). To further enhance the 
success rate, infliximab could possibly be further optimized by 1) treating only patients 
with severe and active sarcoidosis; 2) co-medication with methotrexate or azathioprine 
to reduce development of ADA; 3) therapy monitoring through sIL-2R and infliximab 
levels, combined with blood B- and T-cell analysis.
 The complexity of treating chronic inflammatory diseases is illustrated by numerous 
failed drug trials, while the need for new therapeutics is needed due to the substantial 
occurrence of refractory disease. A translational approach and implementing advances 
in other immune-mediated diseases remains necessary to improve treatment options 
for these refractory patients. Studies into granuloma formation in genetically-defined 
immunodeficiencies can provide candidate pathways, whereas insights into immune 
dysregulation in sarcoidosis and Crohn’s disease can provide immunological markers 
to identify CVID patients at risk for granulomatous complications. Recent insights into 
disease pathogenesis and the potential involvement of B cells open new avenues for 
treatment and, in particular, patients with granulomatous inflammatory disease may 
benefit from targeting B cells or B-T cell interactions with new therapeutics. 
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Granulomas are organized clusters of immune cells containing macrophages, T cells and 
B cells. Granulomas are most often formed upon infection, such as tuberculosis, in order 
to contain the infection. Granulomas can also be formed in chronic immune mediated 
diseases such as sarcoidosis and Crohn’s diseases as a sign of chronic inflammation. 
Both diseases were initially regarded Th1 mediated disease, yet increasing evidence has 
brought the involvement of Th17 cells, Tregs and B cells to the attention.  Sarcoidosis 
and Crohn’s disease are diseases with very different clinical presentations with mainly 
gastrointestinal involvement in Crohn’s disease and a more systemic involvement 
in sarcoidosis commonly involving the respiratory tract, lymph nodes, eyes and skin. 
Despite these different clinical entities, treatment options are quite similar including 
corticosteroids, disease modifying drugs, such as methotrexate and azathioprine and 
tumor necrosis factor (TNF) blockers such as infliximab. 
 In Chapter 2, we studied the involvement of B cells in Crohn’s disease in intestinal 
tissue and peripheral blood in patients without systemic treatment and during 
infliximab therapy. Granulomatous tissue of patients with Crohn’s disease contained 
large B-cell infiltrates. Circulating transitional B cells and CD21low cells were elevated 
while IgM memory B cells were reduced in patients without systemic therapy. Patients 
responding well to infliximab did have normal numbers of transitional and IgM memory 
cells. Furthermore IgM memory B cells showed reduced replication histories and somatic 
hypermutation (SHM) levels suggestive of impaired generation, while switched IgA and 
IgG memory carried increased SHM levels indicating chronic stimulation. Together, 
these results suggest an aberrant and chronic B-cell response, which can be partially 
restored by infliximab.
 In Chapter 3 the earlier described B-cell infiltrates around granulomas in Crohn’s 
disease were further studied. Granulomas are the most distinctive histopathological 
feature in Crohn’s disease, yet are only found in up to a third of all cases. We hypothesized 
that by staining for B cells in biopsies of patients with Crohn’s disease, the prevalence 
of granulomas could be increased. Indeed, granuloma rate increased with a 1.8 fold 
from 20% to 36% of cases. When subtotal colectomy samples of inflammatory bowel 
disease (IBD) patients were studied, three out of 39 patients retrospectively supported 
a diagnosis of Crohn’s disease instead of ulcerative colitis. Furthermore dense B-cell 
infiltrates in Crohn’s disease were significantly related to the presence of granulomas. 
Accurate diagnostic differentiation between Crohn’s disease and ulcerative colitis can 
improve treatment outcome after surgery, but can also be important as many new 
disease specific treatment agents become available. Therefore including CD20 staining 
in standard IBD diagnostics can potentially improve the diagnostic process as well as 
disease management. 
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 Chapter 4 investigated different immunological markers  including sIL-2R, BAFF, 
infliximab trough levels and T – and B-cell subsets in patients with sarcoidosis starting 
infliximab therapy. Mixed therapeutic outcomes are reported in literature and we 
aimed through analyzing these markers to establish markers that determine potential 
response. 9/11 (82%) of patients in this study showed an objective clinical response. 
sIL-2r levels declined after the first infusion, while IgG and BAFF levels did not chance. 
Patients with a good and lasting clinical response showed increasing numbers of 
IgM+ memory B cells as did regulatory T cells, Th17 and Th17.1 cells. Patients who did 
not show a lasting response during this study with formation of anti-drug antibodies 
(ADA) showed a different phenotype at baseline with lower levels of sIL-2R and Tregs, 
with higher IgM-only B cells when compared to responders to infliximab. This chapter 
confirmed the potential of monitoring of lymphocytic subsets, infliximab trough levels, 
sIL-2R and ADA for therapy success in patients with sarcoidosis. 
 In chapter 5, we studied the efficacy of infliximab in patients with neurosarcoidosis, 
a less common but often severe manifestation of sarcoidosis. In this retrospective, 
multicenter study, 28 patients were included. Most patients had a severe clinical 
presentation before infliximab was started with parenchyma localization, pituitary gland 
involvement, peripheral nerve involvement and chronic meningitis. Infliximab resulted 
in a complete remission in six(21%) patients, improvement in fourteen (50%) patients, 
stable disease in seven (25%) and deterioration in one (4%) patient. Furthermore, in the 
majority of patients (68%) successful discontinuation or tapering of corticosteroids was 
achieved. Relapse occurred in 26% of the patients after discontinuation of infliximab, yet 
most patients showed a therapeutic response again after reintroduction of infliximab. 
This study concludes that infliximab is an effective and relatively safe therapeutic agent 
in patients with neurosarcoidosis leading to clinical improvement or even remission in 
most patients. 
 Chapter 6 discussed the general findings described in the previous chapters. This 
thesis provides more evidence that B cells are actively involved in granuloma formation 
and/or preservation, possibly trough B-T cell interaction. Our studies with infliximab 
suggest that infliximab is a therapeutic agent in patients with sarcoidosis including 
pulmonary and extra-pulmonary disease and neurosarcoidosis. Immunological 
monitoring has the potential to further optimize response rates in patients starting 
treatment with infliximab. Still, a substantial fraction of patients with chronic inflammatory 
diseases have refractory disease. The complexity of treating these disorders is reflected 
by numerous failed drug trials. Our results with chronic sarcoidosis patients treated with 
sandostatin are of no exception as no clinically significant effect was observed. 
 With this thesis, we provide new evidence for the involvement of B cells in the 
immunopathogenesis of granulomatous inflammatory diseases. This opens new 
targeted treatment options for these disorders, by either targeting B cells or through 
B-T cell interactions. 
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NEDERLANDSE SAMENVAT TING
Granulomen zijn georganiseerde clusters van afweercellen met onder andere 
macrofagen, T cellen en B cellen. Granulomen worden vaak gevormd bij infecties zoals 
tuberculose, om verder verspreiding in het lichaam te voorkomen. Echter kunnen 
granulomen ook gevormd worden in chronische immuun-gemedieerde ziekten zoals 
sarcoïdose en de ziekte van Crohn, als teken van langdurige ontsteking. Beide ziekten 
werden initieel gezien als Th1 gemedieerde ziekten, maar nieuwe inzichten suggereren 
ook betrokkenheid van Th17, regulatoire T cellen en B cellen. Sarcoïdose en de ziekte van 
Crohn zijn beide verschillende soorten ziekten met verschillende klinische kenmerken. 
Zo heeft de ziekte van Crohn voornamelijk gastro-intestinale betrokkenheid terwijl bij 
sarcoïdose bijvoorbeeld de longen, lymfklieren, ogen en huid kunnen zijn aangedaan. 
Ondanks de verschillende ziektekenmerken zijn de behandelingen die gebruikt worden 
veelal hetzelfde. Bij beide ziekten worden corticosteroïden (bijvoorbeeld prednison), 
immuun modulerende medicijnen zoals azathioprine en methorexaat en tumor necrosis 
factor (TNF) blokkers zoals infliximab gebruikt. 
 In Hoofdstuk 2 hebben wij de betrokkenheid van B cellen bij de ziekte van 
Crohn bestudeerd door darmbiopten en bloed te onderzoeken van patiënten zonder 
medicijnen en patiënten behandeld met infliximab. Granulomateus darmweefsel 
van patiënten met Crohn lieten grote B-cel infiltraten zien. In het bloed werden grote 
hoeveelheden transitionele en CD21low cellen gezien terwijl IgM geheugencellen 
verlaagd waren bij patiënten zonder medicatie. Patiënten die goed reageren op 
infliximab lieten wel normale IgM geheugencellen zien.  Daarnaast zagen wij op 
moleculair niveau dat IgM geheugencellen minder celdelingen hebben doorgemaakt 
met ook minder somatische hypermutaties (SHM). Dit suggereert een defect in de 
aanmaak van deze geheugencellen. Dit in tegenstelling tot IgA en IgG geheugencellen 
welke juist meer SHM hadden wat een indicatie is voor chronische stimulatie van 
deze cellen. Samen laten deze resultaten zien dat er sprake is van een veranderde en 
chronische B-cel respons, welke gedeeltelijk genormaliseerd wordt door infliximab. 
 In Hoofdstuk 3 bestuderen wij de eerder beschreven B-cel infiltraten rondom 
granulomen uit biopten van patiënten met de ziekte van Crohn. Van alle verschillen 
in histopathologie tussen Crohn en colitis ulcerosa (een andere inflammatoire 
darmziekte), is het granuloom het meest kenmerkende verschil tussen deze ziekten. 
Het probleem is dat granulomen slechts in ongeveer een derde van alle Crohn biopten 
wordt gevonden. Onze hypothese was dat door het kleuren voor B cellen in deze 
biopten, wij meer granulomen zouden vinden. Het aantal gevonden granulomen steeg 
inderdaad met 1.8 keer van 20% naar 36% . Wanneer chirurgisch verwijderde stukken 
darm van subtotale colectomie operaties werd onderzocht, waren er daarnaast nog 3 
van de 39 patiënten die achteraf meer een diagnose Crohn in plaats van colitis ulcerosa 
hadden. Daarnaast vonden wij een relatie tussen de hoeveelheid B cellen in een biopt 
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en de kans op granulomen; hoe meer B cellen hoe groter de kans dat er granulomen te 
zien waren. Het is belangrijk om goed onderscheid te kunnen maken tussen de ziekte 
van Crohn en colitis ulcerosa omdat dit een verschillende uitkomst in chirurgische 
opties kan betekenen, maar ook gezien nieuwe ziekte specifieke medicijnen die de 
komende jaren op de markt zullen komen. Daarom wijst dit onderzoek uit dat door 
CD20 (B-cel kleuring) aan de standaard diagnostische kleuring toe te voegen, mogelijk 
de diagnostisering van inflammatoire darmziekten kan verbeteren en daarmee ook de 
uiteindelijke behandeling van de juiste ziekte. 
 Hoofdstuk 4 laat verschillende immunologische markers zien zoals sIL-2R, BAFF, 
infliximab dalspiegels en T- en B-cel subsets in patiënten met sarcoïdose die gaan 
starten met infliximab behandeling. In de literatuur worden goede en minder goede 
resultaten met dit middel beschreven. Door middel van deze studie probeerden wij 
door het bestuderen van verschillende markers de potentiële therapeutische respons 
te kunnen bepalen. 9/11 (82%) van de patiënten in deze studie liet een objectief goede 
klinische respons zien. sIL-2R waarden daalden al na het eerste infliximab infuus, terwijl 
IgG en BAFF waarden niet veranderden. Patiënten die langdurig goed reageerden op 
infliximab hadden stijgende IgM geheugencellen naast ook regulatoire T cellen, Th17 
en Th17.1 cellen. Patiënten die niet langdurig reageerden op infliximab met de vorming 
van autoantistoffen tegen infliximab, lieten voor de studie al lagere sIL-2R waarden en 
regulatoire T cellen zien met juist hogere IgM geheugencellen. Doordat patiënten die 
goed of juist niet goed reageren op infliximab al voor start van behandeling andere 
immunologische patronen laten zien kan het nuttig zijn om  lymfocyten subsets, 
infliximab dalspiegels en sIL-2R waarden te vervolgen.
 In Hoofdstuk 5 bestuderen wij de effectiviteit van infliximab bij patiënten met 
neurosarcoidose, een minder vaak voorkomende maar vaak ernstige vorm van 
sarcoïdose. 28 Patiënten vanuit het Erasmus MC in Rotterdam en AMC in Amsterdam, 
zijn beschreven in deze retrospectieve studie. De meeste patiënten hadden een 
ernstig klinisch beeld bij presentatie met hersenparenchym, hypofyse of perifere 
zenuwbetrokkenheid en chronische meningitis. Zes (21%) patiënten kwamen in 
complete remissie, veertien (50%) lieten verbetering zien, zeven (25%) hadden stabiele 
ziekte en bij één (4%) patiënt verslechterde de ziekte. Daarnaast kon in de meerderheid 
van de patiënten (68%), steroïden therapie worden afgebouwd of gestaakt. Wanneer 
infliximab werd gestaakt kwam de ziekte in 26% van de gevallen weer terug. Echter bij 
herstarten van infliximab reageerden patiënten vaak toch weer goed op de medicatie. 
Infliximab is een effectieve en relatief veilig vorm van medicatie bij patiënten met 
neurosarcoïdose wat leidt tot klinische verbetering of remissie bij de meeste patiënten. 
Hoofdstuk 6 bevat de resultaten uit de voorgaande hoofdstukken. Dit proefschrift levert 
meer bewijs dat B cellen actief betrokken zijn in de granuloom vorming en/of behoud 
hiervan, mogelijk door B - T cel interactie. Onze studies met infliximab laten zien dat het 
een effectief geneesmiddel lijkt te zijn in zowel pulmonale als extrapulmonale ziekte 
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en neurosarcoidose. Monitoring met immunologische markers kan mogelijk gebruikt 
worden om het succespercentage van infliximab nog verder te verbeteren. Daarnaast 
blijft er een groep patiënten met chronische inflammatoire ziekten die niet reageert op 
de gangbare medicatie. Dat er meerdere medicijnstudies zijn gepubliceerd die geen 
verbetering van ziekte laten zien, illustreert de complexiteit van deze ziekten. Onze 
eigen studie waarin wij patiënten met chronische sarcoïdose behandeld hebben met 
sandostatine is daarin geen uitzondering; ook hier werd geen klinisch effect worden 
aangetoond.
 Met dit proefschrift wordt nieuw bewijs geleverd voor de betrokkenheid van B 
cellen bij de immunopathogenese van granulomateuze inflammatoire ziekten. Dit biedt 
kansen voor nieuwe vormen van therapie; bijvoorbeeld door therapie gericht tegen B 
cellen of B - T cel interactie. 

DANKWOORD

145
D
D
ankw
oord
Ineens is het zover, het dankwoord is het allerlaatste wat nog geschreven dient te 
worden in dit proefschrift. Velen hebben bijgedragen aan de totstandkoming van dit 
proefschrift; van begeleiding van supervisoren, hulp van vele collega’s en het eindeloze 
begrip van familie en vrienden. Mijn dank is groot!
Beste Prof.dr. van Hagen, beste Martin, al in het begin van mijn studie Geneeskunde 
was ik onder de indruk van jouw geweldige enthousiasme en kennis van de Klinische 
Immunologie. Dank voor de begeleiding de afgelopen jaren, de vrijheid en het 
vertrouwen dat ik kreeg bij het opzetten van nieuwe studies, bezoeken aan het 
buitenland en de steun bij het afronden van dit proefschrift en het starten van mijn 
opleiding. 
Beste dr. van Laar, beste Jan, jij hebt letterlijk aan de wieg van dit proefschrift 
gestaan door mij als tweedejaars Geneeskunde student te enthousiasmeren voor de 
Immunologie na een casusbespreking over systeemziekten. Jij werd mijn mentor en ik 
mocht meelopen op de poli, grote visites bijwonen en assisteren met onderzoek. Dit 
heeft uiteindelijk geleid tot mijn afstudeeronderzoek, oudste co-schap en het starten 
van mijn promotieonderzoek op jullie afdeling. Dank voor jouw niet aflatende steun, 
mentorschap en positivisme in al deze jaren.
Beste dr. van Zelm, beste Menno, jij kreeg er ineens een student bij in jouw lab die nog 
niet eens normaal kon pipetteren. Uiteindelijk bleek dat dit best aan te leren was en 
ben ik uitgegroeid tot volwaardig BCD lid. Jouw kritische blik en streven naar diepgang 
hebben dit proefschrift zeker naar een hoger niveau getild en van mij een beter 
onderzoeker gemaakt. Jouw vertrek naar Melbourne was niet altijd gemakkelijk voor 
de groep, maar heeft mij de unieke mogelijkheid geboden een half jaartje in jouw lab 
te mogen werken, waar ik je erg dankbaar voor ben. Het gaat jullie goed in Australië! 
Prof.dr. Hofland, prof.dr. Baeten, prof.dr. Aerts, prof.dr. van der Woude, prof.dr. van Saase, 
prof.dr. van de Beek; hartelijk dank voor de tijd en moeite om mijn proefschrift kritisch 
door te nemen en jullie bereidheid plaats te nemen in de promotiecommissie. 
Beste dr. Lam, beste King, initieel stond jij niet heel erg te kijken op mijn verzoek om 
granulomen te gaan zoeken in darmbiopten. Toen wij granulomen vonden, sputterde 
jij eerst nog dat het geluk was; uiteindelijk bleek jij de enthousiasteling die avonden 
darmweefsel ging zitten scoren op B-cel aantallen. Dankjewel voor je humor, je wijze 
raad en steun die mij door die stapels biopten hebben geholpen en je bereidheid in de 
commissie deel te nemen.
Hierbij wil ik alle coauteurs bedanken voor de geleverde bijdragen aan publicaties en 
dit proefschrift. 
146 Dankwoord
Beste Paul en Virgil dank voor jullie bijdrage aan het sandostatine manuscript. Daarnaast 
ben ik ook dankbaar voor de vele klinische lessen die ik van jullie heb geleerd in al die 
jaren en gezelligheid op congressen. 
Beste Wim en Marco, dank voor de bijdrage aan de follow up sarcoïdose studie, maar 
daarnaast ook voor jullie kritische vragen tijdens meetings en de bereidheid van jullie 
groep om te helpen met het verwerken van samples als dat nodig was. 
Beste dr. Ouwendijk, Corry, Lenny en Conny van het Ikazia Ziekenhuis, dank voor jullie 
hulp bij de inclusie van Crohn patiënten en de gezelligheid als ik bloed kwam ophalen. 
Beste Mirjam, dank voor de steun en wijze raad wanneer ik dat zo nodig had. Veel succes 
met jouw nieuwe stap in Leiden. 
Sarcoïdose is bij uitstek een ziekte die de expertise van meerdere specialismen behoeft. 
Dank ook aan dr. Wijsenbeek, drs. Miedema, drs. Siepman en de andere specialisten 
die hierbij betrokken zijn in het Erasmus MC.  Speciale dank aan dr. Brouwer en Daan 
Fritz van het AMC; mooi dat wij onze krachten hebben gebundeld en data hebben 
samengevoegd in het neurosarcoidose infliximab manuscript. 
Beste Judy, dankjewel voor jouw hulp bij alle grant-aanvragen en jouw hulp met het 
afronden van dit proefschrift.
Beste Lieke, dankjewel voor de kans die je mij hebt gegeven te assisteren bij jouw 
onderzoek en de begeleiding van mijn afstudeeronderzoek.
Lieve Christina en Britt, wat ben ik blij dat jullie mijn paranimfen willen zijn. Door dik en 
dun hebben jullie mij gesteund in al die jaren, hele therapeutische sessies zijn over onze 
app gegaan! Jullie promoties zijn de volgende!
Jorn, samen begonnen als student bij Menno op het lab, samen promotieonderzoek 
gedaan, samen naar Australië, allebei in opleiding tot internist en nu promoveren op 
dezelfde dag! Ik waardeer onze tijd in Australië heel erg en ben blij dat ik jou nog vaak 
zal tegenkomen in de komende jaren. 
Lieve Naomi, toen ik bij jou op de werkkamer kwam was je niet heel blij…hoe is dat 
veranderd! Ik had mij geen betere roomy kunnen wensen met alle steun en gezelligheid; 
gelukkig ook nu we in twee verschillende werelddelen wonen. Ik ben zo trots op hoe 
goed jij het doet in New York!
Willem-Jan, wij begrepen elkaar als clinici tussen alle biologen. Wat een lol was het met 
jou, met als hoogtepunt onze gezamenlijke roadtrip in Australië met Mel en Anton. Ik 
ga jou nog vaak in consult vragen. 
147
D
D
ankw
oord
Ruud, toen jij bij Menno begon was jij bijna gepromoveerd en bijna kinderarts. Allebei 
delen wij een liefde voor systeemziekten en sarcasme en dat bleek de basis van onze 
vriendschap. Veel succes terug in Toronto!
Tim (vd Houwen) en Tim (Both); alle drie als student begonnen bij de Klinische 
Immunologie en nu in opleiding tot internist. Onze tripjes naar de Wetenschapsdagen 
in Antwerpen zijn onvergetelijk. Ook jullie ga ik nog vaak tegenkomen gelukkig.
Diana, jij liet mij zien dat je soms moest vechten om tot een afgerond proefschrift te 
komen, want onderzoek doen is lang niet altijd gemakkelijk of leuk. Op jou kon ik altijd 
terugvallen met flowcytometrie, staining of gating problemen. Of eigenlijk ieder ander 
probleem; bedankt!
Dear old-BCD group; Magda, Magda, Benjamin and Edwin; thank you for taking me in 
the group and helping me out all those years!
Aan alle (oud) promovendi en postdocs van de afdeling Immunologie; dank voor de 
input bij alle meetings en gezelligheid bij congressen en PhD uitjes. Special thanks to 
the roomies in the final stretch of my PhD: Dew, Jamie and Iris. Prayer, Chris and Rina 
thank you for your support, the laughter and fun we shared at conferences and nice 
dinners we had. Liza, jij bracht de Brabantse gezelligheid op de afdeling, waarvoor dank. 
Dear people of the ‘van Zelm group’ and of the Dept. of Immunology and Pathology 
of Monash University in Melbourne. Thank you all for giving me the best experience in 
your lab with learning new things but also the joy and laughter, drinks and dinners we 
shared. It was the best! Special thanks to Pei for taking on our project and processing all 
those samples!
Beth, my best and only roommate, thank you for making my time in Melbourne even 
more memorable to me!
Beste dr. van Kasteren en stafleden Interne Geneeskunde van het ETZ in Tilburg. Dank 
voor jullie hulp en vertrouwen in mij bij mijn terugkeer naar de kliniek. Ik leer iedere dag 
weer van jullie. 
Lieve assistenten Interne Geneeskunde van het Elisabeth; wat is het een feest om deel 
uit te mogen maken van dit hechte team. Bedankt voor alle hulp en flexibele opstelling 
rondom het afronden van dit proefschrift. Het is mooi om te zien dat wij er voor elkaar 
zijn als het nodig is, maar ook samen mooie feestjes kunnen bouwen.
Lieve Eline, Femke, Hanna en Nathalie; ik leerde jullie allemaal ruim elf jaar geleden 
kennen in de eerste weken van de studie Geneeskunde en wat ben ik blij dat ik jullie 
(plus partners en kinderen) nog steeds mijn vrienden mag noemen. 
148 Dankwoord
Beste Bert, Margriet, Martijn en Thymen Kerver, dank voor jullie steun en gastvrijheid in 
Rotterdam, we weten dat we bij jullie altijd welkom zijn!
Lieve Maarten en Josefa, thank you for years of support, dinners and fun trips. Josefa 
thank you so much for editing parts of this thesis. Maarten, jij bent meer dan alleen een 
(peet)oom voor mij, onze band is heel bijzonder.
Lieve opa en oma, wat ben ik blij dat jullie er bij zijn vandaag. Dankjewel dat jullie zo lang 
en goed voor Anton hebben gezorgd voor onze definitieve verhuizing naar Eindhoven.
Lieve pap en mam, dank voor het ongekende vertrouwen wat jullie altijd in mij hebben 
gehad, ook als ik dat zelf even niet zo zag. Als klein meisje herinner ik me dat jullie mij 
voorhielden dat ik alles kon worden wat ik wilde. En dat meenden jullie; ook al had papa 
mij stiekem graag op de boerderij gehouden. Het harde werken wat met de paplepel 
is ingegoten bleek ook de afgelopen jaren goed van pas te komen… Stefan en Mark, ik 
ben blij met twee nuchtere broers als jullie. Jullie zijn altijd welkom bij ons. Nu allebei 
de proefschriften zijn afgerond hopen wij wat vaker naar Zeeland te komen voor een 
goede barbecue. 
Lieve Anton, 
01100101 01101001 01101110 01100100 01100101 01101100 01101001 01101010 
01101011 00100000 01101001 01110011 00100000 01100100 01100001 01100001 
01110010 00100000 01101111 01101111 01101011 00100000 01101101 01101001 
01101010 01101110 00100000 01110000 01110010 01101111 01100101 01100110 
01110011 01100011 01101000 01110010 01101001 01100110 01110100 00101110 
00100000 01001001 01101011 00100000 01101000 01100001 01100100 00100000 
01101000 01100101 01110100 00100000 01111010 01101111 01101110 01100100 
01100101 01110010 00100000 01101010 01101111 01110101 00100000 01101110 
01101111 01101111 01101001 01110100 00100000 01100111 01100101 01101011 
01110101 01101110 01100100 00101100 00100000 01101010 01101001 01101010 
00100000 01100010 01100101 01101110 01110100 00100000 01101101 01101001 
01101010 01101110 00100000 01100111 01110010 01101111 01101111 01110100 
01110011 01110100 01100101 00100000 01110011 01110100 01100101 01110101 
01101110 00100000 01100101 01101110 00100000 01110100 01101111 01100101 
01110110 01100101 01110010 01101100 01100001 01100001 01110100 00101110 
00100000 01000100 01100001 01101110 01101011 01101010 01100101 01110111 
01100101 01101100 00100000 01100100 01100001 01110100 00100000 01101010 
01101001 01101010 00100000 01100101 01110010 00100000 01100001 01101100 
01110100 01101001 01101010 01100100 00100000 01110110 01101111 01101111 
01110010 00100000 01101101 01100101 00100000 01100010 01100101 01101110 
01110100 00101110


ABOUT THE AUTHOR

153
A
A
bout the author
Marieke Timmermans was born on November 19th in 1988 in Den Bosch, the Netherlands. 
She grew up on a farm in Aardenburg (Zeeland, The Netherlands) with her two brothers 
Stefan and Mark and their parents Bert and Mieke. She graduated secondary School 
‘Het Zwin College’ in 2007 and started studying Medicine at the Erasmus University in 
Rotterdam. 
 Already in the second year of Medical School, Marieke became interested in the 
field of Clinical Immunology and started participating in outpatient and clinical patient 
meetings and assisted in research projects. In 2013, Marieke obtained her medical 
degree cum laude. She  started working on her PhD project (promotor prof.dr. P.M. 
van Hagen) on the research she already started as a student; the involvement of B cells 
in granulomatous inflammatory diseases. She obtained several grants to finance the 
studies in this thesis and in 2016 she received a research award from the ‘Sarcoidose 
Belangenvereniging Nederland’, the Dutch sarcoidosis foundation. In 2016, Marieke 
took the opportunity to do a five-month working visit in the lab of her co-promotor 
dr.M.C. van Zelm at Monash University, Melbourne, Australia. Marieke returned back to 
clinical work in 2017 when she started working as an ANIOS in Internal Medicine at the 
ETZ hospital in Tilburg. In January 2018 Marieke was allowed to start her residency in 
Internal Medicine under the supervision of dr. M. van Kasteren; ETZ Tilburg and dr. A. 
Zandbergen; Erasmus MC Rotterdam. 
 In the beginning of Medical School, Marieke met her partner Anton Kerver and they 
supported each other through the writing of two dissertations and multiple residencies. 
They happily live together in Eindhoven. 

PHD PORTFOLIO

157
L
List of publications
Name PhD Student: Wilhelmina Maria Cornelia Timmermans
Erasmus MC Department: Internal Medicine and Immunology
Research School: Molecular Medicine
PhD period: January 2014 – October 2018
Promotor: Prof.dr. P.M. van Hagen
Co-promotores:  Dr. J.A.M. van Laar       
 Dr. M.C. van Zelm 
      
PHD TRAINING
IN-DEPTH COURSES
2013  Basiscursus Klinische Onderzoekers (BROK)
2014  Biomedical English Writing 
2014  Advanced Immunology
2014  Molecular Medicine 
2014  WASOG conference, Izmir, Turkey
2015  Research Integrity
2015  Flowcytometry
2016  Seminars and minisymposia Dept. Immunology and Pathology  
  Monash University
2014 – 2017 Regular seminars dept. Internal Medicine/Clinical Immunology
2014 – 2017 Seminars and minisymposia dept. Immunology Erasmus MC
TEACHING
2013 – 2016 Lectures Winter-course master Infection and Immunity 
2014 – 2015 Supervising research projects medical students
2015 – 2016 Clinical Immunology cases, bachelor medicine
PRESENTATIONS
2012 – 2016 Internal Medicine Science Days, Antwerp, Belgium; yearly presentations
2013  WASOG, Paris, France; poster presentations
2014  Molecular Medicine day, Rotterdam, The Netherlands; poster presentation
2014  NVVI Annual Meeting, Kaatsheuvel, The Netherlands; poster presentation
2015  ‘Sarcoïdose Belangenvereniging’ meeting with patients, The Netherlands; 
  oral presentation
2015  EWIMID Amsterdam, The Netherlands; poster presentation
2015  NVVI Annual Meeting, Noordwijkerhout, The Netherlands;  
  poster presentation
158 List of publications
AWARDS AND FUNDS 
2013 Travelgrant Gerrit Jan Mulder Stichting WASOG Paris
2014 Novartis investigator initiated trial: ‘Sandostatin treatment in sarcoidosis’
2015 Grant Coolsingel Foundation project: ‘Op zoek naar het granuloom’                    
2015 Grant CCU Foundation (Dutch Digestive Foundation) project:  ‘Op zoek  
 naar  het granuloom’
2015 Research award Sarcoïdose Belangenvereniging Nederland
2015 Travelgrant Erasmus Trustfonds for research visit Monash University
2015 Travelgrant NVVI for research visit Monash University
2016 Travelgrant Catharina van Tussenbroekstichting for research visit Monash
 University 
 


LIST OF PUBLICATIONS

163
L
List of publications
1.    Blood B- and T-cell kinetics, SIL-2R, infliximab trough levels and ADA formation 
indicate therapeutic succes of Infliximab in patients  with sarcoidosis. 
 Wilhelmina MC Timmermans, Willem A Dik, Marco WJ Schreurs, Jelle R Miedema, 
Marlies S Wijsenbeek, P Martin van Hagen, Menno C van Zelm, Jan AM van Laar – 
Submitted
2. Improved detection of granulomas by staining for B-cells: implications for differential 
diagnosis between ulcerative colitis and Crohn’s disease. 
 Wilhelmina MC Timmermans, King H Lam , Folkert J van Kemenade, Paul LA van 
Daele,  P Martin van Hagen, Jan AM van Laar, Menno C van Zelm – Submitted
3. Sandostatin therapy in patients with chronic sarcoidosis. 
 Wilhelmina MC Timmermans, Jan AM van Laar, Virgil ASH Dalm, Boen L Kam, P 
Martin van Hagen, Paul LA van Daele – Published Sarcoidosis vasculitis and diffuse 
lung diseases, 2017
4. Immunopathogenesis of granulomas in chronic autoinflammatory diseases.
  Wilhelmina MC Timmermans, Jan AM van Laar, P. Martin van Hagen, Menno C. van 
Zelm –  Published Journal of Clinical and Translational Immunology, 2016
5. B-cell dysregulation in Crohn’s disease is partially restored with infliximab therapy. 
 Wilhelmina MC Timmermans, Jan AM van Laar, Tim B van der Houwen, Lieke SJ 
Kamphuis, Sophinus J Bartol, Rob J Ouwendijk, P Martin van Hagen, Menno C van 
Zelm – Published Plos One, 2016
6. The effect on memory B-cells in patients with Behçet’s disease treated with TNF-
blockers.
 Tim B van der Houwen, P Martin van Hagen, Wilhelmina MC Timmermans, 
Sophinus J Bartol, Jasper H Kappen, Menno C van Zelm, Jan AM van Laar – Published 
Rheumatology, 2016
7. Somatostatin receptor scintigraphy in patients with sarcoidosis. 
 Lieke S Kamphuis, P Martin van Hagen, Tom O Missotten, G Seerp Baarsma, Virgil 
ASH Dalm, Willem A Dik, Wilhelmina MC Timmermans, Jan AM van Laar  and Dik J 
Kwekkeboom – Published Clinical Nuclear Medicine , 2015
IMMUNOPATHOGENESIS 
OF GRANULOMAS IN 
CHRONIC INFLAMMATORY DISEASES
Relevance to diagnostics, biomarkers and treatment
Marieke Timmermans
IM
M
U
N
O
PATH
O
G
EN
ESIS O
F G
R
A
N
U
LO
M
A
S IN
 CH
RO
N
IC IN
FLA
M
M
ATO
RY D
ISEA
SES   |  M
arieke Tim
m
erm
ans
UITNODIGING
Voor het bijwonen van de 
openbare verdediging van het 
proefschrift van 
Marieke Timmermans
Getiteld
IMMUNOPATHOGENESIS OF 
GRANULOMAS IN CHRONIC 
INFLAMMATORY DISEASES
Relevance to diagnostics, 
biomarkers and treatment
Dinsdag 30 oktober
09:30 uur
Prof.dr. Andries Queridozaal, 
onderwijscentrum Erasmus MC
Wytemaweg 80
3015 CN Rotterdam
Na a oop van de promotie bent 
u van harte uitgenodigd voor 
de receptie in de foyer van het 
onderwijscentrum
Vanaf 20:30 uur bent u van 
harte uitgenodigd voor 
het promotiefeest in de 
Stadsbrouwerij de Pelgrim
Aelbrechtskolk 12
3024 RE Rotterdam
Paranimfen:
Christina Grosserichter-Wagener
Britt de Jong
Promotiefeestmarieke2018@gmail.com
